

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> :		A1	(11) International Publication Number:	WO 98/46765
C12N 15/53, 15/83, 5/10, C12P 7/64, C11B 1/00, A61K 31/20, A23L 1/30, A23K 1/00			(43) International Publication Date: 22 October 1998 (22.10.98)	
(21) International Application Number: PCT/US98/07422			bus, OH 43231 (US). CHAUDHARY, Sunita [IN/US]; 3419 Woodbine Place, Pearland, TX 77584 (US). LEONARD, Amanda, Eun-Yeong [US/US]; 581 Shadewood Court, Gahanna, OH 43230 (US).	
(22) International Filing Date: 10 April 1998 (10.04.98)			(74) Agents: WARD, Michael, R. et al.; Limbach & Limbach L.L.P., 2001 Ferry Building, San Francisco, CA 94111-4262 (US).	
(30) Priority Data: 08/833,610 11 April 1997 (11.04.97) US			(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 08/833,610 (CIP) Filed on 11 April 1997 (11.04.97)				
(71) Applicants (for all designated States except US): CALGENE LLC [US/US]; 1920 Fifth Street, Davis, CA 95616 (US). ABOTT LABORATORIES [US/US]; 100 Abbott Park Road, Abbott Park, IL 60064-3500 (US).				
(72) Inventors; and			Published	
(75) Inventors/Applicants (for US only): KNUTZON, Deborah [US/US]; 6110 Rockhurst Way, Granite Bay, CA 95746 (US). MUKERJI, Pradip [US/US]; 1069 Arcaro Drive, Gahanna, OH 43230 (US). HUANG, Yung-Sheng [CA/US]; 2462 Danvers Court, Upper Arlington, OH 43220 (US). THURMOND, Jennifer [US/US]; 3702 Adirondack, Colum-			With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	
(54) Title: METHODS AND COMPOSITIONS FOR SYNTHESIS OF LONG CHAIN POLYUNSATURATED FATTY ACIDS				
(57) Abstract				
<p>The present invention relates to a fatty acid <math>\Delta 5</math>-desaturase able to catalyze the conversion of dihomo-<math>\gamma</math>-linolenic acid to arachidonic acid. Nucleic acid sequences encoding <math>\Delta 5</math>-desaturase, nucleic acid sequences which hybridize thereto, DNA constructs comprising a <math>\Delta 5</math>-desaturase gene, and recombinant host microorganism or animal expressing increased levels of a <math>\Delta 5</math>-desaturase are described. Methods for desaturating a fatty acid at the <math>\Delta 5</math> position and for producing arachidonic acid by expressing increased levels of a <math>\Delta 5</math>-desaturase are disclosed. Fatty acids, and oils containing them, which have been desaturated by a <math>\Delta 5</math>-desaturase produced by recombinant host microorganisms or animals are provided. Pharmaceutical compositions, infant formulas or dietary supplements containing fatty acids which have been desaturated by a <math>\Delta 5</math>-desaturase produced by a recombinant host microorganism or animal also are described.</p>				

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

<b>AL</b>	Albania	<b>ES</b>	Spain	<b>LS</b>	Lesotho	<b>SI</b>	Slovenia
<b>AM</b>	Armenia	<b>FI</b>	Finland	<b>LT</b>	Lithuania	<b>SK</b>	Slovakia
<b>AT</b>	Austria	<b>FR</b>	France	<b>LU</b>	Luxembourg	<b>SN</b>	Senegal
<b>AU</b>	Australia	<b>GA</b>	Gabon	<b>LV</b>	Larvia	<b>SZ</b>	Swaziland
<b>AZ</b>	Azerbaijan	<b>GB</b>	United Kingdom	<b>MC</b>	Monaco	<b>TD</b>	Chad
<b>BA</b>	Bosnia and Herzegovina	<b>GE</b>	Georgia	<b>MD</b>	Republic of Moldova	<b>TG</b>	Togo
<b>BB</b>	Barbados	<b>GH</b>	Ghana	<b>MG</b>	Madagascar	<b>TJ</b>	Tajikistan
<b>BE</b>	Belgium	<b>GN</b>	Guinea	<b>MK</b>	The former Yugoslav Republic of Macedonia	<b>TM</b>	Turkmenistan
<b>BF</b>	Burkina Faso	<b>GR</b>	Greece	<b>ML</b>	Mali	<b>TR</b>	Turkey
<b>BG</b>	Bulgaria	<b>HU</b>	Hungary	<b>MN</b>	Mongolia	<b>TT</b>	Trinidad and Tobago
<b>BJ</b>	Benin	<b>IE</b>	Ireland	<b>MR</b>	Mauritania	<b>UA</b>	Ukraine
<b>BR</b>	Brazil	<b>IL</b>	Israel	<b>MW</b>	Malawi	<b>UG</b>	Uganda
<b>BY</b>	Belarus	<b>IS</b>	Iceland	<b>MX</b>	Mexico	<b>US</b>	United States of America
<b>CA</b>	Canada	<b>IT</b>	Italy	<b>NE</b>	Niger	<b>UZ</b>	Uzbekistan
<b>CF</b>	Central African Republic	<b>JP</b>	Japan	<b>NL</b>	Netherlands	<b>VN</b>	Viet Nam
<b>CG</b>	Congo	<b>KE</b>	Kenya	<b>NO</b>	Norway	<b>YU</b>	Yugoslavia
<b>CH</b>	Switzerland	<b>KG</b>	Kyrgyzstan	<b>NZ</b>	New Zealand	<b>ZW</b>	Zimbabwe
<b>CI</b>	Côte d'Ivoire	<b>KP</b>	Democratic People's Republic of Korea	<b>PL</b>	Poland		
<b>CM</b>	Cameroon	<b>KR</b>	Republic of Korea	<b>PT</b>	Portugal		
<b>CN</b>	China	<b>KZ</b>	Kazakhstan	<b>RO</b>	Romania		
<b>CU</b>	Cuba	<b>LC</b>	Saint Lucia	<b>RU</b>	Russian Federation		
<b>CZ</b>	Czech Republic	<b>LI</b>	Liechtenstein	<b>SD</b>	Sudan		
<b>DE</b>	Germany	<b>LK</b>	Sri Lanka	<b>SE</b>	Sweden		
<b>DK</b>	Denmark	<b>LR</b>	Liberia	<b>SG</b>	Singapore		
<b>EE</b>	Estonia						

## METHODS AND COMPOSITIONS FOR SYNTHESIS OF LONG CHAIN POLYUNSATURATED FATTY ACIDS

### RELATED APPLICATION

5 This application is a continuation in part application of Serial Number 08/833,610 filed April 11, 1997.

### INTRODUCTION

#### Field of the Invention

This invention relates to modulating levels of enzymes and/or enzyme 10 components relating to production of long chain poly-unsaturated fatty acids (PUFAs) in a microorganism or animal.

#### Background

Two main families of polyunsaturated fatty acids (PUFAs) are the  $\omega 3$  15 fatty acids, exemplified by eicosapentaenoic acid (EPA), and the  $\omega 6$  fatty acids, exemplified by arachidonic acid (ARA). PUFAs are important components of the plasma membrane of the cell, where they may be found in such forms as phospholipids. PUFAs are necessary for proper development, particularly in the developing infant brain, and for tissue formation and repair. PUFAs also serve 20 as precursors to other molecules of importance in human beings and animals, including the prostacyclins, eicosanoids, leukotrienes and prostaglandins.

Four major long chain PUFAs of importance include docosahexaenoic acid (DHA) and EPA, which are primarily found in different types of fish oil, gamma-linolenic acid (GLA), which is found in the seeds of a number of plants, 25 including evening primrose (*Oenothera biennis*), borage (*Borago officinalis*) and black currants (*Ribes nigrum*), and stearidonic acid (SDA), which is found in marine oils and plant seeds. Both GLA and another important long chain PUFA, arachidonic acid (ARA), are found in filamentous fungi. ARA can be

purified from animal tissues including liver and adrenal gland. GLA, ARA, EPA and SDA are themselves, or are dietary precursors to, important long chain fatty acids involved in prostaglandin synthesis, in treatment of heart disease, and in development of brain tissue.

5        Polyunsaturated fatty acids have a number of pharmaceutical and medical applications including treatment of heart disease, cancer and arthritis.

For DHA, a number of sources exist for commercial production including a variety of marine organisms, oils obtained from cold water marine fish, and egg yolk fractions. For ARA, microorganisms including the genera  
10      *Mortierella*, *Entomophthora*, *Phytium* and *Porphyridium* can be used for commercial production. Commercial sources of SDA include the genera *Trichodesma* and *Echium*. Commercial sources of GLA include evening primrose, black currants and borage. However, there are several disadvantages associated with commercial production of PUFAs from natural sources. Natural  
15      sources of PUFAs, such as animals and plants, tend to have highly heterogeneous oil compositions. The oils obtained from these sources therefore can require extensive purification to separate out one or more desired PUFAs or to produce an oil which is enriched in one or more PUFA. Natural sources also are subject to uncontrollable fluctuations in availability. Fish stocks may  
20      undergo natural variation or may be depleted by overfishing. Fish oils have unpleasant tastes and odors, which may be impossible to economically separate from the desired product, and can render such products unacceptable as food supplements. Animal oils, and particularly fish oils, can accumulate environmental pollutants. Weather and disease can cause fluctuation in yields  
25      from both fish and plant sources. Cropland available for production of alternate oil-producing crops is subject to competition from the steady expansion of human populations and the associated increased need for food production on the remaining arable land. Crops which do produce PUFAs, such as borage, have not been adapted to commercial growth and may not perform well in  
30      monoculture. Growth of such crops is thus not economically competitive where more profitable and better established crops can be grown. Large scale

fermentation of organisms such as *Mortierella* is also expensive. Natural animal tissues contain low amounts of ARA and are difficult to process. Microorganisms such as *Porphyridium* and *Mortierella* are difficult to cultivate on a commercial scale.

- 5        Dietary supplements and pharmaceutical formulations containing PUFA can retain the disadvantages of the PUFA source. Supplements such as fish oil capsules can contain low levels of the particular desired component and thus require large dosages. High dosages result in ingestion of high levels of undesired components, including contaminants. Unpleasant tastes and odors of  
10      the supplements can make such regimens undesirable, and may inhibit compliance by the patient. Care must be taken in providing fatty acid supplements, as overaddition may result in suppression of endogenous biosynthetic pathways and lead to competition with other necessary fatty acids in various lipid fractions *in vivo*, leading to undesirable results. For example,  
15      Eskimos having a diet high in  $\omega 3$  fatty acids have an increased tendency to bleed (U.S. Pat. No. 4,874,603).

- A number of enzymes are involved in PUFA biosynthesis. Linolenic acid (LA, 18:2  $\Delta 9, 12$ ) is produced from oleic acid (18:1  $\Delta^0$ ) by a  $\Delta 12$ -desaturase. GLA (18:3  $\Delta 6, 9, 12$ ) is produced from linoleic acid (LA, 18:2  $\Delta 9, 12$ ) by a  $\Delta 6$ -desaturase. ARA (20:4  $\Delta 5, 8, 11, 14$ ) production from dihomogamma-linolenic acid (DGLA, 20:3  $\Delta 8, 11, 14$ ) is catalyzed by a  $\Delta 5$ -desaturase.  
20      However, animals cannot desaturate beyond the  $\Delta 9$  position and therefore cannot convert oleic acid (18:1  $\Delta 9$ ) into linolenic acid (18:2  $\Delta 9, 12$ ). Likewise,  $\alpha$ -linoleic acid (ALA, 18:3  $\Delta 9, 12, 15$ ) cannot be synthesized by mammals.  
25      Other eukaryotes, including fungi and plants, have enzymes which desaturate at positions  $\Delta 12$  and  $\Delta 15$ . The major poly-unsaturated fatty acids of animals therefore are either derived from diet and/or from desaturation and elongation of linoleic acid (18:2  $\Delta 9, 12$ ) or  $\alpha$ -linolenic acid (18:3  $\Delta 9, 12, 15$ ). Therefore it is of interest to obtain genetic material involved in PUFA biosynthesis from  
30      species that naturally produce these fatty acids and to express the isolated

material in a microbial or animal system which can be manipulated to provide production of commercial quantities of one or more PUFAs. Thus there is a need for fatty acid desaturases, genes encoding them, and recombinant methods of producing them. A need further exists for oils containing higher relative proportions of and/or enriched in specific PUFAs. A need also exists for reliable economical methods of producing specific PUFAs.

**Relevant Literature**

Production of gamma-linolenic acid by a  $\Delta 6$ -desaturase is described in USPN 5,552,306. Production of 8, 11-eicosadienoic acid using *Mortierella alpina* is disclosed in USPN 5,376,541. Production of docosahexaenoic acid by dinoflagellates is described in USPN 5,407,957. Cloning of a  $\Delta 6$ -palmitoyl-acyl carrier protein desaturase is described in PCT publication WO 96/13591 and USPN 5,614,400. Cloning of a  $\Delta 6$ -desaturase from borage is described in PCT publication WO 96/21022. Cloning of  $\Delta 9$ -desaturases is described in the published patent applications PCT WO 91/13972, EP 0 550 162 A1, EP 0 561 569 A2, EP 0 644 263 A2, and EP 0 736 598 A1, and in USPN 5,057,419. Cloning of  $\Delta 12$ -desaturases from various organisms is described in PCT publication WO 94/11516 and USPN 5,443,974. Cloning of  $\Delta 15$ -desaturases from various organisms is described in PCT publication WO 93/11245. All publications and U.S. patents or applications referred to herein are hereby incorporated in their entirety by reference.

**Summary of the Invention**

Novel compositions and methods are provided for preparation of poly-unsaturated long chain fatty acids or PUFAs. The compositions include nucleic acids encoding a  $\Delta 5$ -desaturase and/or polypeptides having  $\Delta 5$ -desaturase activity, the polypeptides, and probes for isolating and detecting the same. The methods involve growing a host microorganism or animal which contains and expresses one or more transgenes encoding a  $\Delta 5$ -desaturase and/or a polypeptide having  $\Delta 5$ -desaturase activity. Expression of the desaturase

polypeptide provides for a relative increase in  $\Delta 5$ -desaturated PUFA, or metabolic progeny therefrom, as a result of altered concentrations of enzymes and substrates involved in PUFA biosynthesis. The invention finds use for example in the large scale production of PUFA containing oils which include,  
5 for example, ARA, EPA and/or DHA.

In a preferred embodiment, a nucleic acid sequence comprising a  $\Delta 5$ -desaturase depicted in Figure 3A-D (SEQ ID NO 1), a polypeptide encoded by the nucleic acid, and a purified or isolated polypeptide depicted in Figure 3A-D (SEQ ID NO: 2), and an isolated nucleic acid encoding the polypeptide of  
10 Figure 3A-D (SEQ ID NO: 2) are provided. Another embodiment of the invention is an isolated nucleic acid sequence which encodes a polypeptide, wherein said polypeptide desaturates a fatty acid molecule at carbon 5 from the carboxyl end of the molecule. The nucleic acid is preferably derived from a eukaryotic cell, such as a fungal cell, or a fungal cell of the genus *Mortierella*,  
15 or of the genus/species *Mortierella alpina*. Also preferred is an isolated nucleic acid comprising a sequence which anneals to a nucleotide sequence depicted in Figure 3A-3D (SEQ ID NO: 1), and a nucleic acid which encodes an amino acid sequence depicted in Figure 3A-D (SEQ ID NO: 2). In particular, the nucleic acid encodes an amino acid sequence depicted in Figure 3A-D (SEQ ID NO: 2)  
20 which is selected from the group consisting of amino acid residues 30-38, 41-44, 171-175, 203-212, and 387-394. In an additional embodiment, the invention provides an isolated or purified polypeptide which desaturates a fatty acid molecule at carbon 5 from the carboxyl end of the molecule. Also provided is an isolated nucleic acid sequence which hybridizes to a nucleotide sequence  
25 depicted in Figure 3A-D (SEQ ID NO 1), an isolated nucleic acid sequence having at least about 50% identity to Figure 3A-D (SEQ ID NO 1).

The present invention further includes a nucleic acid construct comprising a nucleotide sequence depicted in a Figure 3A-D (SEQ ID NO: 1) linked to a heterologous nucleic acid; a nucleic acid construct comprising a  
30 nucleotide sequence depicted in a Figure 3A-D (SEQ ID NO: 1) operably linked to a promoter; and a nucleic acid construct comprising a nucleotide sequence

depicted in a Figure 3A-D (SEQ ID NO: 1) operably linked to a promoter which is functional in a microbial cell. In a preferred embodiment, the microbial cell is a yeast cell, and the nucleotide sequence is derived from a fungus, such as a fungus of the genus *Mortierella*, particularly a fungus of the species *Mortierella alpina*.

In another embodiment of the invention, a nucleic acid construct is provided which comprises a nucleotide sequence which encodes a polypeptide comprising an amino acid sequence which corresponds to or is complementary to an amino acid sequence depicted in Figure 3A-D (SEQ ID NO: 2), wherein the nucleotide sequence is operably linked to a promoter which is functional in a host cell, and wherein the nucleotide sequence encodes a polypeptide which desaturates a fatty acid molecule at carbon 5 from the carboxyl end of a fatty acid molecule. Additionally, provided by the invention is a nucleic acid construct comprising a nucleotide sequence which encodes a functionally active  $\Delta 5$ -desaturase, where the desaturase includes an amino acid sequence which corresponds to or is complementary to all of or a portion of an amino acid sequence depicted in a Figure 3A-D (SEQ ID NO: 2), wherein the nucleotide sequence is operably linked to a promoter functional in a host cell.

The invention also includes a host cell comprising a nucleic acid construct of the invention. In a preferred embodiment, a recombinant host cell is provided which comprises at least one copy of a DNA sequence which encodes a functionally active *Mortierella alpina* fatty acid desaturase having an amino acid sequence as depicted in Figure 3A-D (SEQ ID NO: 2), wherein the cell or an ancestor of the cell was transformed with a vector comprising said DNA sequence, and wherein the DNA sequence is operably linked to a promoter. The host cell is either eukaryotic or prokaryotic. Preferred eukaryotic host cells are those selected from the group consisting of a mammalian cell, an insect cell, a fungal cell, and an algae cell. Preferred mammalian cells include an avian cell, a fungal cell such as a yeast, and a marine algae cell. Preferred prokaryotic cells include those selected from the group consisting of a bacteria, a cyanobacteria, cells which contain a

bacteriophage, and/or a virus. The DNA sequence of the recombinant host cell preferably contains a promoter which is functional in the host cell.

The host cells of the invention which contain the DNA sequences of the invention are enriched for fatty acids, such as 20:3 fatty acids. In a preferred 5 embodiment, the host cells are enriched for 20:4 fatty acids as compared to an untransformed host cell which is devoid of said DNA sequence, and/or enriched for 20:5 fatty acids compared to an untransformed host cell which is devoid of said DNA sequence. In yet another preferred embodiment, the invention provides a recombinant host cell which comprises a fatty acid selected from the 10 group consisting of a dihomo- $\gamma$ -linolenic acid, n-6 eicosatrienoic acid, 20:3n-6 acid and 20:3 (8,11,14) acid.

The present invention also includes method for production of arachidonic acid in a microbial cell culture, where the method comprises growing a microbial cell culture having a plurality of microbial cells which 15 contain one or more nucleic acids encoding a polypeptide which converts dihomo- $\gamma$ -linolenic acid to arachidonic acid, wherein the nucleic acid is operably linked to a promoter, under conditions whereby said one or more nucleic acids are expressed, whereby arachidonic acid is produced in the microbial cell culture. In several preferred embodiments of the invention, the 20 polypeptide is an enzyme which desaturates a fatty acid molecule at carbon 5 from the carboxyl end of the fatty acid molecule; the nucleic acid is derived from a *Mortierella* sp.; and the substrate for said polypeptide is exogenously supplied. The microbial cells used in the methods can be either eukaryotic cells or prokaryotic cells. The preferred eukaryotic cells are those selected 25 from the group consisting of a mammalian cell, an insect cell, a fungal cell, and an algae cell. Preferred mammalian cells include an avian cell, a preferred fungal cell is a yeast, and the preferred algae cell is a marine algae cell. The preferred prokaryotic cells include those selected from the group consisting of a bacteria, a cyanobacteria, cells which contain a bacteriophage, and/or a virus. 30 The nucleic acid sequence encoding the polypeptide of the microbial cell preferably contains a promoter which is functional in the host cell which

optionally is an inducible promoter for example by components of the culture broth. The preferred microbial cells used in the methods are yeast cells, such as *Saccharomyces* cells.

In another embodiment of the invention, a recombinant yeast cell is  
5 provided which converts greater than about 5% of 20:3 fatty acid substrate to a 20:4 fatty acid product.

Also provided is an oil comprising one or more PUFA. The amount of said one or more PUFAs is approximately 0.3-30% arachidonic acid (ARA), approximately 0.2-30% dihomo- $\gamma$ -linolenic acid (DGLA), and approximately  
10 0.2-30%  $\gamma$ -linolenic acid (GLA). A preferred oil of the invention is one in which the ratio of ARA:DGLA:GLA is approximately 1.0:19.0:30 to 6.0:1.0:0.2. Another preferred embodiment of the invention is a pharmaceutical composition comprising the oils in a pharmaceutically acceptable carrier. Further provided is a nutritional composition comprising the oils of the  
15 invention. The nutritional compositions of the invention preferably are administered to a mammalian host parenterally or internally. A preferred composition of the invention for internal consumption is an infant formula. In a preferred embodiment, the nutritional compositions of the invention are in a liquid form or a solid form.

20 The present invention also includes a method for desaturating a fatty acid, where the method comprises culturing a recombinant microbial cell of the invention under conditions suitable for expression of a polypeptide encoded by the nucleic acid, wherein the host cell further comprises a fatty acid substrate of the polypeptide. In a preferred embodiment, a fatty acid desaturated by the  
25 methods is provided, including an oil comprising the fatty acid.

The present invention is also directed to purified nucleotide and peptide sequences presented in SEQ ID NO:1-34. The present invention is further directed toward methods of using the sequences presented in SEQ ID NO:1-34 as probes to identify related sequences, as components of expression systems  
30 and as components of systems useful for producing transgenic oil.

The present invention is further directed to methods of obtaining altered long chain poly unsaturated fatty acid biosystems by growing transgenic microbes which encode transgene expression products which desaturate a fatty acid molecule at carbon 5 from the carboxyl end of the fatty acid molecule.

5 The present invention is further directed to formulas, dietary supplements or dietary supplements in the form of a liquid or a solid containing the long chain fatty acids of the invention. These formulas and supplements may be administered to a human or an animal.

10 The formulas and supplements of the invention may further comprise at least one macronutrient selected from the group consisting of coconut oil, soy oil, canola oil, mono- and diglycerides, glucose, edible lactose, electrodialysed whey, electrodialysed skim milk, milk whey, soy protein, and other protein hydrolysates.

15 The formulas of the present invention may further include at least one vitamin selected from the group consisting of Vitamins A, C, D, E, and B complex; and at least one mineral selected from the group consisting of calcium, magnesium, zinc, manganese, sodium, potassium, phosphorus, copper, chloride, iodine, selenium, and iron.

20 The present invention is further directed to a method of treating a patient having a condition caused by insufficient intake or production of polyunsaturated fatty acids comprising administering to the patient a dietary substitute of the invention in an amount sufficient to effect treatment of the patient.

The present invention is further directed to cosmetic and pharmaceutical compositions of the material of the invention.

25 The present invention is also directed to an isolated nucleotide sequence comprising a nucleotide sequence selected from the group consisting of: SEQ ID NO:13; SEQ ID NO:15; SEQ ID NO:17; SEQ ID NO:19; SEQ ID NO:21; SEQ ID NO:22; SEQ ID NO:22; SEQ ID NO:24; SEQ ID NO:25; SEQ ID NO:26 and SEQ ID NO:27.

The present invention is also directed to an isolated peptide sequence comprising a peptide sequence selected from the group consisting of: SEQ ID NO:14; SEQ ID NO:16; SEQ ID NO:18; SEQ ID NO:20; SEQ ID NO:28; SEQ ID NO:29; SEQ ID NO:30; SEQ ID NO:31; SEQ ID NO:32; SEQ ID NO:33 and SEQ ID NO:34.

The present invention is further directed to transgenic oils in pharmaceutically acceptable carriers. The present invention is further directed to nutritional supplements, cosmetic agents and infant formulae containing transgenic oils.

The present invention is further directed to a method for obtaining altered long chain polyunsaturated fatty acid biosynthesis comprising the steps of: growing a microbe having cells which contain a transgene which encodes a transgene expression product which desaturates a fatty acid molecule at carbon 5 from the carboxyl end of said fatty acid molecule, wherein the transgene is operably associated with an expression control sequence, under conditions whereby the transgene is expressed, whereby long chain polyunsaturated fatty acid biosynthesis in the cells is altered.

The present invention is further directed to the use of chain polyunsaturated fatty acid selected from the group consisting of ARA, DGLA and EPA.

The present invention is further directed toward pharmaceutical compositions comprising at least one nutrient selected from the group consisting of a vitamin, a mineral, a carbohydrate, a sugar, an amino acid, a free fatty acid, a phospholipid, an antioxidant, and a phenolic compound.

Brief Description of the Drawings

Figure 1 shows possible pathways for the synthesis of arachidonic acid (20:4 Δ5, 8, 11, 14) and stearidonic acid (18:4 Δ6, 9, 12, 15) from palmitic acid (C<sub>16</sub>) from a variety of organisms, including algae, *Mortierella* and humans.

- 5 These PUFAs can serve as precursors to other molecules important for humans and other animals, including prostacyclins, leukotrienes, and prostaglandins, some of which are shown.

Figure 2 shows possible pathways for production of PUFAs in addition to ARA, including EPA and DHA, for a variety of organisms.

- 10 Figure 3A-D shows the DNA sequence of the *Mortierella alpina* Δ5-desaturase and the deduced amino acid sequence.

Figure 4 shows the deduced amino acid sequence of the PCR fragment (see Example 1)

- 15 Figure 5A and 5B show alignments of the protein sequence of the Δ5-desaturase with Δ6-desaturases.

Figure 6A and 6B show the effect of the timing of substrate addition relative to induction on conversion of substrate to product in SC334 containing the Δ5-desaturase gene.

- 20 Figure 7A and 7B show the effect of inducer concentration on Δ5-desaturase expression in SC334.

Figure 8A and 8B show the effect of induction temperature on Δ5-desaturase activity in SC334.

Figure 9A and 9B show the effect of host strain on the conversion of substrate to product in strains expressing the Δ5-desaturase gene at 15°C.

- 25 Figure 10A and 10B show the effect of host strain on the conversion of substrate to product in strains expressing the Δ5-desaturase gene at 30°C.

Figure 11 shows the effect of a host strain expressing choline transferase as well as the  $\Delta 5$ -desaturase gene on the conversion of substrate to product.

Figure 12A and 12B show the effect of media composition and temperature on the conversion of substrate to product in two host strains  
5 expressing the  $\Delta 5$ -desaturase gene.

Figure 13 shows alignment of the protein sequence of Ma 29 and contig 253538a.

Figure 14 shows alignment of the protein sequence of Ma 524 and contig 253538a.

10

#### Brief Description of the Sequence Listings

SEQ ID NO:1 shows a DNA sequence of the *Mortierella alpina*  $\Delta 5$ -desaturase.

15 SEQ ID NO:2 shows an amino acid sequence of *Mortierella alpina*  $\Delta 5$ -desaturase.

SEQ ID NO: 3 shows the deduced amino acid sequence of the *M. alpina* PCR fragment (see Example 1).

SEQ ID NO: 4 - SEQ ID NO: 7 show the deduced amino acid sequences of various  $\Delta 6$ -desaturases.

20 SEQ ID NO: 8 and SEQ ID NO: 9 show PCR primer sequences for  $\Delta 6$ -desaturases

SEQ ID NO: 10 shows a primer for reverse transcription of total RNA.

25 SEQ ID NO: 11 and SEQ ID NO: 12 show amino acid motifs for desaturase sequences.

SEQ ID NO: 13 and SEQ ID NO: 14 show the nucleotide and amino acid sequence of a *Dictyostelium discoideum* desaturase sequence.

SEQ ID NO: 15 and SEQ ID NO: 16 show the nucleotide and amino acid sequence of a *Phaeodactylum tricornutum* desaturase sequence.

SEQ ID NO: 17-20 show the nucleotide and deduced amino acid sequence of a *Schizochytrium* cDNA clone.

5       SEQ ID NO: 21-27 show nucleotide sequences for human desaturases.

SEQ ID NO: 28 - SEQ ID NO: 34 show peptide sequences for human desaturases.

#### Detailed Description of the Invention

10       In order to ensure a complete understanding of the invention, the following definitions are provided:

**Δ5-Desaturase:** Δ5 desaturase is an enzyme which introduces a double bond between carbons 5 and 6 from the carboxyl end of a fatty acid molecule.

15       **Δ6-Desaturase:** Δ6-desaturase is an enzyme which introduces a double bond between carbons 6 and 7 from the carboxyl end of a fatty acid molecule.

**Δ9-Desaturase:** Δ9-desaturase is an enzyme which introduces a double bond between carbons 9 and 10 from the carboxyl end of a fatty acid molecule.

20       **Δ12-Desaturase:** Δ12-desaturase is an enzyme which introduces a double bond between carbons 12 and 13 from the carboxyl end of a fatty acid molecule.

**Fatty Acids:** Fatty acids are a class of compounds containing a long hydrocarbon chain and a terminal carboxylate group. Fatty acids include the following:

Fatty Acid		
12:0	lauric acid	
16:0	palmitic acid	
16:1	palmitoleic acid	

<b>Fatty Acid</b>		
18:0	stearic acid	
18:1	oleic acid	Δ9-18:1
18:2 Δ5,9	taxoleic acid	Δ5,9-18:2
18:2 Δ6,9	6,9-octadecadienoic acid	Δ6,9-18:2
18:2	linoleic acid	Δ9,12-18:2 (LA)
18:3 Δ6,9,12	gamma-linolenic acid	Δ6,9,12-18:3 (GLA)
18:3 Δ5,9,12	pinolenic acid	Δ5,9,12-18:3
18:3	alpha-linolenic acid	Δ9,12,15-18:3 (ALA)
18:4	stearidonic acid	Δ6,9,12,15-18:4 (SDA)
20:0	Arachidic acid	
20:1	Eicoscenic Acid	
22:0	behehic acid	
22:1	erucic acid	
22:2	Docasadienoic acid	
20:4 ω6	arachidonic acid	Δ5,8,11,14-20:4 (ARA)
20:3 ω6	ω6-eicosatrienoic dihomo-gamma linolenic	Δ8,11,14-20:3 (DGLA)
20:5 ω3	Eicosapentanoic (Timnodonic acid)	Δ5,8,11,14,17-20:5 (EPA)
20:3 ω3	ω3-eicosatrienoic	Δ11,16,17-20:3
20:4 ω3	ω3-eicosatetraenoic	Δ8,11,14,17-20:4
22:5 ω3	Docasapentaenoic	Δ7,10,13,16,19-22:5 (ω3DPA)
22:6 ω3	Docosahexaenoic (cervonic acid)	Δ4,7,10,13,16,19-22:6 (DHA)
24:0	Lignoceric acid	

Taking into account these definitions, the present invention is directed to novel DNA sequences, DNA constructs, methods and compositions are provided which permit modification of the poly-unsaturated long chain fatty acid content of, for example, microbial cells or animals. Host cells are manipulated to express a sense or antisense transcript of a DNA encoding a polypeptide(s) which catalyzes the conversion of DGLA to ARA. The substrate(s) for the expressed enzyme may be produced by the host cell or may be exogenously supplied. To achieve expression, the transformed DNA is

operably associated with transcriptional and translational initiation and termination regulatory regions that are functional in the host cell. Constructs comprising the gene to be expressed can provide for integration into the genome of the host cell or can autonomously replicate in the host cell. For production 5 of ARA, the expression cassettes generally used include a cassette which provides for  $\Delta 5$ -desaturase activity, particularly in a host cell which produces or can take up DGLA. Production of  $\omega 6$ -type unsaturated fatty acids, such as ARA, is favored in a host microorganism or animal which is substantially free of ALA. The host is selected or obtained by removing or inhibiting activity of a 10  $\Delta 15$ - or  $\omega 3$ - type desaturase (see Figure 2). The endogenous desaturase activity can be affected by providing an expression cassette for an antisense  $\Delta 15$  or  $\omega 3$  transcript, by disrupting a target  $\Delta 15$ - or  $\omega 3$ -desaturase gene through insertion, substitution and/or deletion of all or part of the target gene, or by adding a  $\Delta 15$ - or  $\omega 3$ -desaturase inhibitor. Production of LA also can be increased by 15 providing expression cassettes for  $\Delta 9$  and/or  $\Delta 12$ -desaturases where their respective enzymatic activities are limiting.

#### MICROBIAL PRODUCTION OF FATTY ACIDS

Microbial production of fatty acids has several advantages over 20 purification from natural sources such as fish or plants. Many microbes are known with greatly simplified oil compositions compared with those of higher organisms, making purification of desired components easier. Microbial production is not subject to fluctuations caused by external variables such as weather and food supply. Microbially produced oil is substantially free of 25 contamination by environmental pollutants. Additionally, microbes can provide PUFAs in particular forms which may have specific uses. For example, *Spirulina* can provide PUFAs predominantly at the first and third positions of triglycerides; digestion by pancreatic lipases preferentially releases fatty acids from these positions. Following human or animal ingestion of triglycerides 30 derived from *Spirulina*, these PUFAs are released by pancreatic lipases as free

fatty acids and thus are directly available, for example, for infant brain development. Additionally, microbial oil production can be manipulated by controlling culture conditions, notably by providing particular substrates for microbially expressed enzymes, or by addition of compounds which suppress undesired biochemical pathways. In addition to these advantages, production of fatty acids from recombinant microbes provides the ability to alter the naturally occurring microbial fatty acid profile by providing new synthetic pathways in the host or by suppressing undesired pathways, thereby increasing levels of desired PUFAs, or conjugated forms thereof, and decreasing levels of undesired PUFAs.

#### **PRODUCTION OF FATTY ACIDS IN ANIMALS**

Production of fatty acids in animals also presents several advantages. Expression of desaturase genes in animals can produce greatly increased levels of desired PUFAs in animal tissues, making recovery from those tissues more economical. For example, where the desired PUFAs are expressed in the breast milk of animals, methods of isolating PUFAs from animal milk are well established. In addition to providing a source for purification of desired PUFAs, animal breast milk can be manipulated through expression of desaturase genes, either alone or in combination with other human genes, to provide animal milks with a PUFA composition substantially similar to human breast milk during the different stages of infant development. Humanized animal milks could serve as infant formulas where human nursing is impossible or undesired, or in cases of malnourishment or disease.

Depending upon the host cell, the availability of substrate, and the desired end product(s), several polypeptides, particularly desaturases, are of interest. By "desaturase" is intended a polypeptide which can desaturate one or more fatty acids to produce a mono- or poly-unsaturated fatty acid or precursor thereof of interest. Of particular interest are polypeptides which can catalyze the conversion of DGLA to produce ARA which includes enzymes which desaturate at the  $\Delta 5$  position. By "polypeptide" is meant any chain of amino acids, regardless of length or post-translational modification, for example,

glycosylation or phosphorylation. Considerations for choosing a specific polypeptide having desaturase activity include the pH optimum of the polypeptide, whether the polypeptide is a rate limiting enzyme or a component thereof, whether the desaturase used is essential for synthesis of a desired poly-  
5 unsaturated fatty acid, and/or co-factors required by the polypeptide. The expressed polypeptide preferably has parameters compatible with the biochemical environment of its location in the host cell. For example, the polypeptide may have to compete for substrate with other enzymes in the host cell. Analyses of the  $K_m$  and specific activity of the polypeptide in question  
10 therefore are considered in determining the suitability of a given polypeptide for modifying PUFA production in a given host cell. The polypeptide used in a particular situation is one which can function under the conditions present in the intended host cell but otherwise can be any polypeptide having desaturase activity which has the desired characteristic of being capable of modifying the  
15 relative production of a desired PUFA.

For production of ARA, the DNA sequence used encodes a polypeptide having  $\Delta 5$ -desaturase activity. In particular instances, this can be coupled with an expression cassette which provides for production of a polypeptide having  $\Delta 6$ -desaturase activity and the host cell can optionally be depleted of any  $\Delta 15$ -desaturase activity present, for example by providing a transcription cassette for production of antisense sequences to the  $\Delta 15$ -desaturase transcription product, by disrupting the  $\Delta 15$ -desaturase gene, or by using a host cell which naturally has, or has been mutated to have, low  $\Delta 15$ -desaturase activity. Inhibition of undesired desaturase pathways also can be accomplished through the use of specific desaturase inhibitors such as those described in U.S. Patent No.  
20 4,778,630. The choice of combination of cassettes used can depend in part on the PUFA profile of the host cell. Where the host cell  $\Delta 5$ -desaturase activity is limiting, overexpression of  $\Delta 5$ -desaturase alone generally will be sufficient to provide for enhanced ARA production in the presence of an appropriate  
25 substrate such as DGLA. ARA production also can be increased by providing expression cassettes for  $\Delta 9$ - or  $\Delta 12$ -desaturase genes when the activities of  
30

those desaturases are limiting. A scheme for the synthesis of arachidonic acid (20:4  $\Delta^{5, 8, 11, 14}$ ) from palmitic acid (C<sub>16</sub>) is shown in Figure 1. A key enzyme in this pathway is a  $\Delta 5$ -desaturase which converts DH- $\gamma$ -linolenic acid (DGLA, eicosatrienoic acid) to ARA. Conversion of  $\alpha$ -linolenic acid (ALA) to 5 stearidonic acid by a  $\Delta 6$ -desaturase is also shown. Production of PUFAs in addition to ARA, including EPA and DHA is shown in Figure 2.

### SOURCES OF POLYPEPTIDES HAVING DESATURASE ACTIVITY

A source of polypeptides having desaturase activity and oligonucleotides encoding such polypeptides are organisms which produce a desired poly-unsaturated fatty acid. As an example, microorganisms having an ability to produce ARA can be used as a source of  $\Delta 5$ -desaturase activity. Such microorganisms include, for example, those belonging to the genera *Mortierella*, *Conidiobolus*, *Pythium*, *Phytophthora*, *Penicillium*, *Porphyridium*, *Coidosporium*, *Mucor*, *Fusarium*, *Aspergillus*, *Rhodotorula*, and *Entomophthora*. Within the genus *Porphyridium*, of particular interest is *Porphyridium cruentum*. Within the genus *Mortierella*, of particular interest are *Mortierella elongata*, *Mortierella exigua*, *Mortierella hygrophila*, *Mortierella ramanniana*, var. *angulispora*, and *Mortierella alpina*. Within the genus *Mucor*, of particular interest are *Mucor circinelloides* and *Mucor javanicus*.

DNAs encoding desired desaturases can be identified in a variety of ways. As an example, a source of the desired desaturase, for example genomic or cDNA libraries from *Mortierella*, is screened with detectable enzymatically- or chemically-synthesized probes, which can be made from DNA, RNA, or non-naturally occurring nucleotides, or mixtures thereof. Probes may be enzymatically synthesized from DNAs of known desaturases for normal or reduced-stringency hybridization methods. Oligonucleotide probes also can be used to screen sources and can be based on sequences of known desaturases, including sequences conserved among known desaturases, or on peptide sequences obtained from the desired purified protein. Oligonucleotide probes based on amino acid sequences can be degenerate to encompass the degeneracy

of the genetic code, or can be biased in favor of the preferred codons of the source organism. Oligonucleotides also can be used as primers for PCR from reverse transcribed mRNA from a known or suspected source; the PCR product can be the full length cDNA or can be used to generate a probe to obtain the  
5 desired full length cDNA. Alternatively, a desired protein can be entirely sequenced and total synthesis of a DNA encoding that polypeptide performed.

Once the desired genomic or cDNA has been isolated, it can be sequenced by known methods. It is recognized in the art that such methods are subject to errors, such that multiple sequencing of the same region is routine and  
10 is still expected to lead to measurable rates of mistakes in the resulting deduced sequence, particularly in regions having repeated domains, extensive secondary structure, or unusual base compositions, such as regions with high GC base content. When discrepancies arise, resequencing can be done and can employ special methods. Special methods can include altering sequencing conditions  
15 by using: different temperatures; different enzymes; proteins which alter the ability of oligonucleotides to form higher order structures; altered nucleotides such as ITP or methylated dGTP; different gel compositions, for example adding formamide; different primers or primers located at different distances from the problem region; or different templates such as single stranded DNAs.  
20 Sequencing of mRNA also can be employed.

For the most part, some or all of the coding sequence for the polypeptide having desaturase activity is from a natural source. In some situations, however, it is desirable to modify all or a portion of the codons, for example, to enhance expression, by employing host preferred codons. Host preferred  
25 codons can be determined from the codons of highest frequency in the proteins expressed in the largest amount in a particular host species of interest. Thus, the coding sequence for a polypeptide having desaturase activity can be synthesized in whole or in part. All or portions of the DNA also can be synthesized to remove any destabilizing sequences or regions of secondary  
30 structure which would be present in the transcribed mRNA. All or portions of the DNA also can be synthesized to alter the base composition to one more

preferable in the desired host cell. Methods for synthesizing sequences and bringing sequences together are well established in the literature. *In vitro* mutagenesis and selection, site-directed mutagenesis, or other means can be employed to obtain mutations of naturally occurring desaturase genes to 5 produce a polypeptide having desaturase activity *in vivo* with more desirable physical and kinetic parameters for function in the host cell, such as a longer half-life or a higher rate of production of a desired polyunsaturated fatty acid.

**Mortierella alpina Desaturase**

Of particular interest is the *Mortierella alpina*  $\Delta 5$ -desaturase which has 10 446 amino acids; the amino acid sequence is shown in Figure 3. The gene encoding the *Mortierella alpina*  $\Delta 5$ -desaturase can be expressed in transgenic microorganisms or animals to effect greater synthesis of ARA from DGLA. Other DNAs which are substantially identical to the *Mortierella alpina*  $\Delta 5$ -desaturase DNA, or which encode polypeptides which are substantially identical 15 to the *Mortierella alpina*  $\Delta 5$ -desaturase polypeptide, also can be used. By substantially identical is intended an amino acid sequence or nucleic acid sequence exhibiting in order of increasing preference at least 60%, 80%, 90% or 95% homology to the *Mortierella alpina*  $\Delta 5$ -desaturase amino acid sequence or nucleic acid sequence encoding the amino acid sequence. For polypeptides, the 20 length of comparison sequences generally is at least 16 amino acids, preferably at least 20 amino acids, or most preferably 35 amino acids. For nucleic acids, the length of comparison sequences generally is at least 50 nucleotides, preferably at least 60 nucleotides, and more preferably at least 75 nucleotides, and most preferably, 110 nucleotides. Homology typically is measured using 25 sequence analysis software, for example, the Sequence Analysis software package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, Wisconsin 53705, MEGAlign (DNAStar, Inc., 1228 S. Park St., Madison, Wisconsin 53715), and MacVector (Oxford Molecular Group, 2105 S. Bascom Avenue, Suite 200, 30 Campbell, California 95008). Such software matches similar sequences by

assigning degrees of homology to various substitutions, deletions, and other modifications. Conservative substitutions typically include substitutions within the following groups: glycine and alanine; valine, isoleucine and leucine; aspartic acid, glutamic acid, asparagine, and glutamine; serine and threonine; 5 lysine and arginine; and phenylalanine and tyrosine. Substitutions may also be made on the basis of conserved hydrophobicity or hydrophilicity (Kyte and Doolittle, *J. Mol. Biol.* 157: 105-132, 1982), or on the basis of the ability to assume similar polypeptide secondary structure (Chou and Fasman, *Adv. Enzymol.* 47: 45-148, 1978).

10

Other Desaturases

Encompassed by the present invention are related desaturases from the same or other organisms. Such related desaturases include variants of the disclosed Δ5-desaturase naturally occurring within the same or different species of *Mortierella*, as well as homologues of the disclosed Δ5-desaturase from other 15 species. Also included are desaturases which, although not substantially identical to the *Mortierella alpina* Δ5-desaturase, desaturate a fatty acid molecule at carbon 5 from the carboxyl end of a fatty acid molecule. Related desaturases can be identified by their ability to function substantially the same as the disclosed desaturases; that is, are still able to effectively convert DGLA 20 to ARA. Related desaturases also can be identified by screening sequence databases for sequences homologous to the disclosed desaturase, by hybridization of a probe based on the disclosed desaturase to a library constructed from the source organism, or by RT-PCR using mRNA from the source organism and primers based on the disclosed desaturase. Such 25 desaturases include those from humans, *Dictyostelium discoideum* and *Phaeodactylum tricornutum*.

The regions of a desaturase polypeptide important for desaturase activity can be determined through routine mutagenesis, expression of the resulting 30 mutant polypeptides and determination of their activities. Mutants may include deletions, insertions and point mutations, or combinations thereof. A typical

functional analysis begins with deletion mutagenesis to determine the N- and C-terminal limits of the protein necessary for function, and then internal deletions, insertions or point mutants are made to further determine regions necessary for function. Other techniques such as cassette mutagenesis or total synthesis also  
5 can be used. Deletion mutagenesis is accomplished, for example, by using exonucleases to sequentially remove the 5' or 3' coding regions. Kits are available for such techniques. After deletion, the coding region is completed by ligating oligonucleotides containing start or stop codons to the deleted coding region after 5' or 3' deletion, respectively. Alternatively, oligonucleotides  
10 encoding start or stop codons are inserted into the coding region by a variety of methods including site-directed mutagenesis, mutagenic PCR or by ligation onto DNA digested at existing restriction sites. Internal deletions can similarly be made through a variety of methods including the use of existing restriction sites in the DNA, by use of mutagenic primers via site directed mutagenesis or  
15 mutagenic PCR. Insertions are made through methods such as linker-scanning mutagenesis, site-directed mutagenesis or mutagenic PCR. Point mutations are made through techniques such as site-directed mutagenesis or mutagenic PCR.

Chemical mutagenesis also can be used for identifying regions of a desaturase polypeptide important for activity. A mutated construct is expressed,  
20 and the ability of the resulting altered protein to function as a desaturase is assayed. Such structure-function analysis can determine which regions may be deleted, which regions tolerate insertions, and which point mutations allow the mutant protein to function in substantially the same way as the native desaturase. All such mutant proteins and nucleotide sequences encoding them  
25 are within the scope of the present invention.

#### EXPRESSION OF DESATURASE GENES

Once the DNA encoding a desaturase polypeptide has been obtained, it is placed in a vector capable of replication in a host cell, or is propagated *in vitro* by means of techniques such as PCR or long PCR. Replicating vectors  
30 can include plasmids, phage, viruses, cosmids and the like. Desirable vectors include those useful for mutagenesis of the gene of interest or for expression of

the gene of interest in host cells. The technique of long PCR has made *in vitro* propagation of large constructs possible, so that modifications to the gene of interest, such as mutagenesis or addition of expression signals, and propagation of the resulting constructs can occur entirely *in vitro* without the use of a 5 replicating vector or a host cell.

For expression of a desaturase polypeptide, functional transcriptional and translational initiation and termination regions are operably linked to the DNA encoding the desaturase polypeptide. Expression of the polypeptide coding region can take place *in vitro* or in a host cell. Transcriptional and 10 translational initiation and termination regions are derived from a variety of nonexclusive sources, including the DNA to be expressed, genes known or suspected to be capable of expression in the desired system, expression vectors, chemical synthesis, or from an endogenous locus in a host cell.

#### Expression In Vitro

15        *In vitro* expression can be accomplished, for example, by placing the coding region for the desaturase polypeptide in an expression vector designed for *in vitro* use and adding rabbit reticulocyte lysate and cofactors; labeled amino acids can be incorporated if desired. Such *in vitro* expression vectors may provide some or all of the expression signals necessary in the system used. 20 These methods are well known in the art and the components of the system are commercially available. The reaction mixture can then be assayed directly for the polypeptide, for example by determining its activity, or the synthesized polypeptide can be purified and then assayed.

#### Expression In A Host Cell

25        Expression in a host cell can be accomplished in a transient or stable fashion. Transient expression can occur from introduced constructs which contain expression signals functional in the host cell, but which constructs do not replicate and rarely integrate in the host cell, or where the host cell is not proliferating. Transient expression also can be accomplished by inducing the

activity of a regulatable promoter operably linked to the gene of interest, although such inducible systems frequently exhibit a low basal level of expression. Stable expression can be achieved by introduction of a construct that can integrate into the host genome or that autonomously replicates in the host cell. Stable expression of the gene of interest can be selected for through the use of a selectable marker located on or transfected with the expression construct, followed by selection for cells expressing the marker. When stable expression results from integration, integration of constructs can occur randomly within the host genome or can be targeted through the use of constructs containing regions of homology with the host genome sufficient to target recombination with the host locus. Where constructs are targeted to an endogenous locus, all or some of the transcriptional and translational regulatory regions can be provided by the endogenous locus.

When increased expression of the desaturase polypeptide in the source organism is desired, several methods can be employed. Additional genes encoding the desaturase polypeptide can be introduced into the host organism. Expression from the native desaturase locus also can be increased through homologous recombination, for example by inserting a stronger promoter into the host genome to cause increased expression, by removing destabilizing sequences from either the mRNA or the encoded protein by deleting that information from the host genome, or by adding stabilizing sequences to the mRNA (USPN 4,910,141).

When it is desirable to express more than one different gene, appropriate regulatory regions and expression methods, introduced genes can be propagated in the host cell through use of replicating vectors or by integration into the host genome. Where two or more genes are expressed from separate replicating vectors, it is desirable that each vector has a different means of replication. Each introduced construct, whether integrated or not, should have a different means of selection and should lack homology to the other constructs to maintain stable expression and prevent reassortment of elements among constructs. Judicious choices of regulatory regions, selection means and method of

propagation of the introduced construct can be experimentally determined so that all introduced genes are expressed at the necessary levels to provide for synthesis of the desired products.

As an example, where the host cell is a yeast, transcriptional and  
5 translational regions functional in yeast cells are provided, particularly from the host species. The transcriptional initiation regulatory regions can be obtained, for example from genes in the glycolytic pathway, such as alcohol dehydrogenase, glyceraldehyde-3-phosphate dehydrogenase (GPD), phosphoglucoisomerase, phosphoglycerate kinase, etc. or regulatable genes  
10 such as acid phosphatase, lactase, metallothionein, glucoamylase, etc. Any one of a number of regulatory sequences can be used in a particular situation, depending upon whether constitutive or induced transcription is desired, the particular efficiency of the promoter in conjunction with the open-reading frame of interest, the ability to join a strong promoter with a control region from a  
15 different promoter which allows for inducible transcription, ease of construction, and the like. Of particular interest are promoters which are activated in the presence of galactose. Galactose-inducible promoters (GAL1, GAL7, and GAL10) have been extensively utilized for high level and regulated expression of protein in yeast (Lue *et al.*, *Mol. Cell. Biol.* Vol. 7, p. 3446, 1987; Johnston, *Microbiol. Rev.* Vol. 51, p. 458, 1987). Transcription from the GAL promoters is activated by the GAL4 protein, which binds to the promoter region and activates transcription when galactose is present. In the absence of galactose, the antagonist GAL80 binds to GAL4 and prevents GAL4 from activating transcription. Addition of galactose prevents GAL80 from inhibiting  
20 activation by GAL4.  
25

Nucleotide sequences surrounding the translational initiation codon ATG have been found to affect expression in yeast cells. If the desired polypeptide is poorly expressed in yeast, the nucleotide sequences of exogenous genes can be modified to include an efficient yeast translation initiation  
30 sequence to obtain optimal gene expression. For expression in *Saccharomyces*, this can be done by site-directed mutagenesis of an inefficiently expressed gene

by fusing it in-frame to an endogenous *Saccharomyces* gene, preferably a highly expressed gene, such as the lactase gene.

The termination region can be derived from the 3' region of the gene from which the initiation region was obtained or from a different gene. A large number of termination regions are known to and have been found to be satisfactory in a variety of hosts from the same and different genera and species. The termination region usually is selected more as a matter of convenience rather than because of any particular property. Preferably, the termination region is derived from a yeast gene, particularly *Saccharomyces*, *Schizosaccharomyces*, *Candida* or *Kluyveromyces*. The 3' regions of two mammalian genes,  $\gamma$  interferon and  $\alpha$ 2 interferon, are also known to function in yeast.

#### INTRODUCTION OF CONSTRUCTS INTO HOST CELLS

Constructs comprising the gene of interest may be introduced into a host cell by standard techniques. These techniques include transformation, protoplast fusion, lipofection, transfection, transduction, conjugation, infection, ballistic impact, electroporation, microinjection, scraping, or any other method which introduces the gene of interest into the host cell. Methods of transformation which are used include lithium acetate transformation (*Methods in Enzymology*, Vol. 194, p. 186-187, 1991). For convenience, a host cell which has been manipulated by any method to take up a DNA sequence or construct will be referred to as "transformed" or "recombinant" herein.

The subject host will have at least have one copy of the expression construct and may have two or more, depending upon whether the gene is integrated into the genome, amplified, or is present on an extrachromosomal element having multiple copy numbers. Where the subject host is a yeast, four principal types of yeast plasmid vectors can be used: Yeast Integrating plasmids (YIps), Yeast Replicating plasmids (YRps), Yeast Centromere plasmids (YCps), and Yeast Episomal plasmids (YEps). YIps lack a yeast replication origin and must be propagated as integrated elements in the yeast genome. YRps have a chromosomally derived autonomously replicating sequence and

are propagated as medium copy number (20 to 40), autonomously replicating, unstably segregating plasmids. YCps have both a replication origin and a centromere sequence and propagate as low copy number (10-20), autonomously replicating, stably segregating plasmids. YEps have an origin of replication 5 from the yeast 2 $\mu$ m plasmid and are propagated as high copy number, autonomously replicating, irregularly segregating plasmids. The presence of the plasmids in yeast can be ensured by maintaining selection for a marker on the plasmid. Of particular interest are the yeast vectors pYES2 (a YEplasmid available from Invitrogen, confers uracil prototrophy and a GAL1 galactose-inducible promoter for expression), pRS425-pG1 (a YEplasmid obtained from Dr. T. H. Chang, Ass. Professor of Molecular Genetics, Ohio State University, containing a constitutive GPD promoter and conferring leucine prototrophy), and pYX424 (a YEplasmid having a constitutive TP1 promoter and conferring leucine prototrophy; Alber, T. and Kawasaki, G. (1982). *J. Mol. & Appl. 10 Genetics* 1: 419).

The transformed host cell can be identified by selection for a marker contained on the introduced construct. Alternatively, a separate marker construct may be introduced with the desired construct, as many transformation techniques introduce many DNA molecules into host cells. Typically, 15 transformed hosts are selected for their ability to grow on selective media. Selective media may incorporate an antibiotic or lack a factor necessary for growth of the untransformed host, such as a nutrient or growth factor. An introduced marker gene therefor may confer antibiotic resistance, or encode an essential growth factor or enzyme, and permit growth on selective media when 20 expressed in the transformed host. Selection of a transformed host also can occur when the expressed marker protein can be detected, either directly or indirectly. The marker protein may be expressed alone or as a fusion to another protein. The marker protein can be detected by its enzymatic activity; for example  $\beta$  galactosidase can convert the substrate X-gal to a colored product, 25 and luciferase can convert luciferin to a light-emitting product. The marker protein can be detected by its light-producing or modifying characteristics; for 30

example, the green fluorescent protein of *Aequorea victoria* fluoresces when illuminated with blue light. Antibodies can be used to detect the marker protein or a molecular tag on, for example, a protein of interest. Cells expressing the marker protein or tag can be selected, for example, visually, or 5 by techniques such as FACS or panning using antibodies. For selection of yeast transformants, any marker that functions in yeast may be used. Desirably, resistance to kanamycin and the amino glycoside G418 are of interest, as well as ability to grow on media lacking uracil, leucine, lysine or tryptophan.

The  $\Delta 5$ -desaturase-mediated production of PUFAs can be performed in 10 either prokaryotic or eukaryotic host cells. Prokaryotic cells of interest include *Escherichia*, *Bacillus*, *Lactobacillus*, *cyanobacteria* and the like. Eukaryotic cells include mammalian cells such as those of lactating animals, avian cells such as of chickens, and other cells amenable to genetic manipulation including insect, fungal, and algae cells. The cells may be cultured or formed as part or 15 all of a host organism including an animal. Viruses and bacteriophage also may be used with the cells in the production of PUFAs, particularly for gene transfer, cellular targeting and selection. In a preferred embodiment, the host is any microorganism or animal which produces DGLA and/or can assimilate exogenously supplied DGLA, and preferably produces large amounts of DGLA. 20 Examples of host animals include mice, rats, rabbits, chickens, quail, turkeys, bovines, sheep, pigs, goats, yaks, etc., which are amenable to genetic manipulation and cloning for rapid expansion of the transgene expressing population. For animals, a  $\Delta 5$ -desaturase transgene can be adapted for expression in target organelles, tissues and body fluids through modification of 25 the gene regulatory regions. Of particular interest is the production of PUFAs in the breast milk of the host animal.

#### Expression In Yeast

Examples of host microorganisms include *Saccharomyces cerevisiae*, *Saccharomyces carlsbergensis*, or other yeast such as *Candida*, *Kluyveromyces* 30 or other fungi, for example, filamentous fungi such as *Aspergillus*, *Neurospora*,

*Penicillium*, etc. Desirable characteristics of a host microorganism are, for example, that it is genetically well characterized, can be used for high level expression of the product using ultra-high density fermentation, and is on the GRAS (generally recognized as safe) list since the proposed end product is

5 intended for ingestion by humans. Of particular interest is use of a yeast, more particularly baker's yeast (*S. cerevisiae*), as a cell host in the subject invention. Strains of particular interest are SC334 (Mat  $\alpha$  pep4-3 prbl-1122 ura3-52 leu2-3, 112 regl-501 gal1; *Gene* 83:57-64, 1989, Hovland P. et al.), YTC34 ( $\alpha$  ade2-101 his3 $\Delta$ 200 lys2-801 ura3-52; obtained from Dr. T. H. Chang, Ass. Professor

10 of Molecular Genetics, Ohio State University), YTC41 (a/ $\alpha$  ura3-52/ura3=52 lys2-801/lys2-801 ade2-101/ade2-101 trp1- $\Delta$ 1/trp1- $\Delta$ 1 his3 $\Delta$ 200/his3 $\Delta$ 200 leu2 $\Delta$ 1/leu2 $\Delta$ 1; obtained from Dr. T. H. Chang, Ass. Professor of Molecular Genetics, Ohio State University), BJ1995 (obtained from the Yeast Genetic Stock Centre, 1021 Donner Laboratory, Berkeley, CA 94720), INVSC1 (Mat  $\alpha$

15 hiw3 $\Delta$ 1 leu2 trp1-289 ura3-52; obtained from Invitrogen, 1600 Faraday Ave., Carlsbad, CA 92008) and INVSC2 (Mat  $\alpha$  his3 $\Delta$ 200 ura3-167; obtained from Invitrogen).

#### Expression In Avian Species

For producing PUFAs in avian species and cells, such as chickens,  
20 turkeys, quail and ducks, gene transfer can be performed by introducing a nucleic acid sequence encoding a  $\Delta$ 5-desaturase into the cells following procedures known in the art. If a transgenic animal is desired, pluripotent stem cells of embryos can be provided with a vector carrying a  $\Delta$ 5-desaturase encoding transgene and developed into adult animal (USPN 5,162,215; Ono et  
25 al. (1996) *Comparative Biochemistry and Physiology A* 113(3):287-292; WO 9612793; WO 9606160). In most cases, the transgene will be modified to express high levels of the desaturase in order to increase production of PUFAs. The transgene can be modified, for example, by providing transcriptional and/or translational regulatory regions that function in avian cells, such as promoters  
30 which direct expression in particular tissues and egg parts such as yolk. The

gene regulatory regions can be obtained from a variety of sources, including chicken anemia or avian leukosis viruses or avian genes such as a chicken ovalbumin gene.

#### Expression In Insect Cells

- 5 Production of PUFA's in insect cells can be conducted using baculovirus expression vectors harboring a Δ5-desaturase transgene. Baculovirus expression vectors are available from several commercial sources such as Clonetech. Methods for producing hybrid and transgenic strains of algae, such as marine algae, which contain and express a desaturase transgene also are  
10 provided. For example, transgenic marine algae may be prepared as described in USPN 5,426,040. As with the other expression systems described above, the timing, extent of expression and activity of the desaturase transgene can be regulated by fitting the polypeptide coding sequence with the appropriate transcriptional and translational regulatory regions selected for a particular use.  
15 Of particular interest are promoter regions which can be induced under preselected growth conditions. For example, introduction of temperature sensitive and/or metabolite responsive mutations into the desaturase transgene coding sequences, its regulatory regions, and/or the genome of cells into which the transgene is introduced can be used for this purpose.

20 Expression In Plants

- Production of PUFA's in plants can be conducted using various plant transformation systems such as the use of *Agrobacterium tumefaciens*, plant viruses, particle cell transformation and the like which are disclosed in Applicant's related applications U.S. Application Serial Nos. 08/834,033 and  
25 08/956,985 and continuation-in-part applications filed simultaneously with this application all of which are hereby incorporated by reference.

The transformed host cell is grown under appropriate conditions adapted for a desired end result. For host cells grown in culture, the conditions are

typically optimized to produce the greatest or most economical yield of PUFAs, which relates to the selected desaturase activity. Media conditions which may be optimized include: carbon source, nitrogen source, addition of substrate, final concentration of added substrate, form of substrate added, aerobic or 5 anaerobic growth, growth temperature, inducing agent, induction temperature, growth phase at induction, growth phase at harvest, pH, density, and maintenance of selection. Microorganisms such as yeast, for example, are preferably grown using selected media of interest, which include yeast peptone broth (YPD) and minimal media (contains amino acids, yeast nitrogen base, and 10 ammonium sulfate, and lacks a component for selection, for example uracil). Desirably, substrates to be added are first dissolved in ethanol. Where necessary, expression of the polypeptide of interest may be induced, for example by including or adding galactose to induce expression from a GAL promoter.

15

Expression In An Animal

Expression in cells of a host animal can likewise be accomplished in a transient or stable manner. Transient expression can be accomplished via known methods, for example infection or lipofection, and can be repeated in order to maintain desired expression levels of the introduced construct (*see* Ebert, PCT 20 publication WO 94/05782). Stable expression can be accomplished via integration of a construct into the host genome, resulting in a transgenic animal. The construct can be introduced, for example, by microinjection of the construct into the pronuclei of a fertilized egg, or by transfection, retroviral infection or other techniques whereby the construct is introduced into a cell line which may 25 form or be incorporated into an adult animal (U.S. Patent No. 4,873,191; U.S. Patent No. 5,530,177; U.S. Patent No. 5,565,362; U.S. Patent No. 5,366,894; Wilmut *et al.* (1997) *Nature* 385:810). The recombinant eggs or embryos are transferred to a surrogate mother (U.S. Patent No. 4,873,191; U.S. Patent No. 30 5,530,177; U.S. Patent No. 5,565,362; U.S. Patent No. 5,366,894; Wilmut *et al.* (supra)).

After birth, transgenic animals are identified, for example, by the presence of an introduced marker gene, such as for coat color, or by PCR or Southern blotting from a blood, milk or tissue sample to detect the introduced construct, or by an immunological or enzymological assay to detect the expressed protein or the products produced therefrom (U.S. Patent No. 4,873,191; U.S. Patent No. 5,530,177; U.S. Patent No. 5,565,362; U.S. Patent No. 5,366,894; Wilmut *et al.* (*supra*)). The resulting transgenic animals may be entirely transgenic or may be mosaics, having the transgenes in only a subset of their cells. The advent of mammalian cloning, accomplished by fusing a nucleated cell with an enucleated egg, followed by transfer into a surrogate mother, presents the possibility of rapid, large-scale production upon obtaining a "founder" animal or cell comprising the introduced construct; prior to this, it was necessary for the transgene to be present in the germ line of the animal for propagation (Wilmut *et al.* (*supra*)).

Expression in a host animal presents certain efficiencies, particularly where the host is a domesticated animal. For production of PUFAs in a fluid readily obtainable from the host animal, such as milk, the desaturase transgene can be expressed in mammary cells from a female host, and the PUFA content of the host cells altered. The desaturase transgene can be adapted for expression so that it is retained in the mammary cells, or secreted into milk, to form the PUFA reaction products localized to the milk (PCT publication WO 95/24488). Expression can be targeted for expression in mammary tissue using specific regulatory sequences, such as those of bovine  $\alpha$ -lactalbumin,  $\alpha$ -casein,  $\beta$ -casein,  $\gamma$ -casein,  $\kappa$ -casein,  $\beta$ -lactoglobulin, or whey acidic protein, and may optionally include one or more introns and/or secretory signal sequences (U.S. Patent No. 5,530,177; Rosen, U.S. Patent No. 5,565,362; Clark *et al.*, U.S. Patent No. 5,366,894; Garner *et al.*, PCT publication WO 95/23868). Expression of desaturase transgenes, or antisense desaturase transcripts, adapted in this manner can be used to alter the levels of specific PUFAs, or derivatives thereof, found in the animals milk. Additionally, the  $\Delta 5$ -desaturase transgene can be expressed either by itself or with other transgenes, in order to produce

animal milk containing higher proportions of desired PUFAs or PUFA ratios and concentrations that resemble human breast milk (Prieto *et al.*, PCT publication WO 95/24494).

#### PURIFICATION OF FATTY ACIDS

- 5       The fatty acids desaturated in the Δ5 position may be found in the host microorganism or animal as free fatty acids or in conjugated forms such as acylglycerols, phospholipids, sulfolipids or glycolipids, and may be extracted from the host cell through a variety of means well-known in the art. Such means may include extraction with organic solvents, sonication, supercritical fluid extraction using for example carbon dioxide, and physical means such as presses, or combinations thereof. Of particular interest is extraction with methanol and chloroform. Where desirable, the aqueous layer can be acidified to protonate negatively charged moieties and thereby increase partitioning of desired products into the organic layer. After extraction, the organic solvents
- 10      can be removed by evaporation under a stream of nitrogen. When isolated in conjugated forms, the products may be enzymatically or chemically cleaved to release the free fatty acid or a less complex conjugate of interest, and can then be subject to further manipulations to produce a desired end product. Desirably, conjugated forms of fatty acids are cleaved with potassium hydroxide.
- 15      If further purification is necessary, standard methods can be employed. Such methods may include extraction, treatment with urea, fractional crystallization, HPLC, fractional distillation, silica gel chromatography, high speed centrifugation or distillation, or combinations of these techniques. Protection of reactive groups, such as the acid or alkenyl groups, may be done at
- 20      any step through known techniques, for example alkylation or iodination. Methods used include methylation of the fatty acids to produce methyl esters. Similarly, protecting groups may be removed at any step. Desirably, purification of fractions containing ARA, DHA and EPA may be accomplished by treatment with urea and/or fractional distillation.

## USES OF FATTY ACIDS

There are several uses for fatty acids of the subject invention. Probes based on the DNAs of the present invention may find use in methods for isolating related molecules or in methods to detect organisms expressing desaturases. When used as probes, the DNAs or oligonucleotides must be detectable. This is usually accomplished by attaching a label either at an internal site, for example via incorporation of a modified residue, or at the 5' or 3' terminus. Such labels can be directly detectable, can bind to a secondary molecule that is detectably labeled, or can bind to an unlabelled secondary molecule and a detectably labeled tertiary molecule; this process can be extended as long as is practical to achieve a satisfactorily detectable signal without unacceptable levels of background signal. Secondary, tertiary, or bridging systems can include use of antibodies directed against any other molecule, including labels or other antibodies, or can involve any molecules which bind to each other, for example a biotin-streptavidin/avidin system. Detectable labels typically include radioactive isotopes, molecules which chemically or enzymatically produce or alter light, enzymes which produce detectable reaction products, magnetic molecules, fluorescent molecules or molecules whose fluorescence or light-emitting characteristics change upon binding. Examples of labelling methods can be found in USPN 5,011,770. Alternatively, the binding of target molecules can be directly detected by measuring the change in heat of solution on binding of probe to target via isothermal titration calorimetry, or by coating the probe or target on a surface and detecting the change in scattering of light from the surface produced by binding of target or probe, respectively, as may be done with the BIACore system.

PUFAs produced by recombinant means find applications in a wide variety of areas. Supplementation of humans or animals with PUFAs in various forms can result in increased levels not only of the added PUFAs, but of their metabolic progeny as well. For example, where the inherent  $\Delta 5$ -desaturase pathway is dysfunctional in an individual, treatment with ARA can result not

only in increased levels of ARA, but also of downstream products of ARA such as prostaglandins (see Figure 1). Complex regulatory mechanisms can make it desirable to combine various PUFAs, or to add different conjugates of PUFAs, in order to prevent, control or overcome such mechanisms to achieve the  
5 desired levels of specific PUFAs in an individual.

### NUTRITIONAL COMPOSITIONS

The present invention also includes nutritional compositions. Such compositions, for purposes of the present invention, include any food or preparation for human consumption including for enteral or parenteral  
10 consumption, which when taken into the body (a) serve to nourish or build up tissues or supply energy and/or (b) maintain, restore or support adequate nutritional status or metabolic function.

The nutritional composition of the present invention comprises at least one oil or acid produced in accordance with the present invention and may  
15 either be in a solid or liquid form. Additionally, the composition may include edible macronutrients, vitamins and minerals in amounts desired for a particular use. The amount of such ingredients will vary depending on whether the composition is intended for use with normal, healthy infants, children or adults having specialized needs such as those which accompany certain metabolic  
20 conditions (e.g., metabolic disorders).

Examples of macronutrients which may be added to the composition include but are not limited to edible fats, carbohydrates and proteins. Examples of such edible fats include but are not limited to coconut oil, soy oil, and mono- and diglycerides. Examples of such carbohydrates include but are not limited to  
25 glucose, edible lactose and hydrolyzed starch. Additionally, examples of proteins which may be utilized in the nutritional composition of the invention include but are not limited to soy proteins, electrodialysed whey, electrodialysed skim milk, milk whey, or the hydrolysates of these proteins.

With respect to vitamins and minerals, the following may be added to  
30 the nutritional compositions of the present invention: calcium, phosphorus,

potassium, sodium, chloride, magnesium, manganese, iron, copper, zinc, selenium, iodine, and Vitamins A, E, D, C, and the B complex. Other such vitamins and minerals may also be added.

The components utilized in the nutritional compositions of the present invention will of semi-purified or purified origin. By semi-purified or purified is meant a material which has been prepared by purification of a natural material or by synthesis.

Examples of nutritional compositions of the present invention include but are not limited to infant formulas, dietary supplements, and rehydration compositions. Nutritional compositions of particular interest include but are not limited to those utilized for enteral and parenteral supplementation for infants, specialist infant formulae, supplements for the elderly, and supplements for those with gastrointestinal difficulties and/or malabsorption.

#### Nutritional Compositions

A typical nutritional composition of the present invention will contain edible macronutrients, vitamins and minerals in amounts desired for a particular use. The amounts of such ingredients will vary depending on whether the formulation is intended for use with normal, healthy individuals temporarily exposed to stress, or to subjects having specialized needs due to certain chronic or acute disease states (e.g., metabolic disorders). It will be understood by persons skilled in the art that the components utilized in a nutritional formulation of the present invention are of semi-purified or purified origin. By semi-purified or purified is meant a material that has been prepared by purification of a natural material or by synthesis. These techniques are well known in the art (See, e.g., Code of Federal Regulations for Food Ingredients and Food Processing; Recommended Dietary Allowances, 10<sup>th</sup> Ed., National Academy Press, Washington, D.C., 1989).

In a preferred embodiment, a nutritional formulation of the present invention is an enteral nutritional product, more preferably an adult or child

ental nutritional product. Accordingly in a further aspect of the invention, a nutritional formulation is provided that is suitable for feeding adults, who are experiencing stress. The formula comprises, in addition to the PUFAs of the invention; macronutrients, vitamins and minerals in amounts designed to  
5 provide the daily nutritional requirements of adults.

The macronutritional components include edible fats, carbohydrates and proteins. Exemplary edible fats are coconut oil, soy oil, and mono- and diglycerides and the PUFA oils of this invention. Exemplary carbohydrates are glucose, edible lactose and hydrolyzed cornstarch. A typical protein source  
10 would be soy protein, electrodialysed whey or electrodialysed skim milk or milk whey, or the hydrolysates of these proteins, although other protein sources are also available and may be used. These macronutrients would be added in the form of commonly accepted nutritional compounds in amount equivalent to those present in human milk or an energy basis, i.e., on a per calorie basis.

15 Methods for formulating liquid and enteral nutritional formulas are well known in the art and are described in detail in the examples.

The enteral formula can be sterilized and subsequently utilized on a ready-to-feed (RTF) basis or stored in a concentrated liquid or a powder. The powder can be prepared by spray drying the enteral formula prepared as  
20 indicated above, and the formula can be reconstituted by rehydrating the concentrate. Adult and infant nutritional formulas are well known in the art and commercially available (e.g., Similac®, Ensure®, Jevity® and Alimentum® from Ross Products Division, Abbott Laboratories). An oil or acid of the present invention can be added to any of these formulas in the amounts  
25 described below.

The energy density of the nutritional composition when in liquid form, can typically range from about 0.6 Kcal to 3.0 Kcal per ml. When in solid or powdered form, the nutritional supplement can contain from about 1.2 to more than 9 Kcals per gm, preferably 3 to 7 Kcals per gram. In general, the  
30 osmolality of a liquid product should be less than 700 mOsm and more preferably less than 660 mOsm.

The nutritional formula would typically include vitamins and minerals, in addition to the PUFAs of the invention, in order to help the individual ingest the minimum daily requirements for these substances. In addition to the PUFAs listed above, it may also be desirable to supplement the nutritional composition 5 with zinc, copper, and folic acid in addition to antioxidants. It is believed that these substances will also provide a boost to the stressed immune system and thus will provide further benefits to the individual. The presence of zinc, copper or folic acid is optional and is not required in order to gain the beneficial effects on immune suppression. Likewise a pharmaceutical composition can be 10 supplemented with these same substances as well.

In a more preferred embodiment, the nutritional contains, in addition to the antioxidant system and the PUFA component, a source of carbohydrate wherein at least 5 weight % of said carbohydrate is an indigestible oligosaccharide. In yet a more preferred embodiment, the nutritional 15 composition additionally contains protein, taurine and carnitine.

The PUFAs, or derivatives thereof, made by the disclosed method can be used as dietary substitutes, or supplements, particularly infant formulas, for patients undergoing intravenous feeding or for preventing or treating malnutrition. Typically, human breast milk has a fatty acid profile comprising 20 from about 0.15 % to about 0.36 % as DHA, from about 0.03 % to about 0.13 % as EPA, from about 0.30 % to about 0.88 % as ARA, from about 0.22 % to about 0.67 % as DGLA, and from about 0.27 % to about 1.04 % as GLA. Additionally, the predominant triglyceride in human milk has been reported to be 1,3-di-oleoyl-2-palmitoyl, with 2-palmitoyl glycerides reported as better 25 absorbed than 2-oleoyl or 2-linoleoyl glycerides (USPN 4,876,107). Thus, fatty acids such as ARA, DGLA, GLA and/or EPA produced by the invention can be used to alter the composition of infant formulas to better replicate the PUFA composition of human breast milk. In particular, an oil composition for use in a pharmacologic or food supplement, particularly a breast milk substitute or 30 supplement, will preferably comprise one or more of ARA, DGLA and GLA.

More preferably the oil will comprise from about 0.3 to 30% ARA, from about 0.2 to 30% DGLA, and from about 0.2 to about 30% GLA.

- In addition to the concentration, the ratios of ARA, DGLA and GLA can be adapted for a particular given end use. When formulated as a breast milk supplement, or substitute an oil composition which contains two or more of ARA, DGLA and GLA will be provided in a ratio of about 1:19:30 to about 6:1:0.2, respectively. For example, the breast milk of animals can vary in ratios of ARA:DGLA:DGL ranging from 1:19:30 to 6:1:0.2, which includes intermediate ratios which are preferably about 1:1:1, 1:2:1, 1:1:4. When produced together in a host cell, adjusting the rate and percent of conversion of a precursor substrate such as GLA and DGLA to ARA can be used to precisely control the PUFA ratios. For example, a 5% to 10% conversion rate of DGLA to ARA can be used to produce an ARA to DGLA ratio of about 1:19, whereas a conversion rate of about 75% to 80% can be used to produce an ARA to DGLA ratio of about 6:1. Therefore, whether in a cell culture system or in a host animal, regulating the timing, extent and specificity of desaturase expression as described can be used to modulate the PUFA levels and ratios. Depending on the expression system used, e.g., cell culture or an animal expressing oil(s) in its milk, the oils also can be isolated and recombined in the desired concentrations and ratios. Amounts of oils providing these ratios of PUFA can be determined following standard protocols. PUFA<sub>s</sub>, or host cells containing them, also can be used as animal food supplements to alter an animal's tissue or milk fatty acid composition to one more desirable for human or animal consumption.
- For dietary supplementation, the purified PUFA<sub>s</sub>, or derivatives thereof, may be incorporated into cooking oils, fats or margarines formulated so that in normal use the recipient would receive the desired amount. The PUFA<sub>s</sub> may also be incorporated into infant formulas, nutritional supplements or other food products, and may find use as anti-inflammatory or cholesterol lowering agents.

### **Pharmaceutical Compositions**

The present invention also encompasses a pharmaceutical composition comprising one or more of the acids and/or resulting oils produced in accordance with the methods described herein. More specifically, such a 5 pharmaceutical composition may comprise one or more of the acids and/oils as well as a standard, well-known, non-toxic pharmaceutically acceptable carrier, adjuvant or vehicle such as, for example, phosphate buffered saline, water, ethanol, polyols, vegetable oils, a wetting agent or an emulsion such as a water/oil emulsion. The composition may be in either a liquid or solid form.

10 For example, the composition may be in the form of a tablet, capsule, ingestible liquid or powder, injectible, or topical ointment or cream.

Possible routes of administration include, for example, oral, rectal and parenteral. The route of administration will, of course, depend upon the desired effect. For example, if the composition is being utilized to treat rough, dry, or 15 aging skin, to treat injured or burned skin, or to treat skin or hair affected by a disease or condition, it may perhaps be applied topically.

The dosage of the composition to be administered to the patient may be determined by one of ordinary skill in the art and depends upon various factors such as weight of the patient, age of the patient, immune status of the patient, 20 etc.

With respect to form, the composition may be, for example, a solution, a dispersion, a suspension, an emulsion or a sterile powder which is then reconstituted.

Additionally, the composition of the present invention may be utilized 25 for cosmetic purposes. It may be added to pre-existing cosmetic compositions such that a mixture is formed or may be used as a sole composition.

Pharmaceutical compositions may be utilized to administer the PUFA component to an individual. Suitable pharmaceutical compositions may comprise physiologically acceptable sterile aqueous or non-aqueous solutions, 30 dispersions, suspensions or emulsions and sterile powders for reconstitution into

sterile solutions or dispersions for ingestion. Examples of suitable aqueous and non-aqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols (propyleneglycol, polyethyleneglycol, glycerol, and the like), suitable mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters  
5 such as ethyl oleate. Proper fluidity can be maintained, for example, by the maintenance of the required particle size in the case of dispersions and by the use of surfactants. It may also be desirable to include isotonic agents, for example sugars, sodium chloride and the like. Besides such inert diluents, the composition can also include adjuvants, such as wetting agents, emulsifying and  
10 suspending agents, sweetening, flavoring and perfuming agents.

Suspensions, in addition to the active compounds, may contain suspending agents, as for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth or mixtures of  
15 these substances, and the like.

Solid dosage forms such as tablets and capsules can be prepared using techniques well known in the art. For example, PUFA's of the invention can be tableted with conventional tablet bases such as lactose, sucrose, and cornstarch in combination with binders such as acacia, cornstarch or gelatin, disintegrating  
20 agents such as potato starch or alginic acid and a lubricant such as stearic acid or magnesium stearate. Capsules can be prepared by incorporating these excipients into a gelatin capsule along with the antioxidants and the PUFA component. The amount of the antioxidants and PUFA component that should be incorporated into the pharmaceutical formulation should fit within the  
25 guidelines discussed above.

As used in this application, the term "treat" refers to either preventing, or reducing the incidence of, the undesired occurrence. For example, to treat immune suppression refers to either preventing the occurrence of this suppression or reducing the amount of such suppression. The terms "patient" and "individual" are being used interchangeably and both refer to an animal.  
30 The term "animal" as used in this application refers to any warm-blooded

mammal including, but not limited to, dogs, humans, monkeys, and apes. As used in the application the term "about" refers to an amount varying from the stated range or number by a reasonable amount depending upon the context of use. Any numerical number or range specified in the specification should be  
5 considered to be modified by the term about.

"Dose" and "serving" are used interchangeably and refer to the amount of the nutritional or pharmaceutical composition ingested by the patient in a single setting and designed to deliver effective amounts of the antioxidants and the structured triglyceride. As will be readily apparent to those skilled in the  
10 art, a single dose or serving of the liquid nutritional powder should supply the amount of antioxidants and PUFAs discussed above. The amount of the dose or serving should be a volume that a typical adult can consume in one sitting. This amount can vary widely depending upon the age, weight, sex or medical condition of the patient. However as a general guideline, a single serving or  
15 dose of a liquid nutritional produce should be considered as encompassing a volume from 100 to 600 ml, more preferably from 125 to 500 ml and most preferably from 125 to 300 ml.

The PUFAs of the present invention may also be added to food even when supplementation of the diet is not required. For example, the composition  
20 may be added to food of any type including but not limited to margarines, modified butters, cheeses, milk, yogurt, chocolate, candy, snacks, salad oils, cooking oils, cooking fats, meats, fish and beverages.

#### Pharmaceutical Applications

For pharmaceutical use (human or veterinary), the compositions are  
25 generally administered orally but can be administered by any route by which they may be successfully absorbed, e.g., parenterally (i.e. subcutaneously, intramuscularly or intravenously), rectally or vaginally or topically, for example, as a skin ointment or lotion. The PUFAs of the present invention may be administered alone or in combination with a pharmaceutically acceptable  
30 carrier or excipient. Where available, gelatin capsules are the preferred form of oral administration. Dietary supplementation as set forth above also can

provide an oral route of administration. The unsaturated acids of the present invention may be administered in conjugated forms, or as salts, esters, amides or prodrugs of the fatty acids. Any pharmaceutically acceptable salt is encompassed by the present invention; especially preferred are the sodium, 5 potassium or lithium salts. Also encompassed are the N-alkylpolyhydroxamine salts, such as N-methyl glucamine, found in PCT publication WO 96/33155. The preferred esters are the ethyl esters. As solid salts, the PUFAs also can be administered in tablet form. For intravenous administration, the PUFAs or derivatives thereof may be incorporated into commercial formulations such as 10 Intralipids. The typical normal adult plasma fatty acid profile comprises 6.64 to 9.46% of ARA, 1.45 to 3.11% of DGLA, and 0.02 to 0.08% of GLA. These PUFAs or their metabolic precursors can be administered, either alone or in mixtures with other PUFAs, to achieve a normal fatty acid profile in a patient. Where desired, the individual components of formulations may be individually 15 provided in kit form, for single or multiple use. A typical dosage of a particular fatty acid is from 0.1 mg to 20 g, or even 100 g daily, and is preferably from 10 mg to 1, 2, 5 or 10 g daily as required, or molar equivalent amounts of derivative forms thereof. Parenteral nutrition compositions comprising from about 2 to about 30 weight percent fatty acids calculated as triglycerides are 20 encompassed by the present invention; preferred is a composition having from about 1 to about 25 weight percent of the total PUFA composition as GLA (USPN 5,196,198). Other vitamins, and particularly fat-soluble vitamins such as vitamin A, D, E and L-carnitine can optionally be included. Where desired, a preservative such as  $\alpha$  tocopherol may be added, typically at about 0.1% by 25 weight.

Suitable pharmaceutical compositions may comprise physiologically acceptable sterile aqueous or non-aqueous solutions, dispersions, suspensions or emulsions and sterile powders for reconstitution into sterile injectible solutions or dispersions. Examples of suitable aqueous and non-aqueous carriers, 30 diluents, solvents or vehicles include water, ethanol, polyols (propyleneglyol, polyethylenegycol, glycerol, and the like), suitable mixtures thereof, vegetable

oils (such as olive oil) and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for example, by the maintenance of the required particle size in the case of dispersions and by the use of surfactants. It may also be desirable to include isotonic agents, for example sugars, sodium chloride and  
5 the like. Besides such inert diluents, the composition can also include adjuvants, such as wetting agents, emulsifying and suspending agents, sweetening, flavoring and perfuming agents.

Suspensions in addition to the active compounds, may contain suspending agents, as for example, ethoxylated isostearyl alcohols,  
10 polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, or mixtures of these substances and the like.

An especially preferred pharmaceutical composition contains diacetyltauric acid esters of mono- and diglycerides dissolved in an aqueous  
15 medium or solvent. Diacetyltauric acid esters of mono- and diglycerides have an HLB value of about 9-12 and are significantly more hydrophilic than existing antimicrobial lipids that have HLB values of 2-4. Those existing hydrophobic lipids cannot be formulated into aqueous compositions. As disclosed herein, those lipids can now be solubilized into aqueous media in combination with  
20 diacetyltauric acid esters of mono-and diglycerides. In accordance with this embodiment, diacetyltauric acid esters of mono- and diglycerides (e.g., DATEM-C12:0) is melted with other active antimicrobial lipids (e.g., 18:2 and 12:0 monoglycerides) and mixed to obtain a homogeneous mixture. Homogeneity allows for increased antimicrobial activity. The mixture can be  
25 completely dispersed in water. This is not possible without the addition of diacetyltauric acid esters of mono- and diglycerides and premixing with other monoglycerides prior to introduction into water. The aqueous composition can then be admixed under sterile conditions with physiologically acceptable diluents, preservatives, buffers or propellants as may be required to form a spray  
30 or inhalant.

The present invention also encompasses the treatment of numerous disorders with fatty acids. Supplementation with PUFAs of the present invention can be used to treat restenosis after angioplasty. Symptoms of inflammation, rheumatoid arthritis, and asthma and psoriasis can be treated with 5 the PUFAs of the present invention. Evidence indicates that PUFAs may be involved in calcium metabolism, suggesting that PUFAs of the present invention may be used in the treatment or prevention of osteoporosis and of kidney or urinary tract stones.

The PUFAs of the present invention can be used in the treatment of 10 cancer. Malignant cells have been shown to have altered fatty acid compositions; addition of fatty acids has been shown to slow their growth and cause cell death, and to increase their susceptibility to chemotherapeutic agents. GLA has been shown to cause reexpression on cancer cells of the E-cadherin cellular adhesion molecules, loss of which is associated with aggressive 15 metastasis. Clinical testing of intravenous administration of the water soluble lithium salt of GLA to pancreatic cancer patients produced statistically significant increases in their survival. PUFA supplementation may also be useful for treating cachexia associated with cancer.

The PUFAs of the present invention can also be used to treat diabetes 20 (USPN 4,826,877; Horrobin *et al.*, Am. J. Clin. Nutr. Vol. 57 (Suppl.), 732S-737S). Altered fatty acid metabolism and composition has been demonstrated in diabetic animals. These alterations have been suggested to be involved in some of the long-term complications resulting from diabetes, including 25 retinopathy, neuropathy, nephropathy and reproductive system damage. Primrose oil, which contains GLA, has been shown to prevent and reverse diabetic nerve damage.

The PUFAs of the present invention can be used to treat eczema, reduce blood pressure and improve math scores. Essential fatty acid deficiency has been suggested as being involved in eczema, and studies have shown beneficial 30 effects on eczema from treatment with GLA. GLA has also been shown to reduce increases in blood pressure associated with stress, and to improve

performance on arithmetic tests. GLA and DGLA have been shown to inhibit platelet aggregation, cause vasodilation, lower cholesterol levels and inhibit proliferation of vessel wall smooth muscle and fibrous tissue (Brenner *et al.*, Adv. Exp. Med. Biol. Vol. 83, p. 85-101, 1976). Administration of GLA or 5 DGLA, alone or in combination with EPA, has been shown to reduce or prevent gastro-intestinal bleeding and other side effects caused by non-steroidal anti-inflammatory drugs (USPN 4,666,701). GLA and DGLA have also been shown to prevent or treat endometriosis and premenstrual syndrome (USPN 4,758,592) and to treat myalgic encephalomyelitis and chronic fatigue after viral infections 10 (USPN 5,116,871).

Further uses of the PUFAs of this invention include use in treatment of AIDS, multiple sclerosis, acute respiratory syndrome, hypertension and inflammatory skin disorders. The PUFAs of the inventions also can be used for formulas for general health as well as for geriatric treatments.

15 **Veterinary Applications**

It should be noted that the above-described pharmaceutical and nutritional compositions may be utilized in connection with animals, as well as humans, as animals experience many of the same needs and conditions as human. For example, the oil or acids of the present invention may be utilized in 20 animal feed supplements.

The following examples are presented by way of illustration, not of limitation.

**Examples**

Example 1 Isolation of a  $\Delta 5$ -desaturase Nucleotide Sequence from 25 *Mortierella alpina*

Example 2 Expression of *M. alpina*  $\Delta 5$ -desaturase Clones in Baker's Yeast

Example 3 Initial Optimization of Culture Conditions

- Example 4 Distribution of PUFAs in Yeast Lipid Fractions
- Example 5 Further Culture Optimization
- Example 6 Identification of Homologues to *M. alpina* Δ5 and Δ6 desaturases
- 5 Example 7 Identification of *M. alpina* Δ5 and Δ6 homologues in other PUFA-producing organisms
- Example 8 Identification of *M. alpina* Δ5 and Δ6 homologues in other PUFA-producing organisms
- Example 9 Human Desaturase Sequences
- 10 Example 10 Nutritional Compositions

#### Example 1

##### Isolation of a Δ5-desaturase Nucleotide Sequence from *Mortierella alpina*

*Motierella alpina* produces arachidonic acid (ARA, 20:4) from the precursor 20:3 by a Δ5-desaturase. A nucleotide sequence encoding the Δ5-desaturase from *Motierella alpina* was obtained through PCR amplification using *M. alpina* 1<sup>st</sup> strand cDNA and degenerate oligonucleotide primers corresponding to amino acid sequences conserved between Δ6-desaturases from *Synechocystis* and *Spirulina*. The procedure used was as follows:

- Total RNA was isolated from a 3-day old PUFA-producing culture of  
20 *Motierella alpina* using the protocol of Hoge *et al.* (1982) *Experimental Mycology* 6:225-232. The RNA was used to prepare double-stranded cDNA using BRL's lambda-ZipLox system, following the manufacturer's instructions. Several size fractions of the *M. alpina* cDNA were packaged separately to yield libraries with different average-sized inserts. The "full-length" library contains  
25 approximately  $3 \times 10^6$  clones with an average insert size of 1.77 kb. The "sequencing-grade" library contains approximately  $6 \times 10^5$  clones with an average insert size of 1.1 kb.

5 $\mu$ g of total RNA was reverse transcribed using BRL Superscript RTase and the primer TSyn (5'-CCAAGCTTCTGCAGGAGCTTTTTTT TTTTTTTT-3'), SEQ ID NO:10. Degenerate oligonucleotides were designed to regions conserved between the two cyanobacterial  $\Delta$ 6-desaturase sequences.

- 5 The specific primers used were D6DESAT-F3 (SEQ ID NO:8) (5'-CUACUACUACUACAYCAYACOTAYACOAAAYAT-3') and D6DESAT-R3 (SEQ ID NO:9) (5'-CAUCAUCAUCAUOGGRAAOARRTGRTG-3'), where Y=C+T, R=A+G, and O=I+C. PCR amplification was carried out in a 25 $\mu$ l volume containing: template derived from 40 ng total RNA, 2 pM each primer,
- 10 200  $\mu$ M each deoxyribonucleotide triphosphate, 60 mM Tris-Cl, pH 8.5, 15 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, 2 mM MgCl<sub>2</sub>. Samples were subjected to an initial denaturation step of 95 degrees (all temperatures Celsius) for 5 minutes, then held at 72 degrees while 0.2 U of Taq polymerase were added. PCR thermocycling conditions were as follows: 94 degrees for 1 min., 45 degrees for 1.5 min., 72
- 15 degrees for 2 min. PCR was continued for 35 cycles. PCR using these primers on the *M. alpina* first-strand cDNA produced a 550 bp reaction product. Comparison of the deduced amino acid sequence of the *M. alpina* PCR fragment SEQ ID NO:3 revealed regions of homology with  $\Delta$ 6-desaturases (*see* Figure 5). However, there was only about 28% identity over the region
- 20 compared.

The PCR product was used as a probe to isolate corresponding cDNA clones from a *M. alpina* library. The longest cDNA clone, Ma29, was designated pCGN5521 and has been completely sequenced on both strands. The cDNA is contained as a 1481 bp insert in the vector pZL1 (Bethesda Research Laboratories) and, beginning with the first ATG, contains an open reading frame encoding 446 amino acids. The reading frame contains the sequence deduced from the PCR fragment. The sequence of the cDNA insert was found to contain regions of homology to  $\Delta$ 6-desaturases (*see* Figure 5). For example, three conserved "histidine boxes" (that have been observed in membrane-bound desaturases (Okuley *et al.*, (1994) *The Plant Cell* 6:147-158)) were found to be present in the *Mortierella* sequence at amino acid positions

171-175, 207-212, and 387-391 (see Figure 3). However, the typical "HXXHH" amino acid motif for the third histidine box for the *Mortierella* desaturase was found to be QXXHH, SEQ ID NO:11-12. Surprisingly, the amino-terminus of the encoded protein, showed significant homology to 5 cytochrome b5 proteins. Thus, the *Mortierella* cDNA clone appears to represent a fusion between a cytochrome b5 and a fatty acid desaturase. Since cytochrome b5 is believed to function as the electron donor for membrane-bound desaturase enzymes, it is possible that the N-terminal cytochrome b5 domain of this desaturase protein is involved in its function. This may be 10 advantageous when expressing the desaturase in heterologous systems for PUFA production.

#### Example 2

##### Expression of *M. alpina* Desaturase Clones in Baker's Yeast

###### Yeast Transformation

15      Lithium acetate transformation of yeast was performed according to standard protocols (*Methods in Enzymology*, Vol. 194, p. 186-187, 1991). Briefly, yeast were grown in YPD at 30°C. Cells were spun down, resuspended in TE, spun down again, resuspended in TE containing 100 mM lithium acetate, spun down again, and resuspended in TE/lithium acetate. The resuspended 20 yeast were incubated at 30°C for 60 minutes with shaking. Carrier DNA was added, and the yeast were aliquoted into tubes. Transforming DNA was added, and the tubes were incubated for 30 min. at 30°C. PEG solution (35% (w/v) PEG 4000, 100 mM lithium acetate, TE pH7.5) was added followed by a 50 min. incubation at 30°C. A 5 min. heat shock at 42°C was performed, the cells 25 were pelleted, washed with TE, pelleted again and resuspended in TE. The resuspended cells were then plated on selective media.

###### Desaturase Expression in Transformed Yeast

The cDNA clones from *Mortierella alpina* were screened for desaturase activity in baker's yeast. A canola Δ15-desaturase (obtained by PCR using 1<sup>st</sup>

strand cDNA from *Brassica napus* cultivar 212/86 seeds using primers based on the published sequence (Arondel *et al.* *Science* 258:1353-1355)) was used as a positive control. The  $\Delta$ 15-desaturase gene and the gene from cDNA clone Ma29 was inserted into the expression vector pYES2 (Invitrogen), resulting in plasmids pCGR-2 and pCGR-4, respectively. These plasmids were transfected into *S. cerevisiae* yeast strain 334 and expressed after induction with galactose and in the presence of substrates that allowed detection of specific desaturase activity. The control strain was *S. cerevisiae* strain 334 containing the unaltered pYES2 vector. The substrates used, the products produced and the indicated desaturase activity were: DGLA (conversion to ARA would indicate  $\Delta$ 5-desaturase activity), linolenic acid (conversion to GLA would indicate  $\Delta$ 6-desaturase activity; conversion to ALA would indicate  $\Delta$ 15-desaturase activity), oleic acid (an endogenous substrate made by *S. cerevisiae*, conversion to linolenic acid would indicate  $\Delta$ 12-desaturase activity, which *S. cerevisiae* lacks), or ARA (conversion to EPA would indicate  $\Delta$ 17-desaturase activity). The results are provided in Table 1 below. The lipid fractions were extracted as follows: Cultures were grown for 48-52 hours at 15°C. Cells were pelleted by centrifugation, washed once with sterile ddH<sub>2</sub>O, and repelleted. Pellets were vortexed with methanol; chloroform was added along with tritidecanoic acid (as an internal standard). The mixtures were incubated for at least one hour at room temperature or at 4°C overnight. The chloroform layer was extracted and filtered through a Whatman filter with one gram of anhydrous sodium sulfate to remove particulates and residual water. The organic solvents were evaporated at 40°C under a stream of nitrogen. The extracted lipids were then derivatized to fatty acid methyl esters (FAME) for gas chromatography analysis (GC) by adding 2 ml of 0.5 N potassium hydroxide in methanol to a closed tube. The samples were heated to 95°C to 100°C for 30 minutes and cooled to room temperature. Approximately 2 ml of 14 % boron trifluoride in methanol was added and the heating repeated. After the extracted lipid mixture cooled, 2 ml of water and 1 ml of hexane were added to extract the FAME for analysis by GC. The percent conversion was calculated by dividing the product produced

by the sum of (the product produced and the substrate added) and then multiplying by 100. To calculate the oleic acid percent conversion, as no substrate was added, the total linolenic acid produced was divided by the sum of (oleic acid and linolenic acid produced), then multiplying by 100.

**Table 1*****M. alpina Desaturase Expression in Baker's Yeast***

CLONE	TYPE OF ENZYME ACTIVITY	% CONVERSION OF SUBSTRATE
pCGR-2	Δ6	0 (18:2 to 18:3ω6)
(canola Δ15 desaturase)	Δ15	16.3 (18:2 to 18:3ω3)
	Δ5	2.0 (20:3 to 20:4ω6)
	Δ17	2.8 (20:4 to 20:5ω3)
	Δ12	1.8 (18:1 to 18:2ω6)
pCGR-4	Δ6	0
( <i>M. alpina</i> Ma29)	Δ15	0
	Δ5	15.3
	Δ17	0.3
	Δ12	3.3

5        The Δ15-desaturase control clone exhibited 16.3% conversion of the substrate. The pCGR-4 clone expressing the Ma29 cDNA converted 15.3% of the 20:3 substrate to 20:4ω6, indicating that the gene encodes a Δ5-desaturase. The background (non-specific conversion of substrate) was between 0-3% in these cases. We also found substrate inhibition of the activity by using  
10      different concentrations of the substrate. When substrate was added to 100 μM, the percent conversion to product dropped compared to when substrate was added to 25 μM (see below). Additionally, by varying the DGLA substrate concentrations, between about 5 μM to about 200 μM percent conversion of DGLA to ARA ranged from about 5% to 75% with the *M. alpina* Δ5-desaturase.  
15

These data show that desaturases with different substrate specificities can be expressed in a heterologous system and used to produce poly-unsaturated long chain fatty acids.

Table 2 represents fatty acids of interest as a percent of the total lipid extracted from the yeast host *S. cerevisiae* 334 with the indicated plasmid. No glucose was present in the growth media. Affinity gas chromatography was used to separate the respective lipids. GC/MS was employed to verify the identity product(s). The expected product for the *B. napus*  $\Delta 15$ -desaturase,  $\alpha$ -linolenic acid, was detected when its substrate, linolenic acid, was added exogenously to the induced yeast culture. This finding demonstrates that yeast expression of a desaturase gene can produce functional enzyme and detectable amounts of product under the current growth conditions. Both exogenously added substrates were taken up by yeast, although slightly less of the longer chain PUFA, dihomo- $\gamma$ -linolenic acid (20:3), was incorporated into yeast than linolenic acid (18:2) when either was added in free form to the induced yeast cultures. Arachidonic acid was detected as a novel PUFA in yeast when dihomo- $\gamma$ -linolenic acid was added as the substrate to *S. cerevisiae* 334 (pCGR-4). This identifies pCGR-4 (MA29) as the  $\Delta 5$ -desaturase from *M. alpina*. Prior to this, no isolation and expression of a  $\Delta 5$ -desaturase from any source has been reported.

**Table 2**  
**Fatty Acid as a Percentage of Total Lipid Extracted from Yeast**

Plasmid in Yeast (enzyme)	18:2 Incorporated	$\alpha$ -18:3 Produced	$\gamma$ -18:3 Produced	20:3 Incorporated	20:4 Produced	18:1* Present	18:2 Produced
pYES2 (control)	66.9	0	0	58.4	0	4	0
pCGR-2 ( $\Delta$ 15)	60.1	5.7	0	50.4	0	0.7	0
pCGR-4 ( $\Delta$ 5)	67	0	0	32.3	5.8	0.8	0

100  $\mu$ M substrate added

\* 18:1 is an endogenous fatty acid in yeast

**Key To Tables**

- |                |                                   |
|----------------|-----------------------------------|
| 18:1           | =oleic acid                       |
| 18:2           | =linolenic acid                   |
| $\alpha$ -18:3 | = $\alpha$ -linolenic acid        |
| $\gamma$ -18:3 | = $\gamma$ -linolenic acid        |
| 18:4           | =stearidonic acid                 |
| 20:3           | =dihomo- $\gamma$ -linolenic acid |
| 20:4           | =arachidonic acid                 |

Example 3Optimization of Culture Conditions

Table 3A shows the effect of exogenous free fatty acid substrate concentration on yeast uptake and conversion to fatty acid product as a percentage of the total yeast lipid extracted. In all instances, low amounts of exogenous substrate (1-10  $\mu$ M) resulted in low fatty acid substrate uptake and product formation. Between 25 and 50  $\mu$ M concentration of free fatty acid in the growth and induction media gave the highest percentage of fatty acid product formed, while the 100  $\mu$ M concentration and subsequent high uptake into yeast appeared to decrease or inhibit the desaturase activity. The feedback inhibition of high fatty acid substrate concentration was well illustrated when the percent conversion rates of the respective fatty acid substrates to their respective products were compared in Table 3B. In all cases, 100  $\mu$ M substrate concentration in the growth media decreased the percent conversion to product.

The effect of media composition was also evident when glucose was present in the growth media for the  $\Delta 5$ -desaturase, since the percent of substrate uptake was decreased at 25  $\mu$ M (Table 3A). However, the percent conversion by  $\Delta 5$ -desaturase increased by 18% and the percent product formed remained the same in the presence of glucose in the growth media.

**Table 3A**  
**Effect of Added Substrate on the Percentage of Incorporated  
 Substrate and Product Formed in Yeast Extracts**

Plasmid in Yeast	pCGR-2 (Δ15)	pCGR-4 (Δ5)
substrate/product	18:2 /α-18:3	20:3/20:4
1 μM sub.	ND	0.5/1.7
10 μM sub.	ND	3.3/4
25 μM sub.	ND	5.1/6.1
25 μM <sup>0</sup> sub.	36.6/7.20	9.3/5.40
50 μM sub.	53.1/6.50	ND
100 μM sub.	60.1/5.70	32.3/5.80

**Table 3B**  
**Effect of Substrate Concentration in Media on the Percent Conversion  
 of Fatty Acid Substrate to Product in Yeast Extracts**

Plasmid in Yeast	pCGR-2 (Δ15)	pCGR-4 (Δ5)
substrate/product	18:2 →α-18:3	20:3→20:4
1 μM sub.	ND	77.3
10 μM sub.	ND	54.8
25 μM sub.	ND	54.2
25 μM <sup>0</sup> sub.	16.4	36.7
50 μM sub.	10.90	ND
100 μM sub.	8.70	15.20

◊ no glucose in media

\* Yeast peptone broth (YPD)

\* 18:1 is an endogenous yeast lipid

sub. is substrate concentration

ND (not done)

10

15 Table 4 shows the amount of fatty acid produced by a recombinant desaturase from induced yeast cultures when different amounts of free fatty acid substrate were used. Fatty acid weight was determined since the total amount of lipid varied dramatically when the growth conditions were changed, such as the presence of glucose in the yeast growth and induction media. To better

determine the conditions when the recombinant desaturase would produce the most PUFA product, the quantity of individual fatty acids were examined. The absence of glucose reduced the amount of arachidonic acid produced by  $\Delta 5$ -desaturase by half. For  $\Delta 5$ -desaturase the amount of total yeast lipid was decreased by almost half in the absence of glucose.

5

**Table 4**  
**Fatty Acid Produced in  $\mu\text{g}$  from Yeast Extracts**

Plasmid in Yeast (enzyme)	pCGR-4 ( $\Delta 5$ )	pCGR-7 ( $\Delta 12$ )
product	20:4	18:2*
1 $\mu\text{M}$ sub.	8.3	ND
10 $\mu\text{M}$ sub.	19.2	ND
25 $\mu\text{M}$ sub.	31.2	115.7
25 $\mu\text{M}$ $\diamond$ sub.	16.8	39.0

$\diamond$  no glucose in media

10

sub. is substrate concentration

ND (not done)

\*18:1, the substrate, is an endogenous yeast lipid

**Example 4**  
**Distribution of PUFAs in Yeast Lipid Fractions**

15

Table 5 illustrates the uptake of free fatty acids and their new products formed in yeast lipids as distributed in the major lipid fractions. A total lipid extract was prepared as described above. The lipid extract was separated on TLC plates, and the fractions were identified by comparison to standards. The bands were collected by scraping, and internal standards were added. The fractions were then saponified and methylated as above, and subjected to gas chromatography. The gas chromatograph calculated the amount of fatty acid by comparison to a standard. It would appear that the substrates are accessible in the phospholipid form to the desaturases.

20

**Table 5**  
**Fatty Acid Distribution in Various Yeast Lipid Fractions in µg**

Fatty acid fraction	Phospholipid	Diglyceride	Free Fatty Acid	Triglyceride	Cholesterol Ester
SC (pCGR-4) substrate 20:3	15.1	1.9	22.9	12.6	3.3
SC (pCGR-4) product 20:4	42.6	0.9	6.8	4.9	0.4

SC = *S. cerevisiae* (plasmid)

5

**Example 5**

**Further Culture Optimization**

10

The growth and induction conditions for optimal activities of desaturases in *Saccharomyces cerevisiae* were evaluated. Various culture conditions that were manipulated for optimal activity were: I) induction temperature, ii) concentration of inducer, iii) timing of substrate addition, iv) concentration of substance, v) sugar source, vi) growth phase at induction. These studies were done using Δ5-desaturase gene from *Mortierella alpina* (MA 29). In addition, the effect of changing host strain on expression of the Δ5-desaturase gene was also determined.

15

As described above, the best rate of conversion of substrate to ARA was observed at a substrate concentration of 1 µM, however, the percentage of ARA in the total fatty acids was highest at 25 µM substrate concentration. To determine if the substrate needed to be modified to a readily available form before it could be utilized by the desaturase, the substrate was added either 15 hours before induction or concomitant with inducer addition (indicated as after, in Figure 6A). As it can be seen in Figure 6A, addition of substrate before induction did not have a significant effect on the activity of Δ5-desaturase. In fact, addition of substrate along with the inducer was slightly better for expression/activity of Δ5-desaturase, as ARA levels in the total fatty acids were

20

higher. However, the rate of conversion of substrate to product was slightly lower.

The effect of inducer concentration of expression/activity of *Mortierella* Δ5-desaturase was examined by inducing SC334/pCGR5 with 0.5 or 2% (w/v) 5 of galactose. As shown in Figures 7A and 7B, expression of Δ5-desaturase was higher when induced with 0.5% galactose. Furthermore, rate of conversion of substrate to product was also better when SC334/pCGR5 was induced with 0.5% galactose vs 2% galactose.

To determine the effect of temperature on Δ5-desaturase activity, the 10 SC334 host strain, transformed with pCGR5 (SC334/pCGR5) was grown and induced at 15° C, 25°C, 30°C and 37°C. The quantity of ARA (20:4n6) produced in SC334/pCGR5 cultures, supplemental with substrate 20:3n6, was measured by fatty acid analysis. Figure 8A depicts the quantity of 20:3n6 and 20:4n6, expressed as percentage of total fatty acids. Figure 8B depicts the rate 15 of conversion of substrate to product. Growth and induction of SC334/pCGR5 at 25°C, was the best for the expression of Δ5-desaturase as evidenced by the highest levels of arachidonic acid in the total fatty acids. Additionally the highest rate of conversion of substrate to product also occurred at 25°C. Growth and induction at 15°C gave the lowest expression of ARA, whereas at 20 37°C gave the lowest conversion of substrate to product.

The effect of yeast strain on expression of the Δ5-desaturase gene was studied in 5 different host strains; INVSC1, INVSC2, YTC34, YTC41, and SC334, at 15°C and 30°C. At 15°C, SC334 has the highest percentage of ARA 25 in total fatty acids, suggesting higher activity of Δ5-desaturase in SC334. The rate of conversion of substrate to product, however is lowest in SC334 and highest in INVSC1 (Fig. 9A and B). At 30°C, the highest percentage of product (ARA) in total fatty acids was observed in INVSC2, although the rate of conversion of substrate to product in INVSC2 was slightly lower than INVSC1 (Fig. 10A and B).

ARA, the product of  $\Delta 5$ -desaturase, is stored in the phospholipid fraction (Example 4). Therefore the quantity of ARA produced in yeast is limited by the amount that can be stored in the phospholipid fraction. If ARA could also be stored in other fractions such as the triglyceride fraction, the quantity of ARA produced in yeast might be increased. To test this hypothesis, the  $\Delta 5$ -desaturase gene was expressed in the yeast host strain DBY746 (obtained from the Yeast Genetic Stock Centre, 1021 Donner Laboratory, Berkeley, CA 94720. The genotype of strain DBY746 is Mat $\alpha$ , his3- $\Delta 1$ , leu2-3, leu2-112, ura3-32, trp1-289, gal). The DBY746 yeast strain has an endogenous gene for choline transferase. The presence of this enzyme might enable the DBY746 strain to convert excess phospholipids into triglycerides fraction. Results in Fig. 11 show no increase in the conversion of substrate to product as compared to SC334, which does not have the gene for choline transferase.

To study the effect of media on expression of  $\Delta 5$ -desaturase, pCGR4/SC334 was grown in four different media at two different temperatures (15°C and 30°) and in two different host strains (SC334 and INVSC1). The composition of the media was as follows:

Media A: mm-Ura, + 2% galactose + 2% glucose.

Media B: mm-Ura, + 20% galactose + 2% Glucose + 1M sorbitol (pH5.8)

Media C: mm-Ura, + 2% galactose + 2% raffinose

Media D: mm-Ura, + 2% galactose + 2% raffinose + 1M sorbitol (pH5.8)

mm=minimal media

Results show that the highest conversion rate of substrate to product at 15°C in SC334 was observed in media A. The highest conversion rate overall for  $\Delta 5$ -desaturase in SC334 was at 30° in media D. The highest conversion rate of  $\Delta 5$ -desaturase in INVSC1 was also at 30° in media D (Figures 12A and 12B).

These data show that a DNA encoding a desaturase that can convert DGLA to ARA can be isolated from *Mortierella alpina* and can be expressed in a heterologous system and used to produce poly-unsaturated long chain fatty

acids. Exemplified is the production of ARA from the precursor DGLA by expression of a  $\Delta 5$ -desaturase in yeast.

**Example 6**

**Identification of Homologues to *M. alpina*  $\Delta 5$  and  $\Delta 6$  desaturases**

5       A nucleic acid sequence that encodes a putative  $\Delta 5$  desaturase was identified through a TBLASTN search of the est databases through NCBI using amino acids 100-446 of Ma29 as a query. The truncated portion of the Ma29 sequence was used to avoid picking up homologies based on the cytochrome b5 portion at the N-terminus of the desaturase. The deduced amino acid sequence  
10      of an est from *Dictyostelium discoideum* (accession # C25549) shows very significant homology to Ma29 and lesser, but still significant homology to Ma524. The DNA sequence is presented as SEQ ID NO:13. The amino acid sequence is presented as SEQ ID NO:14.

**Example 7**

15      **Identification of *M. alpina*  $\Delta 5$  and  $\Delta 6$  homologues in other PUFA-producing organisms**

20      To look for desaturases involved in PUFA production, a cDNA library was constructed from total RNA isolated from *Phaeodactylum tricornutum*. A plasmid-based cDNA library was constructed in pSPORT1 (GIBCO-BRL) following manufacturer's instructions using a commercially available kit (GIBCO-BRL). Random cDNA clones were sequenced and nucleic acid sequences that encode putative  $\Delta 5$  or  $\Delta 6$  desaturases were identified through BLAST search of the databases and comparison to Ma29 and Ma524 sequences.

25      One clone was identified from the *Phaeodactylum* library with homology to Ma29 and Ma524; it is called 144-011-B12. The DNA sequence is presented as SEQ ID NO:15. The amino acid sequence is presented as SEQ ID NO:16.

Example 8Identification of *M. alpina* Δ5 and Δ6 homologues in other PUFA-producing organisms

To look for desaturases involved in PUFA production, a cDNA library was constructed from total RNA isolated from *Schizochytrium* species. A plasmid-based cDNA library was constructed in pSPORT1 (GIBCO-BRL) following manufacturer's instructions using a commercially available kit (GIBCO-BRL). Random cDNA clones were sequenced and nucleic acid sequences that encode putative Δ5 or Δ6 desaturases were identified through BLAST search of the databases and comparison to Ma29 and Ma524 sequences.

One clone was identified from the *Schizochytrium* library with homology to Ma29 and Ma524; it is called 81-23-C7. This clone contains a ~1 kb insert. Partial sequence was obtained from each end of the clone using the universal forward and reverse sequencing primers. The DNA sequence from the forward primer is presented as SEQ ID NO:17. The peptide sequence is presented as SEQ ID NO:18. The DNA sequence from the reverse primer is presented as SEQ ID NO:19. The amino acid sequence from the reverse primer is presented as SEQ ID NO:20.

Example 9

20

Human Desaturase Gene Sequences

Human desaturase gene sequences potentially involved in long chain polyunsaturated fatty acid biosynthesis were isolated based on homology between the human cDNA sequences and *Mortierella alpina* desaturase gene sequences. The three conserved "histidine boxes" known to be conserved among membrane-bound desaturases were found. As with some other membrane-bound desaturases the final HXXHH histidine box motif was found to be QXXHH. The amino acid sequence of the putative human desaturases exhibited homology to *M. alpina* Δ5, Δ6, Δ9, and Δ12 desaturases.

The *M. alpina*  $\Delta 5$  desaturase and  $\Delta 6$  desaturase cDNA sequences were used to search the LifeSeq database of Incyte Pharmaceuticals, Inc., Palo Alto, California 94304. The  $\Delta 5$  desaturase sequence was divided into fragments; 1) amino acid no. 1-150, 2) amino acid no. 151-300, and 3) amino acid no. 301-446. The  $\Delta 6$  desaturase sequence was divided into three fragments; 1) amino acid no. 1-150, 2) amino acid no. 151-300, and 3) amino acid no. 301-457. These polypeptide fragments were searched against the database using the "tblastn" algorithm. This algorithm compares a protein query sequence against a nucleotide sequence database dynamically translated in all six reading frames (both strands).

The polypeptide fragments 2 and 3 of *M. alpina*  $\Delta 5$  and  $\Delta 6$  have homologies with the CloneID sequences as outlined in Table 6. The CloneID represents an individual sequence from the Incyte LifeSeq database. After the "tblastn" results have been reviewed, Clone Information was searched with the default settings of Stringency of  $\geq 50$ , and Productscore  $\leq 100$  for different CloneID numbers. The Clone Information Results displayed the information including the ClusterID, CloneID, Library, HitID, Hit Description. When selected, the ClusterID number displayed the clone information of all the clones that belong in that ClusterID. The Assemble command assembles all of the CloneID which comprise the ClusterID. The following default settings were used for GCG (Genetics Computer Group, University of Wisconsin Biotechnology Center, Madison, Wisconsin 53705) Assembly:

	Word Size:	7
25	Minimum Overlap:	14
	Stringency:	0.8
	Minimum Identity:	14
	Maximum Gap:	10
	Gap Weight:	8
30	Length Weight:	2

GCG Assembly Results displayed the contigs generated on the basis of sequence information within the CloneID. A contig is an alignment of DNA sequences based on areas of homology among these sequences. A new 5 sequence (consensus sequence) was generated based on the aligned DNA sequences within a contig. The contig containing the CloneID was identified, and the ambiguous sites of the consensus sequence was edited based on the alignment of the CloneIDs (see SEQ ID NO:21 - SEQ ID NO:25) to generate the best possible sequence. The procedure was repeated for all six CloneID 10 listed in Table 6. This produced five unique contigs. The edited consensus sequences of the 5 contigs were imported into the Sequencher software program (Gene Codes Corporation, Ann Arbor, Michigan 48105). These consensus sequences were assembled. The contig 2511785 overlaps with contig 3506132, and this new contig was called 2535 (SEQ ID NO:27). The contigs from the 15 Sequencher program were copied into the Sequence Analysis software package of GCG.

Each contig was translated in all six reading frames into protein sequences. The *M. alpina* Δ5 (MA29) and Δ6 (MA524) sequences were compared with each of the translated contigs using the FastA search (a Pearson 20 and Lipman search for similarity between a query sequence and a group of sequences of the same type (nucleic acid or protein)). Homology among these sequences suggest the open reading frames of each contig. The homology among the *M. alpina* Δ5 and Δ6 to contigs 2535 and 3854933 were utilized to create the final contig called 253538a. Figure 13 is the FastA match of the final 25 contig 253538a and MA29, and Figure 14 is the FastA match of the final contig 253538a and MA524. The DNA sequences for the various contigs are presented in SEQ ID NO:21 -SEQ ID NO:27. The various peptide sequences are shown in SEQ ID NO:28 - SEQ ID NO:34.

Although the open reading frame was generated by merging the two 30 contigs, the contig 2535 shows that there is a unique sequence in the beginning of this contig which does not match with the contig 3854933. Therefore, it is

possible that these contigs were generated from independent desaturase like human genes.

The contig 253538a contains an open reading frame encoding 432 amino acids. It starts with Gln (CAG) and ends with the stop codon (TGA).

5 The contig 253538a aligns with both *M. alpina* Δ5 and Δ6 sequences, suggesting that it could be either of the desaturases, as well as other known desaturases which share homology with each other. The individual contigs listed in Table 6, as well as the intermediate contig 2535 and the final contig 253538a can be utilized to isolate the complete genes for human desaturases.

10

#### **Uses of the human desaturases**

15

These human sequences can be expressed in yeast and plants utilizing the procedures described in the preceding examples. For expression in mammalian cells and transgenic animals, these genes may provide superior codon bias. These human sequences can also be used to identify related desaturase sequences.

**Table 6**

Sections of the Desaturases	Clone ID from LifeSeq Database	Keyword
151-300 Δ5	3808675	Fatty acid desaturase
301-446 Δ5	354535	Δ6
151-300 Δ6	3448789	Δ6
151-300 Δ6	1362863	Δ6
151-300 Δ6	2394760	Δ6
301-457 Δ6	3350263	Δ6

#### **Example 10**

#### **Nutritional Compositions**

20

The PUFAs of the previous examples can be utilized in various nutritional supplements, infant formulations, nutritional substitutes and other nutrition solutions.

#### **I. INFANT FORMULATIONS**

**A. Isomil® Soy Formula with Iron.**

Usage: As a beverage for infants, children and adults with an allergy or sensitivity to cow's milk. A feeding for patients with disorders for which lactose should be avoided: lactase deficiency, lactose intolerance and galactosemia.

5

**Features:**

10

- Soy protein isolate to avoid symptoms of cow's-milk-protein allergy or sensitivity
- Lactose-free formulation to avoid lactose-associated diarrhea
- Low osmolality (240 mOsm/kg water) to reduce risk of osmotic diarrhea.
- Dual carbohydrates (corn syrup and sucrose) designed to enhance carbohydrate absorption and reduce the risk of exceeding the absorptive capacity of the damaged gut.
- 1.8 mg of Iron (as ferrous sulfate) per 100 Calories to help prevent iron deficiency.
- Recommended levels of vitamins and minerals.
- Vegetable oils to provide recommended levels of essential fatty acids.
- Milk-white color, milk-like consistency and pleasant aroma.

20

Ingredients: (Pareve, ®) 85% water, 4.9% corn syrup, 2.6% sugar (sucrose), 2.1% soy oil, 1.9% soy protein isolate, 1.4% coconut oil, 0.15% calcium citrate, 0.11 % calcium phosphate tribasic, potassium citrate, potassium phosphate monobasic, potassium chloride, mono- and disglycerides, soy lecithin, carrageenan, ascorbic acid, L-methionine, magnesium chloride, potassium phosphate dibasic, sodium chloride, choline chloride, taurine, ferrous sulfate, m-inositol, alpha-tocopheryl acetate, zinc sulfate, L-carnitine, niacinamide, calcium pantothenate, cupric sulfate, vitamin A palmitate, thiamine chloride hydrochloride, riboflavin, pyridoxine hydrochloride, folic

25

acid, manganese sulfate, potassium iodide, phylloquinone, biotin, sodium selenite, vitamin D<sub>3</sub> and cyanocobalamin.

**B. Isomil® DF Soy Formula For Diarrhea.**

5       Usage: As a short-term feeding for the dietary management of diarrhea in infants and toddlers.

**Features:**

- First infant formula to contain added dietary fiber from soy fiber specifically for diarrhea management.
- Clinically shown to reduce the duration of loose, watery stools during mild to severe diarrhea in infants.
- Nutritionally complete to meet the nutritional needs of the infant.
- Soy protein isolate with added L-methionine meets or exceeds an infant's requirement for all essential amino acids.
- Lactose-free formulation to avoid lactose-associated diarrhea.
- Low osmolality (240 mOsm/kg water) to reduce the risk of osmotic diarrhea.
- Dual carbohydrates (corn syrup and sucrose) designed to enhance carbohydrate absorption and reduce the risk of exceeding the absorptive capacity of the damaged gut.
- Meets or exceeds the vitamin and mineral levels recommended by the Committee on Nutrition of the American Academy of Pediatrics and required by the Infant Formula Act.
- 1.8 mg of iron (as ferrous sulfate) per 100 Calories to help prevent iron deficiency.
- Vegetable oils to provide recommended levels of essential fatty acids.

Ingredients: (Pareve, ®) 86% water, 4.8% corn syrup, 2.5% sugar (sucrose), 2.1% soy oil, 2.0% soy protein isolate, 1.4% coconut oil, 0.77% soy

fiber, 0.12% calcium citrate, 0.11 % calcium phosphate tribasic, 0.10% potassium citrate, potassium chloride, potassium phosphate monobasic, mono- and disglycerides, soy lecithin, carrageenan, magnesium chloride, ascorbic acid, L-methionine, potassium phosphate dibasic, sodium chloride, choline chloride, 5 taurine, ferrous sulfate, m-inositol, alpha-tocopheryl acetate, zinc sulfate, L-carnitine, niacinamide, calcium pantothenate, cupric sulfate, vitamin A palmitate, thiamine chloride hydrochloride, riboflavin, pyridoxine hydrochloride, folic acid, manganese sulfate, potassium iodide, phylloquinone, biotin, sodium selenite, vitamin D<sub>3</sub> and cyanocobalamin.

10 **C. Isomil® SF Sucrose-Free Soy Formula With Iron.**

Usage: As a beverage for infants, children and adults with an allergy or sensitivity to cow's-milk protein or an intolerance to sucrose. A feeding for patients with disorders for which lactose and sucrose should be avoided.

Features:

- 15 • Soy protein isolate to avoid symptoms of cow's-milk-protein allergy or sensitivity.
- Lactose-free formulation to avoid lactose-associated diarrhea (carbohydrate source is Polycose® Glucose Polymers).
- Sucrose free for the patient who cannot tolerate sucrose.
- 20 • Low osmolality (180 mOsm/kg water) to reduce risk of osmotic diarrhea.
- 1.8 mg of iron (as ferrous sulfate) per 100 Calories to help prevent iron deficiency.
- Recommended levels of vitamins and minerals.
- 25 • Vegetable oils to provide recommended levels of essential fatty acids.
- Milk-white color, milk-like consistency and pleasant aroma.

Ingredients: (Pareve, ®) 75% water, 11.8% hydrolized cornstarch, 4.1% soy oil, 4.1% soy protein isolate, 2.8% coconut oil, 1.0% modified cornstarch,

0.38% calcium phosphate tribasic, 0.17% potassium citrate, 0.13% potassium chloride, mono- and disglycerides, soy lecithin, magnesium chloride, ascorbic acid, L-methionine, calcium carbonate, sodium chloride, choline chloride, carrageenan, taurine, ferrous sulfate, m-inositol, alpha-tocopheryl acetate, zinc sulfate, L-carnitine, niacinamide, calcium pantothenate, cupric sulfate, vitamin A palmitate, thiamine chloride hydrochloride, riboflavin, pyridoxine hydrochloride, folic acid, manganese sulfate, potassium iodide, phylloquinone, biotin, sodium selenite, vitamin D<sub>3</sub> and cyanocobalamin.

**D. Isomil® 20 Soy Formula With Iron Ready To Feed,  
10 20 Cal/fl oz.**

Usage: When a soy feeding is desired.

Ingredients: (Pareve, ©) 85% water, 4.9% corn syrup, 2.6% sugar (sucrose), 2.1% soy oil, 1.9% soy protein isolate, 1.4% coconut oil, 0.15% calcium citrate, 0.11% calcium phosphate tribasic, potassium citrate, potassium phosphate monobasic, potassium chloride, mono- and disglycerides, soy lecithin, carrageenan, ascorbic acid, L-methionine, magnesium chloride, potassium phosphate dibasic, sodium chloride, choline chloride, taurine, ferrous sulfate, m-inositol, alpha-tocopheryl acetate, zinc sulfate, L-carnitine, niacinamide, calcium pantothenate, cupric sulfate, vitamin A palmitate, thiamine chloride hydrochloride, riboflavin, pyridoxine hydrochloride, folic acid, manganese sulfate, potassium iodide, phylloquinone, biotin, sodium selenite, vitamin D<sub>3</sub> and cyanocobalamin.

**E. Similac® Infant Formula**

Usage: When an infant formula is needed: if the decision is made to discontinue breastfeeding before age 1 year, if a supplement to breastfeeding is needed or as a routine feeding if breastfeeding is not adopted.

Features:

- Protein of appropriate quality and quantity for good growth; heat-denatured, which reduces the risk of milk-associated enteric blood loss.

- Fat from a blend of vegetable oils (doubly homogenized), providing essential linoleic acid that is easily absorbed.
- Carbohydrate as lactose in proportion similar to that of human milk.
- Low renal solute load to minimize stress on developing organs.
- Powder, Concentrated Liquid and Ready To Feed forms.

5

Ingredients: (®-D) Water, nonfat milk, lactose, soy oil, coconut oil,

mono- and diglycerides, soy lecithin, ascorbic acid, carrageenan, choline chloride, taurine, m-inositol, alpha-tocopheryl acetate, zinc sulfate, niacinamid, ferrous sulfate, calcium pantothenate, cupric sulfate, vitamin A palmitate, thiamine chloride hydrochloride, riboflavin, pyridoxine hydrochloride, folic acid, manganese sulfate, phylloquinone, biotin, sodium selenite, vitamin D<sub>3</sub> and cyanocobalamin.

10

#### F. Similac® NeoCare Premature Infant Formula With Iron

Usage: For premature infants' special nutritional needs after hospital discharge. Similac NeoCare is a nutritionally complete formula developed to provide premature infants with extra calories, protein, vitamins and minerals needed to promote catch-up growth and support development.

15

##### Features:

20

- Reduces the need for caloric and vitamin supplementation. More calories (22 Cal/fl oz) than standard term formulas (20 Cal/fl oz).
- Highly absorbed fat blend, with medium-chain triglycerides (MCT oil) to help meet the special digestive needs of premature infants.
- Higher levels of protein, vitamins and minerals per 100 Calories to extend the nutritional support initiated in-hospital.
- More calcium and phosphorus for improved bone mineralization.

25

Ingredients: ®-D Corn syrup solids, nonfat milk, lactose, whey protein concentrate, soy oil, high-oleic safflower oil, fractionated coconut oil (medium-chain triglycerides), coconut oil, potassium citrate, calcium phosphate tribasic, calcium carbonate, ascorbic acid, magnesium chloride, potassium chloride,

sodium chloride, taurine, ferrous sulfate, m-inositol, choline chloride, ascorbyl palmitate, L-carnitine, alpha-tocopheryl acetate, zinc sulfate, niacinamide, mixed tocopherols, sodium citrate, calcium pantothenate, cupric sulfate, thiamine chloride hydrochloride, vitamin A palmitate, beta carotene, riboflavin, 5 pyridoxine hydrochloride, folic acid, manganese sulfate, phylloquinone, biotin, sodium selenite, vitamin D<sub>3</sub> and cyanocobalamin.

**G. Similac Natural Care Low-Iron Human Milk Fortifier Ready To Use, 24 Cal/fl oz.**

Usage: Designed to be mixed with human milk or to be fed alternatively 10 with human milk to low-birth-weight infants.

Ingredients: ©-D Water, nonfat milk, hydrolyzed cornstarch, lactose, fractionated coconut oil (medium-chain triglycerides), whey protein concentrate, soy oil, coconut oil, calcium phosphate tribasic, potassium citrate, magnesium chloride, sodium citrate, ascorbic acid, calcium carbonate, mono- 15 and diglycerides, soy lecithin, carrageenan, choline chloride, m-inositol, taurine, niacinamide, L-carnitine, alpha tocopheryl acetate, zinc sulfate, potassium chloride, calcium pantothenate, ferrous sulfate, cupric sulfate, riboflavin, vitamin A palmitate, thiamine chloride hydrochloride, pyridoxine hydrochloride, biotin, folic acid, manganese sulfate, phylloquinone, vitamin D<sub>3</sub>, 20 sodium selenite and cyanocobalamin.

Various PUFAs of this invention can be substituted and/or added to the infant formulae described above and to other infant formulae known to those in the art..

**II. NUTRITIONAL FORMULATIONS**

25 **A. ENSURE®**

Usage: ENSURE is a low-residue liquid food designed primarily as an oral nutritional supplement to be used with or between meals or, in appropriate amounts, as a meal replacement. ENSURE is lactose- and gluten-free, and is suitable for use in modified diets, including low-cholesterol diets. Although it 30 is primarily an oral supplement, it can be fed by tube.

**Patient Conditions:**

- For patients on modified diets
- For elderly patients at nutrition risk
- For patients with involuntary weight loss
- 5 • For patients recovering from illness or surgery
- For patients who need a low-residue diet

**Ingredients:**

10       ®-D Water, Sugar (Sucrose), Maltodextrin (Corn), Calcium and Sodium Caseinates, High-Oleic Safflower Oil, Soy Protein Isolate, Soy Oil, Canola Oil, Potassium Citrate, Calcium Phosphate Tribasic, Sodium Citrate, Magnesium Chloride, Magnesium Phosphate Dibasic, Artificial Flavor, Sodium Chloride, Soy Lecithin, Choline Chloride, Ascorbic Acid, Carrageenan, Zinc Sulfate, Ferrous Sulfate, Alpha-Tocopheryl Acetate, Gellan Gum, Niacinamide, Calcium Pantothenate, Manganese Sulfate, Cupric Sulfate, Vitamin A  
15       Palmitate, Thiamine Chloride Hydrochloride, Pyridoxine Hydrochloride, Riboflavin, Folic Acid, Sodium Molybdate, Chromium Chloride, Biotin, Potassium Iodide, Sodium Selenate.

**B. ENSURE® BARS**

20       Usage: ENSURE BARS are complete, balanced nutrition for supplemental use between or with meals. They provide a delicious, nutrient-rich alternative to other snacks. ENSURE BARS contain <1 g lactose/bar, and Chocolate Fudge Brownie flavor is gluten-free. (Honey Graham Crunch flavor contains gluten.)

**25       Patient Conditions:**

- For patients who need extra calories, protein, vitamins and minerals
- Especially useful for people who do not take in enough calories and nutrients

- For people who have the ability to chew and swallow
- Not to be used by anyone with a peanut allergy or any type of allergy to nuts.

**Ingredients:**

5 Honey Graham Crunch -- High-Fructose Corn Syrup, Soy Protein Isolate, Brown Sugar, Honey, Maltodextrin (Corn), Crisp Rice (Milled Rice, Sugar [Sucrose], Salt [Sodium Chloride] and Malt), Oat Bran, Partially Hydrogenated Cottonseed and Soy Oils, Soy Polysaccharide, Glycerine, Whey Protein Concentrate, Polydextrose, Fructose, Calcium Caseinate, Cocoa Powder, Artificial Flavors, Canola Oil, High-Oleic Safflower Oil, Nonfat Dry Milk, Whey Powder, Soy Lecithin and Corn Oil. Manufactured in a facility that processes nuts.

10

**Vitamins and Minerals:**

15 Calcium Phosphate Tribasic, Potassium Phosphate Dibasic, Magnesium Oxide, Salt (Sodium Chloride), Potassium Chloride, Ascorbic Acid, Ferric Orthophosphate, Alpha-Tocopheryl Acetate, Niacinamide, Zinc Oxide, Calcium Pantothenate, Copper Gluconate, Manganese Sulfate, Riboflavin, Beta-Carotene, Pyridoxine Hydrochloride, Thiamine Mononitrate, Folic Acid, Biotin, Chromium Chloride, Potassium Iodide, Sodium Selenate, Sodium Molybdate,

20 Phylloquinone, Vitamin D<sub>3</sub> and Cyanocobalamin.

**Protein:**

**Honey Graham Crunch** - The protein source is a blend of soy protein isolate and milk proteins.

	Soy protein isolate	74%
25	Milk proteins	26%

**Fat:**

**Honey Graham Crunch** - The fat source is a blend of partially hydrogenated cottonseed and soybean, canola, high oleic safflower, and corn oils, and soy lecithin.

	Partially hydrogenated cottonseed and soybean oil	76%
	Canola oil	8%
	High-oleic safflower oil	8%
	Corn oil	4%
5	Soy lecithin	4%

**Carbohydrate:**

Honey Graham Crunch - The carbohydrate source is a combination of high-fructose corn syrup, brown sugar, maltodextrin, honey, crisp rice, glycerine, soy polysaccharide, and oat bran.

10	High-fructose corn syrup	24%
	Brown sugar	21%
	Maltodextrin	12%
	Honey	11%
	Crisp rice	9%
15	Glycerine	9%
	Soy polysaccharide	7%
	Oat bran	7%\

**C. ENSURE® HIGH PROTEIN**

20 Usage: ENSURE HIGH PROTEIN is a concentrated, high-protein liquid food designed for people who require additional calories, protein, vitamins, and minerals in their diets. It can be used as an oral nutritional supplement with or between meals or, in appropriate amounts, as a meal replacement. ENSURE HIGH PROTEIN is lactose- and gluten-free, and is 25 suitable for use by people recovering from general surgery or hip fractures and by patients at risk for pressure ulcers.

**Patient Conditions**

- For patients who require additional calories, protein, vitamins, and minerals, such as patients recovering from general surgery or hip fractures, patients at risk 30 for pressure ulcers, and patients on low-cholesterol diets

**Features-**

- Low in saturated fat
- Contains 6 g of total fat and < 5 mg of cholesterol per serving
- Rich, creamy taste
- 5     • Excellent source of protein, calcium, and other essential vitamins and minerals
- For low-cholesterol diets
- Lactose-free, easily digested

**Ingredients:**

10     **Vanilla Supreme:** -D Water, Sugar (Sucrose), Maltodextrin (Corn), Calcium and Sodium Caseinates, High-Oleic Safflower Oil, Soy Protein Isolate, Soy Oil, Canola Oil, Potassium Citrate, Calcium Phosphate Tribasic, Sodium Citrate, Magnesium Chloride, Magnesium Phosphate Dibasic, Artificial Flavor, Sodium Chloride, Soy Lecithin, Choline Chloride, Ascorbic Acid, Carrageenan, Zinc  
15     Sulfate, Ferrous Sulfate, Alpha-Tocopheryl Acetate, Gellan Gum, Niacinamide, Calcium Pantothenate, Manganese Sulfate, Cupric Sulfate, Vitamin A Palmitate, Thiamine Chloride Hydrochloride, Pyridoxine Hydrochloride, Riboflavin, Folio Acid, Sodium Motybdote, Chromium Chloride, Biotin, Potassium Iodide, Sodium Selenate, Phylloquinone, Vitamin D.3 and  
20     Cyanocobalamin.

**Protein:**

The protein source is a blend of two high-biologic-value proteins: casein and soy.

	Sodium and calcium caseinates	85%
25	Soy protein isolate	15%

**Fat:**

The fat source is a blend of three oils: high-oleic safflower, canola, and soy.

High-oleic safflower oil	40%
--------------------------	-----

Canola oil	30%
Soy oil	30%

The level of fat in ENSURE HIGH PROTEIN meets American Heart Association (AHA) guidelines. The 6 grams of fat in ENSURE HIGH PROTEIN represent 24% of the total calories, with 2.6% of the fat being from saturated fatty acids and 7.9% from polyunsaturated fatty acids. These values are within the AHA guidelines of  $\leq$  30% of total calories from fat, < 10% of the calories from saturated fatty acids, and  $\leq$  10% of total calories from polyunsaturated fatty acids.

10           **Carbohydrate:**

ENSURE HIGH PROTEIN contains a combination of maltodextrin and sucrose. The mild sweetness and flavor variety (vanilla supreme, chocolate royal, wild berry, and banana), plus VARI-FLAVORS® Flavor Pacs in pecan, cherry, strawberry, lemon, and orange, help to prevent flavor fatigue and aid in patient compliance.

15           **Vanilla and other nonchocolate flavors**

Sucrose	60%
Maltodextrin	40%

20           **Chocolate**

Sucrose	70%
Maltodextrin	30%

25           **D. ENSURE ® LIGHT**

Usage: ENSURE LIGHT is a low-fat liquid food designed for use as an oral nutritional supplement with or between meals. ENSURE LIGHT is lactose- and gluten-free, and is suitable for use in modified diets, including low-cholesterol diets.

**Patient Conditions:**

- For normal-weight or overweight patients who need extra nutrition in a supplement that contains 50% less fat and 20% fewer calories than ENSURE
- For healthy adults who don't eat right and need extra nutrition

**Features:**

- 5
  - Low in fat and saturated fat
  - Contains 3 g of total fat per serving and < 5 mg cholesterol
  - Rich, creamy taste
  - Excellent source of calcium and other essential vitamins and minerals
  - For low-cholesterol diets
- 10
  - Lactose-free, easily digested

**Ingredients:**

French Vanilla: Ø-D Water, Maltodextrin (Corn), Sugar (Sucrose), Calcium Caseinate, High-Oleic Safflower Oil, Canola Oil, Magnesium Chloride, Sodium Citrate, Potassium Citrate, Potassium Phosphate Dibasic, Magnesium Phosphate Dibasic, Natural and Artificial Flavor, Calcium Phosphate Tribasic, Cellulose Gel, Choline Chloride, Soy Lecithin, Carrageenan, Salt (Sodium Chloride), Ascorbic Acid, Cellulose Gum, Ferrous Sulfate, Alpha-Tocopheryl Acetate, Zinc Sulfate, Niacinamide, Manganese Sulfate, Calcium Pantothenate, Cupric Sulfate, Thiamine Chloride Hydrochloride, Vitamin A Palmitate, Pyridoxine Hydrochloride, Riboflavin, Chromium Chloride, Folic Acid, Sodium Molybdate, Biotin, Potassium Iodide, Sodium Selenate, Phylloquinone, Vitamin D<sub>3</sub> and Cyanocobalamin.

**Protein:**

The protein source is calcium caseinate.

25                  Calcium caseinate                          100%

**Fat**

The fat source is a blend of two oils: high-oleic safflower and canola.

High-oleic safflower oil	70%
Canola oil	30%

The level of fat in ENSURE LIGHT meets American Heart Association (AHA) guidelines. The 3 grams of fat in ENSURE LIGHT represent 13.5% of the total calories, with 1.4% of the fat being from saturated fatty acids and 2.6% from polyunsaturated fatty acids. These values are within the AHA guidelines of  $\leq$  30% of total calories from fat, < 10% of the calories from saturated fatty acids, and  $\leq$  10% of total calories from polyunsaturated fatty acids.

#### **Carbohydrate**

ENSURE LIGHT contains a combination of maltodextrin and sucrose. The chocolate flavor contains corn syrup as well. The mild sweetness and flavor variety (French vanilla, chocolate supreme, strawberry swirl), plus VARI-FLAVORS® Flavor Pacs in pecan, cherry, strawberry, lemon, and orange, help to prevent flavor fatigue and aid in patient compliance.

#### **Vanilla and other nonchocolate flavors**

Sucrose	51%
Maltodextrin	49%

#### **Chocolate**

Sucrose	47.0%
Corn Syrup	26.5%
Maltodextrin	26.5%

#### **Vitamins and Minerals**

An 8-fl-oz serving of ENSURE LIGHT provides at least 25% of the RDIs for 24 key vitamins and minerals.

#### **Caffeine**

Chocolate flavor contains 2.1 mg caffeine/8 fl oz.

**E. ENSURE PLUS®**

Usage: ENSURE PLUS is a high-calorie, low-residue liquid food for use when extra calories and nutrients, but a normal concentration of protein, are needed. It is designed primarily as an oral nutritional supplement to be used 5 with or between meals or, in appropriate amounts, as a meal replacement.

ENSURE PLUS is lactose- and gluten-free. Although it is primarily an oral nutritional supplement, it can be fed by tube.

**Patient Conditions:**

- For patients who require extra calories and nutrients, but a normal 10 concentration of protein, in a limited volume
- For patients who need to gain or maintain healthy weight

**Features**

- Rich, creamy taste
- Good source of essential vitamins and minerals

**Ingredients**

**Vanilla:** ©-D Water, Corn Syrup, Maltodextrin (Corn), Corn Oil, Sodium and Calcium Caseinates, Sugar (Sucrose), Soy Protein Isolate, Magnesium Chloride, Potassium Citrate, Calcium Phosphate Tribasic, Soy Lecithin, Natural and Artificial Flavor, Sodium Citrate, Potassium Chloride, Choline Chloride, 20 Ascorbic Acid, Carrageenan, Zinc Sulfate, Ferrous Sulfate, Alpha-Tocopheryl Acetate, Niacinamide, Calcium Pantothenate, Manganese Sulfate, Cupric Sulfate, Thiamine Chloride Hydrochloride, Pyridoxine Hydrochloride, Riboflavin, Vitamin A Palmitate, Folic Acid, Biotin, Chromium Chloride, Sodium Molybdate, Potassium Iodide, Sodium Selenite, Phylloquinone, 25 Cyanocobalamin and Vitamin D<sub>3</sub>.

**Protein**

The protein source is a blend of two high-biologic-value proteins: casein and soy.

Sodium and calcium caseinates	84%
-------------------------------	-----

Soy protein isolate 16%

**Fat**

The fat source is corn oil.

Corn oil 100%

5      **Carbohydrate**

ENSURE PLUS contains a combination of maltodextrin and sucrose.

The mild sweetness and flavor variety (vanilla, chocolate, strawberry, coffee, butter pecan, and eggnog), plus VARI-FLAVORS® Flavor Pacs in pecan, cherry, strawberry, lemon, and orange, help to prevent flavor fatigue and aid in patient compliance.

10     **Vanilla, strawberry, butter pecan, and coffee flavors**

Corn Syrup 39%

Maltodextrin 38%

Sucrose 23%

15     **Chocolate and eggnog flavors**

Corn Syrup 36%

Maltodextrin 34%

Sucrose 30%

**Vitamins and Minerals**

20     An 8-fl-oz serving of ENSURE PLUS provides at least 15% of the RDIs for 25 key Vitamins and minerals.

**Caffeine**

Chocolate flavor contains 3.1 mg Caffeine/8 fl oz. Coffee flavor contains a trace amount of caffeine.

25

**F.      ENSURE PLUS® HN**

Usage: ENSURE PLUS HN is a nutritionally complete high-calorie, high-nitrogen liquid food designed for people with higher calorie and protein needs or limited volume tolerance. It may be used for oral supplementation or for total nutritional support by tube. ENSURE PLUS HN is lactose- and gluten-free.

5

**Patient Conditions:**

- For patients with increased calorie and protein needs, such as following surgery or injury
- For patients with limited volume tolerance and early satiety

10

**Features**

15

- For supplemental or total nutrition
- For oral or tube feeding
- 1.5 CaVmL
- High nitrogen
- Calorically dense

**Ingredients**

20

**Vanilla:** ©-D Water, Maltodextrin (Corn), Sodium and Calcium Caseinates, Corn Oil, Sugar (Sucrose), Soy Protein Isolate, Magnesium Chloride, Potassium Citrate, Calcium Phosphate Tribasic, Soy Lecithin, Natural and Artificial Flavor, Sodium Citrate, Choline Chloride, Ascorbic Acid, Taurine, L-Carnitine, Zinc Sulfate, Ferrous Sulfate, Alpha-Tocopheryl Acetate, Niacinamide, Carrageenan, Calcium Pantothenate, Manganese Sulfate, Cupric Sulfate, Thiamine Chloride Hydrochloride, Pyridoxine Hydrochloride, Riboflavin, Vitamin A Palmitate, Folic Acid, Biotin, Chromium Chloride, Sodium Molybdate, Potassium Iodide, Sodium Selenite, Phylloquinone, Cyanocobalamin and Vitamin D<sub>3</sub>.

25

**G. ENSURE® POWDER**

Usage: ENSURE POWDER (reconstituted with water) is a low-residue liquid food designed primarily as an oral nutritional supplement to be used with or between meals. ENSURE POWDER is lactose- and gluten-free, and is suitable for use in modified diets, including low-cholesterol diets.

5      **Patient Conditions:**

- For patients on modified diets
- For elderly patients at nutrition risk
- For patients recovering from illness/surgery
- For patients who need a low-residue diet

10     **Features**

- Convenient, easy to mix
  - Low in saturated fat
  - Contains 9 g of total fat and < 5 mg of cholesterol per serving
  - High in vitamins and minerals
- 15
  - For low-cholesterol diets
  - Lactose-free, easily digested

Ingredients:  $\circ$ -D Corn Syrup, Maltodextrin (Corn), Sugar (Sucrose), Corn Oil, Sodium and Calcium Caseinates, Soy Protein Isolate, Artificial Flavor, Potassium Citrate, Magnesium Chloride, Sodium Citrate, Calcium Phosphate Tribasic, Potassium Chloride, Soy Lecithin, Ascorbic Acid, Choline Chloride, Zinc Sulfate, Ferrous Sulfate, Alpha-Tocopheryl Acetate, Niacinamide, Calcium Pantothenate, Manganese Sulfate, Thiamine Chloride Hydrochloride, Cupric Sulfate, Pyridoxine Hydrochloride, Riboflavin, Vitamin A Palmitate, Folic Acid, Biotin, Sodium Molybdate, Chromium Chloride, Potassium Iodide, Sodium Selenate, Phylloquinone, Vitamin D<sub>3</sub> and Cyanocobalamin.

25     **Protein**

The protein source is a blend of two high-biologic-value proteins: casein and soy.

Sodium and calcium caseinates 84%

Soy protein isolate 16%

**Fat**

The fat source is corn oil.

5 Corn oil 100%

**Carbohydrate**

ENSURE POWDER contains a combination of corn syrup, maltodextrin, and sucrose. The mild sweetness of ENSURE POWDER, plus VARI-FLAVORS® Flavor Pacs in pecan, cherry, strawberry, lemon, and 10 orange, helps to prevent flavor fatigue and aid in patient compliance.

**Vanilla**

Corn Syrup 35%

Maltodextrin 35%

Sucrose 30%

15

**H. ENSURE® PUDDING**

Usage: ENSURE PUDDING is a nutrient-dense supplement providing balanced nutrition in a nonliquid form to be used with or between meals. It is appropriate for consistency-modified diets (e.g., soft, pureed, or full liquid) or 20 for people with swallowing impairments. ENSURE PUDDING is gluten-free.

**Patient Conditions:**

- For patients on consistency-modified diets (e.g., soft, pureed, or full liquid)
- For patients with swallowing impairments
- **Features**
- Rich and creamy, good taste
- Good source of essential vitamins and minerals Convenient-needs no refrigeration

- **Gluten-free**

**Nutrient Profile per 5 oz:** Calories 250, Protein 10.9%, Total Fat 34.9%, Carbohydrate 54.2%

## **Ingredients:**

5      **Vanilla:** ©-D Nonfat Milk, Water, Sugar (Sucrose), Partially Hydrogenated  
Soybean Oil, Modified Food Starch, Magnesium Sulfate. Sodium Stearoyl  
Lactylate, Sodium Phosphate Dibasic, Artificial Flavor, Ascorbic Acid, Zinc  
Sulfate, Ferrous Sulfate, Alpha-Tocopheryl Acetate, Choline Chloride,  
Niacinamide, Manganese Sulfate, Calcium Pantothenate, FD&C Yellow #5,  
10     Potassium Citrate, Cupric Sulfate, Vitamin A Palmitate, Thiamine Chloride  
Hydrochloride, Pyridoxine Hydrochloride, Riboflavin, FD&C Yellow #6, Folic  
Acid, Biotin, Phylloquinone, Vitamin D3 and Cyanocobalamin.

## **Protein**

The protein source is nonfat milk.

15 Nonfat milk 100%

## Fat

The fat source is hydrogenated soybean oil.

Hydrogenated soybean oil 100%

## **Carbohydrate**

20 ENSURE PUDDING contains a combination of sucrose and modified food starch. The mild sweetness and flavor variety (vanilla, chocolate, butterscotch, and tapioca) help prevent flavor fatigue. The product contains 9.2 grams of lactose per serving.

### **Vanilla and other nonchocolate flavors**

25	Sucrose	56%
	Lactose	27%
	Modified food starch	17%

### **Chocolate**

Sucrose	58%
Lactose	26%
Modified food starch	16%

5

## I. ENSURE® WITH FIBER

Usage: ENSURE WITH FIBER is a fiber-containing, nutritionally complete liquid food designed for people who can benefit from increased dietary fiber and nutrients. ENSURE WITH FIBER is suitable for people who do not require a low-residue diet. It can be fed orally or by tube, and can be used as a nutritional supplement to a regular diet or, in appropriate amounts, as a meal replacement. ENSURE WITH FIBER is lactose- and gluten-free, and is suitable for use in modified diets, including low-cholesterol diets.

10

### Patient Conditions

- For patients who can benefit from increased dietary fiber and nutrients

15

### Features

- New advanced formula-low in saturated fat, higher in vitamins and minerals
- Contains 6 g of total fat and < 5 mg of cholesterol per serving
- Rich, creamy taste
- Good source of fiber

20

- Excellent source of essential vitamins and minerals
- For low-cholesterol diets
- Lactose- and gluten-free

### Ingredients

Vanilla: ©-D Water, Maltodextrin (Corn), Sugar (Sucrose), Sodium and Calcium Caseinates, Oat Fiber, High-Oleic Safflower Oil, Canola Oil, Soy Protein Isolate, Corn Oil, Soy Fiber, Calcium Phosphate Tribasic, Magnesium Chloride, Potassium Citrate, Cellulose Gel, Soy Lecithin, Potassium Phosphate

Dibasic, Sodium Citrate, Natural and Artificial Flavors, Choline Chloride, Magnesium Phosphate, Ascorbic Acid, Cellulose Gum, Potassium Chloride, Carrageenan, Ferrous Sulfate, Alpha-Tocopheryl Acetate, Zinc Sulfate, Niacinamide, Manganese Sulfate, Calcium Pantothenate, Cupric Sulfate,  
5 Vitamin A Palmitate, Thiamine Chloride Hydrochloride, Pyridoxine Hydrochloride, Riboflavin, Folic Acid, Chromium Chloride, Biotin, Sodium Molybdate, Potassium Iodide, Sodium Selenate, Phylloquinone, Vitamin D<sub>3</sub> and Cyanocobalamin.

**Protein**

10 The protein source is a blend of two high-biologic-value proteins- casein and soy.

Sodium and calcium caseinates	80%
Soy protein isolate	20%

**Fat**

15 The fat source is a blend of three oils: high-oleic safflower, canola, and corn.

High-oleic safflower oil	40%
Canola oil	40%
Corn oil	20%

20 The level of fat in ENSURE WITH FIBER meets American Heart Association (AHA) guidelines. The 6 grams of fat in ENSURE WITH FIBER represent 22% of the total calories, with 2.01 % of the fat being from saturated fatty acids and 6.7% from polyunsaturated fatty acids. These values are within the AHA guidelines of  $\leq$  30% of total calories from fat, < 10% of the calories from saturated fatty acids, and  $\leq$  10% of total calories from polyunsaturated fatty acids.  
25

**Carbohydrate**

ENSURE WITH FIBER contains a combination of maltodextrin and sucrose. The mild sweetness and flavor variety (vanilla, chocolate, and butter

pecan), plus VARI-FLAVORS® Flavor Pacs in pecan, cherry, strawberry, lemon, and orange, help to prevent flavor fatigue and aid in patient compliance.

**Vanilla and other nonchocolate flavors**

	Maltodextrin	66%
5	Sucrose	25%
	Oat Fiber	7%
	Soy Fiber	2%

**Chocolate**

	Maltodextrin	55%
10	Sucrose	36%
	Oat Fiber	7%
	Soy Fiber	2%

**Fiber**

The fiber blend used in ENSURE WITH FIBER consists of oat fiber and  
15 soy polysaccharide. This blend results in approximately 4 grams of total dietary  
fiber per 8-fl-oz can. The ratio of insoluble to soluble fiber is 95:5.

The various nutritional supplements described above and known to  
others of skill in the art can be substituted and/or supplemented with the PUFA  
—of this invention.

20           **J. Oxepa™ Nutritional Product**

Oxepa is low-carbohydrate, calorically dense enteral nutritional product  
designed for the dietary management of patients with or at risk for ARDS. It  
has a unique combination of ingredients, including a patented oil blend  
containing eicosapentaenoic acid (EPA from fish oil),  $\gamma$ -linolenic acid (GLA  
25 from borage oil), and elevated antioxidant levels.

**Caloric Distribution:**

- Caloric density is high at 1.5 Cal/mL (355 Cal/8 fl oz), to minimize the volume required to meet energy needs.
- The distribution of Calories in Oxepa is shown in Table 7.

Table 7. Caloric Distribution of Oxepa			
	per 8 fl oz.	per liter	% of Cal
Calories	355	1,500	---
Fat (g)	22.2	93.7	55.2
Carbohydrate (g)	25	105.5	28.1
Protein (g)	14.8	62.5	16.7
Water (g)	186	785	---

5      **Fat:**

- Oxepa contains 22.2 g of fat per 8-fl oz serving (93.7 g/L).
- The fat source is a oil blend of 31.8% canola oil, 25% medium-chain triglycerides (MCTs), 20% borage oil, 20% fish oil, and 3.2 % soy lecithin. The typical fatty acid profile of Oxepa is shown in Table 8.
- 10     • Oxepa provides a balanced amount of polyunsaturated, monounsaturated, and saturated fatty acids, as shown in Table 10.
- Medium-chain triglycerides (MCTs) -- 25% of the fat blend -- aid gastric emptying because they are absorbed by the intestinal tract without emulsification by bile acids.

15     The various fatty acid components of Oxepa™ nutritional product can be substituted and/or supplemented with the PUFAs of this invention.

Table 8. Typical Fatty Acid Profile			
	% Total Fatty Acids	g/8 fl oz*	g/L*
Caproic (6:0)	0.2	0.04	0.18
Caprylic (8:0)	14.69	3.1	13.07
Capric (10:0)	11.06	2.33	9.87
Palmitic (16:0)	5.59	1.18	4.98
Palmitoleic (16:1n-7)	1.82	0.38	1.62
Stearic (18:0)	1.84	0.39	1.64

Oleic (18:1n-9)	24.44	5.16	21.75
Linoleic (18:2n-6)	16.28	3.44	14.49
$\alpha$ -Linolenic (18:3n-3)	3.47	0.73	3.09
$\gamma$ -Linolenic (18:3n-6)	4.82	1.02	4.29
Eicosapentaenoic (20:5n-3)	5.11	1.08	4.55
n-3-Docosapentaenoic (22:5n-3)	0.55	0.12	0.49
Docosahexaenoic (22:6n-3)	2.27	0.48	2.02
Others	7.55	1.52	6.72

\* Fatty acids equal approximately 95% of total fat.

Table 9. Fat Profile of Oxepa.

% of total calories from fat	55.2
Polyunsaturated fatty acids	31.44 g/L
Monounsaturated fatty acids	25.53 g/L
Saturated fatty acids	32.38 g/L
n-6 to n-3 ratio	1.75:1
Cholesterol	9.49 mg/8 fl oz 40.1 mg/L

### Carbohydrate:

- The carbohydrate content is 25.0 g per 8-fl-oz serving (105.5 g/L).
- 5 • The carbohydrate sources are 45% maltodextrin (a complex carbohydrate) and 55% sucrose (a simple sugar), both of which are readily digested and absorbed.
- 10 • The high-fat and low-carbohydrate content of Oxepa is designed to minimize carbon dioxide (CO<sub>2</sub>) production. High CO<sub>2</sub> levels can complicate weaning in ventilator-dependent patients. The low level of carbohydrate also may be useful for those patients who have developed stress-induced hyperglycemia.
- 15 • Oxepa is lactose-free.

Dietary carbohydrate, the amino acids from protein, and the glycerol moiety of fats can be converted to glucose within the body. Throughout this process, the carbohydrate requirements of glucose-dependent tissues (such as the central nervous system and red blood cells) are met. However, a diet free of

carbohydrates can lead to ketosis, excessive catabolism of tissue protein, and loss of fluid and electrolytes. These effects can be prevented by daily ingestion of 50 to 100 g of digestible carbohydrate, if caloric intake is adequate. The carbohydrate level in Oxepa is also sufficient to minimize gluconeogenesis, if energy needs are being met.

5

**Protein:**

- Oxepa contains 14.8 g of protein per 8-fl-oz serving (62.5 g/L).
- The total calorie/nitrogen ratio (150:1) meets the need of stressed patients.
- Oxepa provides enough protein to promote anabolism and the maintenance of lean body mass without precipitating respiratory problems. High protein intakes are a concern in patients with respiratory insufficiency. Although protein has little effect on CO<sub>2</sub> production, a high protein diet will increase ventilatory drive.
- The protein sources of Oxepa are 86.8% sodium caseinate and 13.2% calcium caseinate.

10

15

20

25

All publications and patent applications mentioned in this specification are indicative of the level of skill of those skilled in the art to which this invention pertains. All publications and patent applications are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated as incorporated by reference.

The invention now being fully described, it will be apparent to one of ordinary skill in the art that many changes and modifications can be made thereto without departing from the spirit or scope of the appended claims.

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

5

(i) APPLICANT: KNUTZON, DEBORAH  
MURKERJI, PRADIP  
HUANG, YUNG-SHENG  
THURMOND, JENNIFER  
CHAUDHARY, SUNITA  
LEONARD, AMANDA

10

(ii) TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR  
SYNTHESIS OF LONG CHAIN POLY-UNSATURATED FATTY ACIDS

15

(iii) NUMBER OF SEQUENCES: 34

20

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: LIMBACH & LIMBACH LLP  
(B) STREET: 2001 FERRY BUILDING  
(C) CITY: SAN FRANCISCO  
(D) STATE: CALIFORNIA  
(E) COUNTRY: USA  
(F) ZIP: 94111

25

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk  
(B) COMPUTER: IBM PC compatible  
(C) OPERATING SYSTEM: PC-DOS/MS-DOS  
(D) SOFTWARE: PatentIn Release #1.0, Version #1.30

30

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER:  
(B) FILING DATE:  
(C) CLASSIFICATION:

35

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: MICHAEL R. WARD  
(B) REGISTRATION NUMBER: 38,651  
(C) REFERENCE/DOCKET NUMBER: CGAB-110

40

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: (415) 433-4150  
(B) TELEFAX: (415) 433-8716  
(C) TELEX: N/A

45

## (2) INFORMATION FOR SEQ ID NO:1:

50

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1483 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

55

(ii) MOLECULE TYPE: DNA (genomic)

60

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

GCTTCCTCCA GTTCATCCTC CATTTCGCCA CCTGCATTCT TTACGACCGT TAAGCAAGAT

60

GGGAACGGAC CAAGGAAAAA CCTTCACCTG GGAAGAGCTG GCGGCCATA ACACCAAGGA 120  
 CGACCTACTC TTGGCCATCC GCGGCAGGGT GTACGATGTC ACAAAAGTTCT TGAGCCGCCA 180  
 5 TCCTGGTGGA GTGGACACTC TCCTGCTCGG AGCTGGCCGA GATGTTACTC CGGTCTTG 240  
 GATGTATCAC GCGTTTGGGG CTGCAGATGC CATTATGAAG AAGTACTATG TCGGTACACT 300  
 10 GGTCTCGAAT GAGCTGCCA TCTTCCCGA GCCAACGGTG TTCCACAAAA CCATCAAGAC 360  
 GAGAGTCGAG GGCTACTTTA CGGATCGGAA CATTGATCCC AAGAATAGAC CAGAGATCTG 420  
 GGGACGATAAC GCTCTTATCT TTGGATCCTT GATCGCTTCC TACTACGCGC AGCTCTTGT 480  
 15 GCCTTCGTT GTCGAACGCA CATGGCTTCA GGTGGTGTGTT GCAATCATCA TGGGATTTGC 540  
 GTGCGCACAA GTCGGACTCA ACCCTTTCA TGATGCGTCT CACTTTTCAG TGACCCACAA 600  
 20 CCCCCACTGTC TGGAAGATTC TGGGAGCCAC GCACGACTTT TTCAACGGAG CATCGTACCT 660  
 GGTGTGGATG TACCAACATA TGCTGGCCA TCACCCCTAC ACCAACATTG CTGGAGCAGA 720  
 TCCCGACGTG TCGACGTCTG AGCCCGATGT TCGTCGTATC AAGCCCAACC AAAAGTGGTT 780  
 25 TGTCAACCAC ATCAAACCAGC ACATGTTTGT TCCCTTCCTG TACGGACTGC TGGCGTTCAA 840  
 GGTGCGCATT CAGGACATCA ACATTTGTGTA CTTTGTCAG ACCAATGACG CTATTCGTGT 900  
 30 CAATCCCATC TCGACATGGC ACACTGTGAT GTTCTGGGC GGCAAGGCTT TCTTTGTCTG 960  
 GTATCGCCTG ATTGTTCCCC TGCACTATCT GCCCCCTGGGC AAGGTGCTGC TCTTGTTCAC 1020  
 GGTTCGCGGAC ATGGTGTGCGT CTTACTGGCT GGCGCTGACC TTCCAGGCGA ACCACGTTGT 1080  
 35 TGAGGAAGTT CAGTGGCCGT TGCCCTGACGA GAACGGGATC ATCCAAAAGG ACTGGGCAGC 1140  
 TATGCAGGTC GAGACTACGC AGGATTACGC ACACGATTG CACCTCTGGA CCAGCATCAC 1200  
 40 TGGCAGCTTG AACTACCAGG CTGTGCACCA TCTGTTCCCC AACGTGTCGC AGCACCATTA 1260  
 TCCCCGATATT CTGGCCATCA TCAAGAACAC CTGCAGCGAG TACAAGGTTTC CATAACCTTGT 1320  
 CAAGGATACG TTTTGGCAAG CATTGCTTC ACATTGGAG CACTTGCCTG TTCTTGGACT 1380  
 45 CCGTCCCAAG GAAGAGTAGA AGAAAAAAAG CGCCGAATGA AGTATTGCC CCTTTTCTC 1440  
 CAAGAATGGC AAAAGGAGAT CAAGTGGACA TTCTCTATGA AGA 1483

## (2) INFORMATION FOR SEQ ID NO:2:

50

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 446 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: not relevant
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

60

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met Gly Thr Asp Gln Gly Lys Thr Phe Thr Trp Glu Glu Leu Ala Ala

1	5	10	15
His Asn Thr Lys Asp Asp Leu Leu Leu Ala Ile Arg Gly Arg Val Tyr			
	20	25	30
5	Asp Val Thr Lys Phe Leu Ser Arg His Pro Gly Gly Val Asp Thr Leu		
	35	40	45
10	Leu Leu Gly Ala Gly Arg Asp Val Thr Pro Val Phe Glu Met Tyr His		
	50	55	60
Ala Phe Gly Ala Ala Asp Ala Ile Met Lys Lys Tyr Tyr Val Gly Thr			
	65	70	75
15	Leu Val Ser Asn Glu Leu Pro Ile Phe Pro Glu Pro Thr Val Phe His		
	85	90	95
Lys Thr Ile Lys Thr Arg Val Glu Gly Tyr Phe Thr Asp Arg Asn Ile			
	100	105	110
20	Asp Pro Lys Asn Arg Pro Glu Ile Trp Gly Arg Tyr Ala Leu Ile Phe		
	115	120	125
25	Gly Ser Leu Ile Ala Ser Tyr Tyr Ala Gln Leu Phe Val Pro Phe Val		
	130	135	140
Val Glu Arg Thr Trp Leu Gln Val Val Phe Ala Ile Ile Met Gly Phe			
	145	150	155
30	Ala Cys Ala Gln Val Gly Leu Asn Pro Leu His Asp Ala Ser His Phe		
	165	170	175
Ser Val Thr His Asn Pro Thr Val Trp Lys Ile Leu Gly Ala Thr His			
	180	185	190
35	Asp Phe Asn Gly Ala Ser Tyr Leu Val Trp Met Tyr Gln His Met		
	195	200	205
40	Leu Gly His His Pro Tyr Thr Asn Ile Ala Gly Ala Asp Pro Asp Val		
	210	215	220
Ser Thr Ser Glu Pro Asp Val Arg Arg Ile Lys Pro Asn Gln Lys Trp			
	225	230	235
45	Phe Val Asn His Ile Asn Gln His Met Phe Val Pro Phe Leu Tyr Gly		
	245	250	255
Leu Leu Ala Phe Lys Val Arg Ile Gln Asp Ile Asn Ile Leu Tyr Phe			
	260	265	270
50	Val Lys Thr Asn Asp Ala Ile Arg Val Asn Pro Ile Ser Thr Trp His		
	275	280	285
55	Thr Val Met Phe Trp Gly Gly Lys Ala Phe Phe Val Trp Tyr Arg Leu		
	290	295	300
Ile Val Pro Leu Gln Tyr Leu Pro Leu Gly Lys Val Leu Leu Phe			
	305	310	315
60	Thr Val Ala Asp Met Val Ser Ser Tyr Trp Leu Ala Leu Thr Phe Gln		
	325	330	335

	Ala Asn His Val Val Glu Val Gln Trp Pro Leu Pro Asp Glu Asn	
	340	345
	Gly Ile Ile Gln Lys Asp Trp Ala Ala Met Gln Val Glu Thr Thr Gln	
5	355	360
	Asp Tyr Ala His Asp Ser His Leu Trp Thr Ser Ile Thr Gly Ser Leu	
	370	375
10	Asn Tyr Gln Ala Val His His Leu Phe Pro Asn Val Ser Gln His His	
	385	390
	Tyr Pro Asp Ile Leu Ala Ile Ile Lys Asn Thr Cys Ser Glu Tyr Lys	
	405	410
15	Val Pro Tyr Leu Val Lys Asp Thr Phe Trp Gln Ala Phe Ala Ser His	
	420	425
20	Leu Glu His Leu Arg Val Leu Gly Leu Arg Pro Lys Glu Glu	
	435	440
	445	

## (2) INFORMATION FOR SEQ ID NO:3:

	(i) SEQUENCE CHARACTERISTICS:	
25	(A) LENGTH: 186 amino acids	
	(B) TYPE: amino acid	
	(C) STRANDEDNESS: not relevant	
	(D) TOPOLOGY: linear	
30	(ii) MOLECULE TYPE: peptide	
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:	
35	Leu His His Thr Tyr Thr Asn Ile Ala Gly Ala Asp Pro Asp Val Ser	
	1 5 10 15	
	Thr Ser Glu Pro Asp Val Arg Arg Ile Lys Pro Asn Gln Lys Trp Phe	
	20 25 30	
40	Val Asn His Ile Asn Gln His Met Phe Val Pro Phe Leu Tyr Gly Leu	
	35 40 45	
45	Leu Ala Phe Lys Val Arg Ile Gln Asp Ile Asn Ile Leu Tyr Phe Val	
	50 55 60	
	Lys Thr Asn Asp Ala Ile Arg Val Asn Pro Ile Ser Thr Trp His Thr	
	65 70 75 80	
50	Val Met Phe Trp Gly Gly Lys Ala Phe Phe Val Trp Tyr Arg Leu Ile	
	85 90 95	
	Val Pro Leu Gln Tyr Leu Pro Leu Gly Lys Val Leu Leu Phe Thr	
	100 105 110	
55	Val Ala Asp Met Val Ser Ser Tyr Trp Leu Ala Leu Thr Phe Gln Ala	
	115 120 125	
60	Asn Tyr Val Val Glu Val Gln Trp Pro Leu Pro Asp Glu Asn Gly	
	130 135 140	
	Ile Ile Gln Lys Asp Trp Ala Ala Met Gln Val Glu Thr Thr Gln Asp	

145	150	155	160	
		Tyr Ala His Asp Ser His Leu Trp Thr Ser Ile Thr Gly Ser Leu Asn		
		165	170	175
5	Tyr Gln Xaa Val His His Leu Phe Pro His			
	180	185		

## (2) INFORMATION FOR SEQ ID NO:4:

10

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 457 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: not relevant
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide

20

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Met Ala Ala Ala Pro Ser Val Arg Thr Phe Thr Arg Ala Glu Val Leu			
1	5	10	15

25

Asn Ala Glu Ala Leu Asn Glu Gly Lys Lys Asp Ala Glu Ala Pro Phe			
20	25	30	

30

Leu Met Ile Ile Asp Asn Lys Val Tyr Asp Val Arg Glu Phe Val Pro			
35	40	45	
Asp His Pro Gly Gly Ser Val Ile Leu Thr His Val Gly Lys Asp Gly			
50	55	60	

35

Thr Asp Val Phe Asp Thr Phe His Pro Glu Ala Ala Trp Glu Thr Leu			
65	70	75	80
Ala Asn Phe Tyr Val Gly Asp Ile Asp Glu Ser Asp Arg Asp Ile Lys			
85	90	95	

40

Asn Asp Asp Phe Ala Ala Glu Val Arg Lys Leu Arg Thr Leu Phe Gln			
100	105	110	

45

Ser Leu Gly Tyr Tyr Asp Ser Ser Lys Ala Tyr Tyr Ala Phe Lys Val			
115	120	125	
Ser Phe Asn Leu Cys Ile Trp Gly Leu Ser Thr Val Ile Val Ala Lys			
130	135	140	

50

Trp Gly Gln Thr Ser Thr Leu Ala Asn Val Leu Ser Ala Ala Leu Leu			
145	150	155	160

60

Gly Leu Phe Trp Gln Gln Cys Gly Trp Leu Ala His Asp Phe Leu His			
165	170	175	

His Gln Val Phe Gln Asp Arg Phe Trp Gly Asp Leu Phe Gly Ala Phe			
180	185	190	

Leu Gly Gly Val Cys Gln Gly Phe Ser Ser Ser Trp Trp Lys Asp Lys			
195	200	205	

His Asn Thr His His Ala Ala Pro Asn Val His Val Glu Asp Pro Asp			
210	215	220	

	Ile Asp Thr His Pro Leu Leu Thr Trp Ser Glu His Ala Leu Glu Met
	225 230 235 240
5	Phe Ser Asp Val Pro Asp Glu Glu Leu Thr Arg Met Trp Ser Arg Phe
	245 250 255
	Met Val Leu Asn Gln Thr Trp Phe Tyr Phe Pro Ile Leu Ser Phe Ala
	260 265 270
10	Arg Leu Ser Trp Cys Leu Gln Ser Ile Leu Phe Val Leu Pro Asn Gly
	275 280 285
	Gln Ala His Lys Pro Ser Gly Ala Arg Val Pro Ile Ser Leu Val Glu
15	290 295 300
	Gln Leu Ser Leu Ala Met His Trp Thr Trp Tyr Leu Ala Thr Met Phe
	305 310 315 320
20	Leu Phe Ile Lys Asp Pro Val Asn Met Leu Val Tyr Phe Leu Val Ser
	325 330 335
	Gln Ala Val Cys Gly Asn Leu Leu Ala Ile Val Phe Ser Leu Asn His
	340 345 350
25	Asn Gly Met Pro Val Ile Ser Lys Glu Glu Ala Val Asp Met Asp Phe
	355 360 365
	Phe Thr Lys Gln Ile Ile Thr Gly Arg Asp Val His Pro Gly Leu Phe
30	370 375 380
	Ala Asn Trp Phe Thr Gly Gly Leu Asn Tyr Gln Ile Glu His His Leu
	385 390 395 400
35	Phe Pro Ser Met Pro Arg His Asn Phe Ser Lys Ile Gln Pro Ala Val
	405 410 415
	Glu Thr Leu Cys Lys Lys Tyr Asn Val Arg Tyr His Thr Thr Gly Met
40	420 425 430
	Ile Glu Gly Thr Ala Glu Val Phe Ser Arg Leu Asn Glu Val Ser Lys
	435 440 445
45	Ala Ala Ser Lys Met Gly Lys Ala Gln
	450 455

## (2) INFORMATION FOR SEQ ID NO:5:

- 50           (i) SEQUENCE CHARACTERISTICS:  
               (A) LENGTH: 446 amino acids  
               (B) TYPE: amino acid  
               (C) STRANDEDNESS: not relevant  
               (D) TOPOLOGY: linear
- 55           (ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

60           Met Ala Ala Gln Ile Lys Lys Tyr Ile Thr Ser Asp Glu Leu Lys Asn  
               1           5           10           15

	His Asp Lys Pro Gly Asp Leu Trp Ile Ser Ile Gln Gly Lys Ala Tyr			
	20	25	30	
5	Asp Val Ser Asp Trp Val Lys Asp His Pro Gly Gly Ser Phe Pro Leu			
	35	40	45	
	Lys Ser Leu Ala Gly Gln Glu Val Thr Asp Ala Phe Val Ala Phe His			
	50	55	60	
10	Pro Ala Ser Thr Trp Lys Asn Leu Asp Lys Phe Phe Thr Gly Tyr Tyr			
	65	70	75	80
15	Leu Lys Asp Tyr Ser Val Ser Glu Val Ser Lys Val Tyr Arg Lys Leu			
	85	90	95	
	Val Phe Glu Phe Ser Lys Met Gly Leu Tyr Asp Lys Lys Gly His Ile			
	100	105	110	
20	Met Phe Ala Thr Leu Cys Phe Ile Ala Met Leu Phe Ala Met Ser Val			
	115	120	125	
	Tyr Gly Val Leu Phe Cys Glu Gly Val Leu Val His Leu Phe Ser Gly			
	130	135	140	
25	Cys Leu Met Gly Phe Leu Trp Ile Gln Ser Gly Trp Ile Gly His Asp			
	145	150	155	160
30	Ala Gly His Tyr Met Val Val Ser Asp Ser Arg Leu Asn Lys Phe Met			
	165	170	175	
	Gly Ile Phe Ala Ala Asn Cys Leu Ser Gly Ile Ser Ile Gly Trp Trp			
	180	185	190	
35	Lys Trp Asn His Asn Ala His His Ile Ala Cys Asn Ser Leu Glu Tyr			
	195	200	205	
40	Asp Pro Asp Leu Gln Tyr Ile Pro Phe Leu Val Val Ser Ser Lys Phe			
	210	215	220	
	Phe Gly Ser Leu Thr Ser His Phe Tyr Glu Lys Arg Leu Thr Phe Asp			
	225	230	235	240
45	Ser Leu Ser Arg Phe Phe Val Ser Tyr Gln His Trp Thr Phe Tyr Pro			
	245	250	255	
	Ile Met Cys Ala Ala Arg Leu Asn Met Tyr Val Gln Ser Leu Ile Met			
	260	265	270	
50	Leu Leu Thr Lys Arg Asn Val Ser Tyr Arg Ala Gln Glu Leu Leu Gly			
	275	280	285	
	Cys Leu Val Phe Ser Ile Trp Tyr Pro Leu Leu Val Ser Cys Leu Pro			
	290	295	300	
55	Asn Trp Gly Glu Arg Ile Met Phe Val Ile Ala Ser Leu Ser Val Thr			
	305	310	315	320
60	Gly Met Gln Gln Val Gln Phe Ser Leu Asn His Phe Ser Ser Val			
	325	330	335	
	Tyr Val Gly Lys Pro Lys Gly Asn Asn Trp Phe Glu Lys Gln Thr Asp			

	340	345	350
	Gly Thr Leu Asp Ile Ser Cys Pro Pro Trp Met Asp Trp Phe His Gly		
	355	360	365
5	Gly Leu Gln Phe Gln Ile Glu His His Leu Phe Pro Lys Met Pro Arg		
	370	375	380
10	Cys Asn Leu Arg Lys Ile Ser Pro Tyr Val Ile Glu Leu Cys Lys Lys		
	385	390	395
	His Asn Leu Pro Tyr Asn Tyr Ala Ser Phe Ser Lys Ala Asn Glu Met		
	405	410	415
15	Thr Leu Arg Thr Leu Arg Asn Thr Ala Leu Gln Ala Arg Asp Ile Thr		
	420	425	430
	Lys Pro Leu Pro Lys Asn Leu Val Trp Glu Ala Leu His Thr		
20	435	440	445
	(2) INFORMATION FOR SEQ ID NO:6:		
	(i) SEQUENCE CHARACTERISTICS:		
	(A) LENGTH: 359 amino acids		
25	(B) TYPE: amino acid		
	(C) STRANDEDNESS: not relevant		
	(D) TOPOLOGY: linear		
30	(ii) MOLECULE TYPE: peptide		
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:		
	Met Leu Thr Ala Glu Arg Ile Lys Phe Thr Gln Lys Arg Gly Phe Arg		
35	1	5	10
	Arg Val Leu Asn Gln Arg Val Asp Ala Tyr Phe Ala Glu His Gly Leu		
	20	25	30
40	Thr Gln Arg Asp Asn Pro Ser Met Tyr Leu Lys Thr Leu Ile Ile Val		
	35	40	45
	Leu Trp Leu Phe Ser Ala Trp Ala Phe Val Leu Phe Ala Pro Val Ile		
45	50	55	60
	Phe Pro Val Arg Leu Leu Gly Cys Met Val Leu Ala Ile Ala Leu Ala		
	65	70	75
	Ala Phe Ser Phe Asn Val Gly His Asp Ala Asn His Asn Ala Tyr Ser		
50	85	90	95
	Ser Asn Pro His Ile Asn Arg Val Leu Gly Met Thr Tyr Asp Phe Val		
	100	105	110
55	Gly Leu Ser Ser Phe Leu Trp Arg Tyr Arg His Asn Tyr Leu His His		
	115	120	125
	Thr Tyr Thr Asn Ile Leu Gly His Asp Val Glu Ile His Gly Asp Gly		
60	130	135	140
	Ala Val Arg Met Ser Pro Glu Gln Glu His Val Gly Ile Tyr Arg Phe		
	145	150	155
	160		

Gln Gln Phe Tyr Ile Trp Gly Leu Tyr Leu Phe Ile Pro Phe Tyr Trp  
 165 170 175  
 5 Phe Leu Tyr Asp Val Tyr Leu Val Leu Asn Lys Gly Lys Tyr His Asp  
 180 185 190  
 His Lys Ile Pro Pro Phe Gln Pro Leu Glu Leu Ala Ser Leu Leu Gly  
 195 200 205  
 10 Ile Lys Leu Leu Trp Leu Gly Tyr Val Phe Gly Leu Pro Leu Ala Leu  
 210 215 220  
 Gly Phe Ser Ile Pro Glu Val Leu Ile Gly Ala Ser Val Thr Tyr Met  
 15 225 230 235 240  
 Thr Tyr Gly Ile Val Val Cys Thr Ile Phe Met Leu Ala His Val Leu  
 245 250 255  
 20 Glu Ser Thr Glu Phe Leu Thr Pro Asp Gly Glu Ser Gly Ala Ile Asp  
 260 265 270  
 Asp Glu Trp Ala Ile Cys Gln Ile Arg Thr Thr Ala Asn Phe Ala Thr  
 25 275 280 285  
 Asn Asn Pro Phe Trp Asn Trp Phe Cys Gly Gly Leu Asn His Gln Val  
 290 295 300  
 30 Thr His His Leu Phe Pro Asn Ile Cys His Ile His Tyr Pro Gln Leu  
 305 310 315 320  
 Glu Asn Ile Ile Lys Asp Val Cys Gln Glu Phe Gly Val Glu Tyr Lys  
 325 330 335  
 35 Val Tyr Pro Thr Phe Lys Ala Ala Ile Ala Ser Asn Tyr Arg Trp Leu  
 340 345 350  
 Glu Ala Met Gly Lys Ala Ser  
 40 355  
 (2) INFORMATION FOR SEQ ID NO:7:  
 (i) SEQUENCE CHARACTERISTICS:  
 45 (A) LENGTH: 365 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS: not relevant  
 (D) TOPOLOGY: linear  
 (ii) MOLECULE TYPE: peptide  
 50 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:  
 Met Thr Ser Thr Thr Ser Lys Val Thr Phe Gly Lys Ser Ile Gly Phe  
 55 1 5 10 15  
 Arg Lys Glu Leu Asn Arg Arg Val Asn Ala Tyr Leu Glu Ala Glu Asn  
 20 25 30  
 60 Ile Ser Pro Arg Asp Asn Pro Pro Met Tyr Leu Lys Thr Ala Ile Ile  
 35 40 45

	Leu Ala Trp Val Val Ser Ala Trp Thr Phe Val Val Phe Gly Pro Asp				
	50	55	60		
5	Val Leu Trp Met Lys Leu Leu Gly Cys Ile Val Leu Gly Phe Gly Val	70	75	80	
	Ser Ala Val Gly Phe Asn Ile Ser His Asp Gly Asn His Gly Gly Tyr	85	90	95	
10	Ser Lys Tyr Gln Trp Val Asn Tyr Leu Ser Gly Leu Thr His Asp Ala	100	105	110	
	Ile Gly Val Ser Ser Tyr Leu Trp Lys Phe Arg His Asn Val Leu His	115	120	125	
15	His Thr Tyr Thr Asn Ile Leu Gly His Asp Val Glu Ile His Gly Asp	130	135	140	
20	Glu Leu Val Arg Met Ser Pro Ser Met Glu Tyr Arg Trp Tyr His Arg	145	150	155	160
	Tyr Gln His Trp Phe Ile Trp Phe Val Tyr Pro Phe Ile Pro Tyr Tyr	165	170	175	
25	Trp Ser Ile Ala Asp Val Gln Thr Met Leu Phe Lys Arg Gln Tyr His	180	185	190	
	Asp His Glu Ile Pro Ser Pro Thr Trp Val Asp Ile Ala Thr Leu Leu	195	200	205	
30	Ala Phe Lys Ala Phe Gly Val Ala Val Phe Leu Ile Ile Pro Ile Ala	210	215	220	
	Val Gly Tyr Ser Pro Leu Glu Ala Val Ile Gly Ala Ser Ile Val Tyr	225	230	235	240
	Met Thr His Gly Leu Val Ala Cys Val Val Phe Met Leu Ala His Val	245	250	255	
40	Ile Glu Pro Ala Glu Phe Leu Asp Pro Asp Asn Leu His Ile Asp Asp	260	265	270	
	Glu Trp Ala Ile Ala Gln Val Lys Thr Thr Val Asp Phe Ala Pro Asn	275	280	285	
45	Asn Thr Ile Ile Asn Trp Tyr Val Gly Gly Leu Asn Tyr Gln Thr Val	290	295	300	
	His His Leu Phe Pro His Ile Cys His Ile His Tyr Pro Lys Ile Ala	305	310	315	320
	Pro Ile Leu Ala Glu Val Cys Glu Glu Phe Gly Val Asn Tyr Ala Val	325	330	335	
55	His Gln Thr Phe Phe Gly Ala Leu Ala Ala Asn Tyr Ser Trp Leu Lys	340	345	350	
	Lys Met Ser Ile Asn Pro Glu Thr Lys Ala Ile Glu Gln	355	360	365	
60	(2) INFORMATION FOR SEQ ID NO:8:				

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 32 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

5 (ii) MOLECULE TYPE: other nucleic acid  
(A) DESCRIPTION: /desc = "Synthetic oligonucleotide"

10 (ix) FEATURE:  
(A) NAME/KEY: misc\_feature  
(B) LOCATION: 21  
(D) OTHER INFORMATION: /number= 1

15 /note= "N=Inosine or Cytosine"

(ix) FEATURE:  
(A) NAME/KEY: misc\_feature  
(B) LOCATION: 27  
20 (D) OTHER INFORMATION: /number= 2

/note= "N=Inosine or Cytosine"

25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:  
CUACUACUAC UACAYCAYAC NTAYACNAAY AT 32

(2) INFORMATION FOR SEQ ID NO:9:

30 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 27 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

35 (ii) MOLECULE TYPE: other nucleic acid  
(A) DESCRIPTION: /desc = "Synthetic oligonucleotide"

40 (ix) FEATURE:  
(A) NAME/KEY: misc\_feature  
(B) LOCATION: 13  
(D) OTHER INFORMATION: /number= 1

/note= "N=Inosine or Cytosine"

45 (ix) FEATURE:  
(A) NAME/KEY: misc\_feature  
(B) LOCATION: 19  
(D) OTHER INFORMATION: /number= 2

50 /note= "N=Inosine or Cytosine"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:  
CAUCAUCAUC AUNGGRAANA RRTGRTG 27

(2) INFORMATION FOR SEQ ID NO:10:

60 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 35 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

CCAAGCTTCT GCAGGAGCTC TTTTTTTTTT TTTTT

35

10

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 5 amino acids

(B) TYPE: amino acid

15

(C) STRANDEDNESS: not relevant

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

20

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

His Xaa Xaa His His

1 5

25

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 5 amino acids

30

(B) TYPE: amino acid

(C) STRANDEDNESS: not relevant

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

35

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

Gln Xaa Xaa His His

1 5

40

(2) INFORMATION FOR SEQ ID NO:13:

45

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 746 nucleic acids

(B) TYPE: nucleic acid

50

(C) STRANDEDNESS: not relevant

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: nucleic acid

55

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

60

CGTATGTCAC TCCATTCAA ACTCGTCAT GGTATCATAA ATATCAACAC ATTTACGCTC	60
CACTCCCTCA TGTTATTTAC ACACTCAAAT ATCGTACTCA AGATTGGGAA GCTTTTGTA	120
AGGATGCTAA AAATGGTGCA ATTGCTGTTA GTGTCGCCAC AAATTTGAT AAGGCCGCTT	180
ACGTCATTGG TAAATTGCTT TTTGTTTCT CCGTTTCAT CCTTCCACTC CGTTATCATA	240
GCTTTACAGA TTAAATTGTT TATTTCTCA TTGCTGAATT CGTCTTTGGT TGGTATCTCA	300
CAATTAAATT CCAAGTTAGT CATGTCGCTG AAGATCTCAA ATTCTTTGCT ACCCCCTGAAA	360
GACCAGATGA ACCATCTCAA ATCAATGAAG ATTGGCAAT CCTTCACIT AAAACTACTC	420

	AAGATTATGG TCATGGTTCA CTCCCTTGTA CCTTTTTAG TGTTTCTTTA AATCATCAAG	480
	TTGTTCATCA TTTATTCCCA TCAATTGCTC AAGATTCTA CCCACAACCTT GTACCAATTG	540
	TAAAAGAAAGT TTGTAAGAA CATAACATTA CTTACCACAT TAAACCAAAC TTCACTGAAG	600
5	CTATTATGTC ACACATTAAT TACCTTTACA AAATGGGTAA TGATCCAGAT TATGTTAAA	660
	AACCATTTAGC CTCAAAAGAT GATTAATGA AATAACTTAA AAACCAATTG TTTACTTTG	720
	ACAAACAGTA ATATTAATAA ATACAA	746

## (2) INFORMATION FOR SEQ ID NO:14:

10

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 227 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS: not relevant  
 (D) TOPOLOGY: linear

15

(ii) MOLECULE TYPE: peptide

20

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

30

Tyr Val Thr Pro Phe Gln Thr Arg Ser Trp Tyr His Lys Tyr Gln	1	5	10	15
His Ile Tyr Ala Pro Leu Leu Tyr Gly Ile Tyr Thr Leu Lys Tyr	20	25	30	
Arg Thr Gln Asp Trp Glu Ala Phe Val Lys Asp Gly Lys Asn Gly	35	40	45	
Ala Ile Arg Val Ser Val Ala Thr Asn Phe Asp Lys Ala Ala Tyr	50	55	60	
Val Ile Gly Lys Leu Ser Phe Val Phe Phe Arg Phe Ile Leu Pro	65	70	75	
Leu Arg Tyr His Ser Phe Thr Asp Leu Ile Cys Tyr Phe Leu Ile	80	85	90	
Ala Glu Phe Val Phe Gly Trp Tyr Leu Thr Ile Asn Phe Gln Val	95	100	105	
Ser His Val Ala Glu Asp Leu Lys Phe Phe Ala Thr Pro Glu Arg	110	115	120	
Pro Asp Glu Pro Ser Gln Ile Asn Glu Asp Trp Ala Ile Leu Gln	125	130	135	
Leu Lys Thr Thr Gln Asp Tyr Gly His Gly Ser Leu Leu Cys Thr	140	145	150	
Phe Phe Ser Gly Ser Leu Asn His Gln Val Val His His Leu Phe	155	160	165	
Pro Ser Ile Ala Gln Asp Phe Tyr Pro Gln Leu Val Pro Ile Val	170	175	180	
Lys Glu Val Cys Lys Glu His Asn Ile Thr Tyr His Ile Lys Pro	185	190	195	
Asn Phe Thr Glu Ala Ile Met Ser His Ile Asn Tyr Leu Tyr Lys	200	205	210	
Met Gly Asn Asp Pro Asp Tyr Val Lys Lys Pro Leu Ala Ser Lys	215	220	225	
Asp Asp ***				

35

## (2) INFORMATION FOR SEQ ID NO:15:

55

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 494 nucleic acids  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: not relevant  
 (D) TOPOLOGY: linear

60

(ii) MOLECULE TYPE: nucleic acid

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

5	TTTTGGAAGG NTCCAAGTTN ACCACGGANT NGGCAAGTTN ACGGGGCGGA AANCGGTTTT CCCCCCAAGC CTTTGTGCA CTGGTTCTGT GGTGGCTTCC AGTACCAAGT CGACCACCAC TTATTCCCCA GCCTGCCCG ACACAATCTG GCCAAGACAC ACGCACTGGT CGAACCGTTC TGCAAGGAGT GGGGTGTCCA GTACCACGAA GCCGACCTCG TGGACGGGAC CATGGAAGTC 10 TTGCACCATT TGCCGAGCGT GGCCGGCGAA TTGCTCCTGG ATTTTGTACG CGACGGACCC GCCATGTAAT CGTCGTTCGT GACGATGCAA GGGTTCACGC ACATCTACAC ACACTCACTC ACACAACTAG TGTAACTCGT ATAGAATTCTG GTGTCGACCT GGACCTTGTT TGACTGGTTG GGGATAGGGT AGCTAGGCGG ACGCGTGGGT CGNCCCCGGG AATTCTGTGA CCGGTACCTG GCCCGCGTNA AAGT	60 120 180 240 300 360 420 480 494
---	---	--

15

## (2) INFORMATION FOR SEQ ID NO:16:

- 20 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 87 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS: not relevant  
 (D) TOPOLOGY: linear

25 (ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

30	Phe Trp Lys Xxx Pro Ser Xxx Pro Arg Xxx Xxx Gln Val Xxx Gly 1                   5                   10                   15 Ala Glu Xxx Gly Phe Pro Pro Lys Pro Phe Val Asp Trp Phe Cys 20                   25                   30 Gly Gly Phe Gln Tyr Gln Val Asp His His Leu Phe Pro Ser Leu 35                   40                   45 Pro Arg His Asn Leu Ala Lys Thr His Ala Leu Val Glu Ser Phe 50                   55                   60 Cys Lys Glu Trp Gly Val Gln Tyr His Glu Ala Asp Leu Val Asp 65                   70                   75 Gly Thr Met Glu Val Leu His His Leu Gly Ser Val Ala Gly Glu 40                   65                   70                   75 Phe Val Val Asp Phe Val Arg Asp Gly Pro Ala Met 80                   85	
----	--	--

45

## (2) INFORMATION FOR SEQ ID NO:17:

- 50 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 520 nucleic acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS: not relevant  
 (D) TOPOLOGY: linear

55 (ii) MOLECULE TYPE: nucleic acid

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

60	GGATGGAGTT CGCTCTGGATC CCTGTGCGCT ACGCGACGTG GTTTAAGCGT CATGGGTGCG CTTGGGTACA CGCCGGGGCA GTCTGGGGC ATGTACTTGT GCGCCTTG TGCTCGGCTGC ATTACATTT TTCTGCAGTT CGCCGTAAGT CACACCCATT TGCCCGTGAG CAACCCGGAG GATCAGCTGC ATTGGCTGGA GTACCGCGG ACCACACTGT GAACATCAGC ACCAAGTCGT	60 120 180 240
----	---	-------------------------

GGTTTGTCA	ATGGTGGATG	TCGAACCTCA	ACTTTCAGAT	CGAGCACCCAC	CTTTTCCCCA	300
CGGCGCCCCA	GTTCCGTTTC	AAGGAGATCA	GCCCAGCGGT	CGAGGCCCTC	TTCAGCGCC	360
ACGGTCTCCC	TTACTACGAC	ATGCCCTACA	CGAGCGCCGT	CTCCACCACC	TTTGCCAACC	420
TCTACTCCGT	CGGCCATTCC	GTCCGGCAGC	CCAAGCGCGA	CTAGCCTCTT	TTCCCTAGACC	480
TTAATTCCCC	ACCCCCACCCCC	ATGTTCTGTC	TTCCCTCCCGC			520

(2) INFORMATION FOR SEQ ID NO:18:

- 10                   (i) SEQUENCE CHARACTERISTICS:  
                      (A) LENGTH: 153 amino acids  
                      (B) TYPE: amino acid  
                      (C) STRANDEDNESS: not relevant  
                      (D) TOPOLOGY: linear

15                   (ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

20	Met Glu Phe Val Trp Ile Ala Val Arg Tyr Ala Thr Trp Phe Lys 1 5 10 15
	Arg His Gly Cys Ala Trp Val His Ala Gly Ala Val Val Gly His 20 25 30
25	Val Leu Val Arg Leu Trp Ser Arg Leu His Leu His Phe Ser Ala 35 40 45
	Val Arg Arg Lys Ser His Pro Phe Ala Arg Glu Gln Pro Gly Gly 50 55 60
30	Ser Ala Ala Leu Ala Arg Val Arg Ala Asp His Thr Val Asn Ile 65 70 75
	Ser Thr Lys Ser Trp Phe Val Thr Trp Trp Met Ser Asn Leu Asn 80 85 90
	Phe Gln Ile Glu His His Leu Phe Pro Thr Ala Pro Gln Phe Arg 95 100 105
35	Phe Lys Glu Ile Ser Pro Arg Val Glu Ala Leu Phe Lys Arg His 110 115 120
	Gly Leu Pro Tyr Tyr Asp Met Pro Tyr Thr Ser Ala Val Ser Thr 125 130 135
40	Thr Phe Ala Asn Leu Tyr Ser Val Gly His Ser Val Gly Asp Ala 140 145 150
	Lys Arg Asp

**45 (2) INFORMATION FOR SEO ID NO:19:**

- 50                    (i) SEQUENCE CHARACTERISTICS:  
                      (A) LENGTH: 429 nucleic acids  
                      (B) TYPE: nucleic acid  
                      (C) STRANDEDNESS: not relevant  
                      (D) TOPOLOGY: linear

55                    (ii) MOLECULE TYPE: nucleic acid

55                    (xi) SEQUENCE DESCRIPTION: SEQ ID NO

60	GCTCCCGCAC	ATGACGTACC	CGCTGGTCGA	GATTGTTGTT	CTCTTCGTGC	TTTCCTTTG	120
	GCTGATGGGT	CAGTCCTCAC	CCCTCGCGCT	CGCTCTCGGC	ATTGTCGTCA	GCGGCATCTC	180
	TCAGGGTTCGC	TGCGGCTGGG	TAATGCATGA	GATGGGCCAT	GGGTCGTTCA	CTGGTGTCA	240
	TTGGCTTGAC	GACGGGTGT	GCGAGTTCTT	TTACGGCGTT	GGTTGTTGGCA	TGAGCGGTCA	300

TTACTGGAAA AACCAGCACA GCAAACACCA CGCAGCGCCA AACCGGCTCG AGCACGATGT 360  
 AGATCTAAC ACCTTGCAT TGGTGGCCT CAACGAGCGC GTGGTGCAC AGGTCCGACC 420

5

## (2) INFORMATION FOR SEQ ID NO:20:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 125 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: not relevant
  - (D) TOPOLOGY: linear

15 (ii) MOLECULE TYPE: peptide

15 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

20	Arg Val Arg Pro Arg Val Arg Arg Glu Gln Leu Ile Lys Glu Gly
	1                       5                       10                       15
	Tyr Phe Asp Pro Ser Leu Pro His Met Thr Tyr Arg Val Val Glu
	20                      25                       30
	Ile Val Val Leu Phe Val Leu Ser Phe Trp Leu Met Gly Gln Ser
	35                      40                       45
25	Ser Pro Leu Ala Leu Ala Leu Gly Ile Val Val Ser Gly Ile Ser
	50                      55                       60
	Gln Gly Arg Cys Gly Trp Val Met His Glu Met Gly His Gly Ser
	65                      70                       75
30	Phe Thr Gly Val Ile Trp Leu Asp Asp Arg Leu Cys Glu Phe Phe
	65                      70                       75
	Tyr Gly Val Gly Cys Gly Met Ser Gly His Tyr Trp Lys Asn Gln
	80                      85                       90
	His Ser Lys His His Ala Ala Pro Asn Arg Leu Glu His Asp Val
	95                      100                       105
35	Asp Leu Asn Thr Leu Pro Leu Val Ala Phe Asn Glu Arg Val Val
	110                    115                       120
	Arg Lys Val Arg Pro
	125

40 (2) INFORMATION FOR SEQ ID NO:21:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 1219 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

45 (ii) MOLECULE TYPE: other nucleic acid (Edited Contig 2692004)

50 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

55	GCACGCCGAC CGGGCGCCGGG AGATCCTGGC AAAGTATCCA GAGATAAAAGT CCTTGATGAA 60
	ACCTGATCCC AATTGATAT GGATTATAAT TATGATGGTT CTCACCCAGT TGGGTGCATT 120
	TTACATAGTA AAAAGACTTGG ACTGGAAATG GGTCAATTT GGGGCCTATG CGTTTGGCAG 180
60	TTGCATTAAC CACTCAATGA CTCTGGCTAT TCATGAGATT GCCCACAAATG CTGCCTTTGG 240
	CAACTGCAAA GCAATGTGGA ATCGCTGGTT TGGAAATGTTT GCTAACTTC CTATTGGGAT 300

	TCCATATTCA ATTTCTTTA AGAGGTATCA CATGGATCAT CATCGGTACC TTGGAGCTGA	360
	TGGCGTCGAT GTAGATATTC CTACCGATTG TGAGGGCTGG TTCTTCTGTA CCGCTTTCA	420
5	AAAGTTTATA TGGGTTATTC TTCAGCCTCT CTTTTATGCC TTTCGACCTC TGTTCATCAA	480
	CCCCAAACCA ATTACGTATC TGGAAAGTTAT CAATACCGTG GCACAGGTCA CTTTGACAT	540
10	TTTAATTAT TACTTTTGG GAATTAAATC CTTAGTCTAC ATGTTGGCAG CATCTTACT	600
	TGGCCTGGGT TTGCACCCAA TTTCTGGACA TTTTATAGCT GAGCATTACA TGTTCTAAA	660
	GGGTCAATGAA ACTTACTCAT ATTATGGGCC TCTGAATTAA CTTACCTTCA ATGTGGGTTA	720
15	TCATAATGAA CATCATGATT TCCCCAACAT TCCTGGAAAA AGTCTTCCAC TGTTGAGGAA	780
	AATAGCAGCT GAATACTATG ACAACCTCCC TCACTACAAT TCCTGGATAA AAGTACTGTA	840
20	TGATTTTG TG ATGGATGATA CAATAAGTCC CTACTCAAGA ATGAAGAGGC ACCAAAAAGG	900
	AGAGATGGTG CTGGAGTAAA TATCATTAGT GCCAAAGGGA TTCTTCTCCA AAACCTTTAGA	960
	TGATAAAATG GAATTTTG C ATTATTAAC TTGAGACCAG TGATGCTCAG AAGCTCCCCCT	1020
25	GGCACAAATT CAGAGTAAGA GCTCGGTGAT ACCAAGAAGT GAATCTGGCT TTTAAACAGT	1080
	CAGCCTGACT CTGTAATGCT CAGTTTCACT CACAGGAAAC TTGTGACTTG TGTATTATCG	1140
	TCATTGAGGA TGTTCACTC ATGTCTGTCA TTTTATAAGC ATATCATTAA AAAAGCTTCT	1200
30	AAAAAGCTAT TTCGCCAGG	1219

(2) INFORMATION FOR SEQ ID NO:22:

- 35                   (i) SEQUENCE CHARACTERISTICS:  
                      (A) LENGTH: 655 base pairs  
                      (B) TYPE: nucleic acid  
                      (C) STRANDEDNESS: single  
                      (D) TOPOLOGY: linear

40                   (ii) MOLECULE TYPE: other nucleic acid (Edited Contig 2153526)

45 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

	TTACCTTCTA CGTCGCTTC TTCCTCACTT ATGTGCCACT ATTGGGGCTG AAAGCTTCCT	60
50	GGGCCTTTTC TTCATAGTCA GGTCCTGGAAAGCAACTGG TTTGTGTGGG TGACACAGAT	120
	GAACCATATT CCCATGGACA TTGATCATGA CCGGAACATG GACTGGTTT CCACCCAGCT	180
55	CCAGGCCACA TCCAATGTCC ACAAGTCTGC CTTCAATGAC TGGTTCAGTG GACACCTCAA	240
	CTTCCAGATT GAGCACCATC TTTTCCCAC GATGCCTCGA CACAATTACC ACAAAAGTGGC	300
	TCCCCGGTG CAGTCCTTGT GTGCCAAGCA TGGCATAGAG TACCAAGTCCA AGCCCCGTCT	360
60	GTCAGCCTTC GCCGACATCA TCCACTCACT AAAGGAGTCA GGGCAGCTCT GGCTAGATGC	420
	CTATCTTCAC CAATAACAAC AGCCACCCCTG CCCAGTCTGG AAGAAGAGGA GGAAGACTCT	480
65	GGAGCCAAGG CAGAGGGGAG CTTGAGGGAC AATGCCACTA TAGTTAATA CTCAGAGGGG	540

GTTGGGTTTG GGGACATAAA GCCTCTGACT CAAACTCCTC CCTTTTATCT TCTAGCCACA 600  
 GTTCTAAGAC CCAAAGTGGG GGGTGGACAC AGAAGTCCT AGGAGGGAAG GAGCT 655

5

## (2) INFORMATION FOR SEQ ID NO:23:

- 10 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 304 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

15 (ii) MOLECULE TYPE: other nucleic acid (Edited Contig 3506132)

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

GTCTTTACT TTGGCAATGG CTGGATTCCCT ACCCTCATCA CGGCCTTGT CCTTGCTACC 60  
 TCTCAGGCCA AAGCTGGATG GCTGCAACAT GATTATGGCC ACCTGTCTGT CTACAGAAAA 120  
 CCCAAGTGGG ACCACCTTGT CCACAAATTC GTCATTGGCC ACTTAAAGGG TGCCCTCTGCC 180  
 25 AACTGGTGGG ATCATCGCCA CTTCCAGCAC CACGCCAAGC CTAACATCTT CCACAAGGAT 240  
 CCCGATGTGA ACATGCTGCA CGTGTTCCTT CTGGGCGAAT GGCAAGCCAT CGAGTACGGC 300  
 AAGA 304

30

## (2) INFORMATION FOR SEQ ID NO:24:

- 35 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 918 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

40 (ii) MOLECULE TYPE: other nucleic acid (Edited Contig 3854933)

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

CAGGGACCTA CCCCGCGCTA CTTCACCTGG GACGAGGTGG CCCAGCGCTC AGGGTGCGAG 60  
 45 GAGGGTGGC TAGTGATCGA CCGTAAGGTG TACAACATCA GCGAGTTCAC CGGCCGGCAT 120  
 CCAGGGGGCT CCCGGGTCA CAGCCACTAC CCCGGGCAGG ATGCCACCGA TCCCTTTGTG 180  
 50 GCCTTCCACA TCAACAAGGG CCTTGTGAAG AAGTATATGA ACTCTCTCCT GATTGGAGAA 240  
 CTGCTCTCAG AGCAGCCCAG CTTTGAGCCC ACCAAGAATA AAGAGCTGAC AGATGAGTTC 300  
 CGGGAGCTGC GGGCCACAGT GGAGCGGATG GGGCTCATGA AGGCCAACCA TGTCTTCTTC 360  
 55 CTGCTGTACC TGCTGCACAT CTTGCTGCTG GATGGTGCAG CCTGGCTCAC CCTTTGGGTC 420  
 TTTGGGACGT CCTTTTGCC CTTCCCTCCTC TGTGCGGTGC TGCTCAGTGC AGTTCAGGCC 480  
 60 CAGGCTGGCT GGCTGCAGCA TGACTTTGGG CACCTGTCGG TCTTCAGCAC CTCAAAGTGG 540  
 AACCATCTGC TACATCATT TGTGATTGGC CACCTGAAGG GGGCCCCCGC CAGTTGGTGG 600  
 AACACATGC ACTTCCAGCA CCATGCCAAG CCCAACTGCT TCCGCAAAGA CCCAGACATC 660

	AACATGCATC CCTTCTTCTT TGCCTGGGG AAGATCCTCT CTGTGGAGCT TGGGAAACAG	720
	AAGAAAAAAAT ATATGCCGT AACCACCAAG CACARATACT TCTTCCTAAT TGGGCCCCA	780
5	GCCTTGCTGC CTCTCTACTT CCAGTGGTAT ATTTTCTATT TTGTTATCCA GCGAAAGAAG	840
	TGGGTGGACT TGGCCTGGAT CAGCAAACAG GAATACGATG AAGCCGGGCT TCCATTGTCC	900
	ACCGCAAATG CTTCTAAA	918

10

## (2) INFORMATION FOR SEQ ID NO:25:

	(i) SEQUENCE CHARACTERISTICS:	
15	(A) LENGTH: 1686 base pairs	
	(B) TYPE: nucleic acid	
	(C) STRANDEDNESS: single	
	(D) TOPOLOGY: linear	
20	(ii) MOLECULE TYPE: other nucleic acid (Edited Contig 2511785)	
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:	
25	GCCACTTAAA GGGTGCCTCT GCCAACTGGT GGAATCATCG CCACCTCCAG CACCACGCCA	60
	AGCCTAACAT CTTCCACAAG GATCCCGATG TGAACATGCT GCACGTGTTT GTTCTGGCG	120
30	AATGGCAGCC CATCGAGTAC GGCAAGAAGA AGCTGAAATA CCTGCCCTAC AATCACCAAGC	180
	ACGAATACTT CTTCTGATT GGGCCGCCGC TGCTCATCCC CATGTATTC CAGTACCAAGA	240
	TCATCATGAC CATGATCGTC CATAAGAACT GGGTGGACCT GGCCTGGGCC GTCAGCTACT	300
35	ACATCCGGTT CTTCATCACC TACATCCCTT TCTACGGCAT CCTGGGAGCC CTCCCTTTCC	360
	TCAACTTCAT CAGGTTCCCTG GAGAGCCACT GGTTTGTGTG GGTACACACAG ATGAATCACA	420
40	TCGTCATGGA GATTGACCAAG GAGGCCTACC GTGACTGGTT CAGTAGCCAG CTGACAGCCA	480
	CCTGCAACGT GGAGCAGTCC TTCTTCAACG ACTGGTTCAG TGGACACCTT AACTTCCAGA	540
	TTGAGCACCA CCTCTTCCCC ACCATGCCCG GGCACAACTT ACACAAAGATC GCCCCGCTGG	600
45	TGAAGTCTCT ATGTGCCAAG CATGGCATTG AATACCAGGA GAAGCCGCTA CTGAGGGCCC	660
	TGCTGGACAT CATCAGGTCC CTGAAGAAAGT CTGGGAAGCT GTGGCTGGAC GCCTACCTTC	720
50	ACAAATGAAG CCACAGCCCC CGGGACACCG TGGGGAAAGGG GTGCAGGTGG GGTGATGGCC	780
	AGAGGAATGA TGGGCTTTTG TTCTGAGGGG TGTCCGAGAG GCTGGTGTAT GCACTGCTCA	840
	CGGACCCCAT GTTGGATCTT TCTCCCTTTC TCCTCTCCTT TTTCTCTCA CATCTCCCC	900
55	ATAGCACCCCT GCCCTCATGG GACCTGCCCT CCCTCAGCCG TCAGCCATCA GCCATGCC	960
	TCCCAGTGCC TCCTAGCCCC TTCTTCCAAG GAGCAGAGAG GTGGCCACCG GGGGTGGCTC	1020
60	TGTCCTACCT CCACTCTCTG CCCCTAAAGA TGGGAGGAGA CCAGCGGTCC ATGGGTCTGG	1080
	CCTGTGAGTC TCCCCTTGCA GCCTGGTCAC TAGGCATCAC CCCCGCTTTG GTTCTTCAGA	1140
	TGCTCTTGGG GTTCATAGGG GCAGGTCTTA GTCGGGCAGG GCCCCTGACC CTCCCGGCCT	1200
65	GGCTTCACTC TCCCTGACGG CTGCCATTGG TCCACCCCTT CATAGAGAGG CCTGCTTTGT	1260

	TACAAAGCTC GGGTCTCCCT CCTGCAGCTC GGTTAAGTAC CCGAGGCCTC TCTTAAGATG	1320
5	TCCAGGGCCC CAGGCCCGCG GGCACAGCCA GCCCAAACCT TGGGCCCTGG AAGAGTCCTC	1380
	CACCCCCATCA CTAGAGTGCT CTGACCCCTGG GCTTTCACGG GCCCCATTCC ACCGCCTCCC	1440
	CAACTTGAGC CTGTGACCTT GGGACCAAAG GGGGAGTCCC TCGTCTCTTG TGACTCAGCA	1500
10	GAGGCAGTGG CCACGTTCA GGGAGGGCCG GCTGGCCTGG AGGCTCAGCC CACCCCTCCAG	1560
	CTTTTCTCA GGGTGTCTG AGGTCCAAGA TTCTGGAGCA ATCTGACCCCT TCTCCAAAGG	1620
15	CTCTGTTATC AGCTGGGCAG TGCCAGCCAA TCCCTGGCCA TTTGGCCCCA GGGGACGTGG	1680
	GCCCTG	1686

20 (2) INFORMATION FOR SEQ ID NO:26:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 1843 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 25 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid (Contig 2535)

30 (xi) SEQUENCE DESCRIPTION: SEQ ID NÓ:26:

	GTCTTTACT TTGGCAATGG CTGGATTCCCT ACCCTCATCA CGGCCTTTGT CCTTGCTACC	60
35	TCTCAGGGCCC AAGCTGGATG GCTGCAACAT GATTATGGCC ACCTGTCTGT CTACAGAAAA	120
	CCCAAGTGGGA ACCACCTTGT CCACAAATTC GTCAATTGGCC ACTTAAAGGG TGCCCTTGCC	180
	AACTGGTGGGA ATCATCGCCA CTTCCAGCAC CACGCCAAGC CTAACATCTT CCACAAGGAT	240
40	CCCGATGTGA ACATGCTGCA CGTGTGTT CTGGCGAAC GGCAGCCCAT CGAGTACGGC	300
	AAGAAGAACG TGAAATACCT GCCCTACAAT CACCAGCACG AATAACTTCTT CCTGATTGGG	360
45	CCGCCGCTGC TCATCCCCAT GTATTTCCAG TACCAAGATCA TCATGACCAT GATCGTCCAT	420
	AAGAACTGGG TGGACCTGGC CTGGGCGTC AGCTACTACA TCCGGTTCTT CATCACCTAC	480
	ATCCCTTTCT ACGGCATCCT GGGAGCCCTC CTTTCTCA ACTTCATCAG GTTCCTGGAG	540
50	AGCCACTGGT TTGTGTGGGT CACACAGATG AATCACATCG TCATGGAGAT TGACCAGGAG	600
	GCCTACCGTG ACTGGTTCAAG TAGCCAGCTG ACAGCCACCT GCAACGTGGA GCAGTCCTTC	660
55	TTCAACGACT GGTTCAAGTGG ACACCTTAAC TTCCAGATTG AGCACCACCT CTTCCCCACC	720
	ATGCCCGGGC ACAACTTACA CAAGATCGCC CCGCTGGTGA AGTCTCTATG TGCCAAGCAT	780
	GGCATTGAAT ACCAGGAGAA GCGCTACTG AGGGCCCTGC TGGACATCAT CAGGTCCCTG	840
60	AAGAAGTCTG GGAAGGCTGTG GCTGGACGCC TACCTTCACA AATGAAGCCA CAGCCCCCGG	900
	GACACCGTGG GGAAGGGGTG CAGGTGGGGT GATGCCAGA GGAATGATGG GCTTTGTTC	960
65	TGAGGGGTGT CCGAGAGGCT GGTGTATGCA CTGCTCACGG ACCCCATGTT GGATCTTCT	1020

CCCTTTCTCC TCTCCTTTT CTCTTCACAT CTCCCCATA GCACCCCTGCC CTCATGGGAC 1080  
 CTGCCCTCCC TCAGCCGTCA GCCATCAGCC ATGGCCCTCC CAGTGCCTCC TAGCCCTTC 1140  
 5 TTCCAAGGAG CAGAGAGGTG GCCACCGGGG GTGGCTCTGT CCTACCTCCA CTCTCTGCC 1200  
 CTAAAGATGG GAGGGAGCCA GCGGTCCATG GGTCTGGCCT GTGAGTCTCC CCTTGCAGCC 1260  
 10 TGGTCACTAG GCATCACCCC CGCTTGGTT CTTCAGATGC TCTTGGGGTT CATAGGGCA 1320  
 GGTCTTAGTC GGGCAGGGCC CCTGACCCCTC CCGGCCTGGC TTCACCTCTCC CTGACGGCTG 1380  
 CCATTGGTCC ACCCTTCAT AGAGAGGCCT GCTTTGTTAC AAAGCTCGGG TCTCCCTCCT 1440  
 15 GCAGCTCGGT TAAGTACCCG AGGCCTCTCT TAAGATGTCC AGGGCCCCAG GCCCAGGGC 1500  
 ACAGCCAGCC CAAACCTTGG GCCCTGGAAG AGTCCTCCAC CCCATCACTA GAGTGCTCTG 1560  
 20 ACCCTGGGCT TTCACGGGCC CCATTCCACC GCCTCCCCAA CTTGAGCCTG TGACCTTGGG 1620  
 ACCAAAGGGG GAGTCCCTCG TCTCTTGTGA CTCAGCAGAG GCAGTGGCCA CGTTCAGGGA 1680  
 GGGGCCGGCT GGCGTGGAGG CTCAGCCCAC CCTCCAGCTT TTCCCTCAGGG TGTCCTGAGG 1740  
 25 TCCAAGATTTC TGGAGCAATC TGACCCCTCT CCAAAGGCTC TGTTATCAGC TGGGCAGTGC 1800  
 CAGCCAATCC CTGGCCATTT GGCCCCAGGG GACGTGGGCC CTG 1843

30 (2) INFORMATION FOR SEQ ID NO:27:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 2257 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

35 (ii) MOLECULE TYPE: other nucleic acid (Edited Contig 253538a)

40 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

CAGGGACCTA CCCCGCGCTA CTTCACCTGG GACGAGGTGG CCCAGCGCTC AGGGTGCAG 60  
 GAGCGGTGGC TAGTGTATCGA CCGTAAGGTG TACAACATCA GCGAGTTCAC CCGCCGGCAT 120  
 45 CCAGGGGGCT CCCGGGTCACT CAGCCACTAC GCCGGGCAGG ATGCCACGGA TCCCTTGTG 180  
 GCCTTCCACA TCAACAAGGG CCTTGTGAAG AAGTATATGA ACTCTCTCCT GATTGGAGAA 240  
 50 CTGTCTCCAG AGCAGCCCAG CTTTGAGCCC ACCAAGAATA AAGAGCTGAC AGATGAGTTC 300  
 CGGGAGCTGC GGGCCACAGT GGAGCGGATG GGGCTATGA AGGCCAACCA TGTCTTCTTC 360  
 55 CTGCTGTACC TGCTGCACAT CTTGCTGCTG GATGGTGCAG CCTGGCTCAC CCTTTGGTC 420  
 TTTGGGACGT CCTTTTGCC CTTCCCTCCTC TGTGCGGTGC TGCTCAGTGC AGTTCAGCAG 480  
 GCCCAAGCTG GATGGCTGCA ACATGATTAT GGCCACCTGT CTGTCTACAG AAAACCCAAG 540  
 60 TGGAACCACC TTGTCCACAA ATTCGTCATT GGCCACTTAA AGGGTGCCTC TGCCAACCTGG 600  
 TGGAATCATC GCCACTTCCA GCACCACGCC AAGCTTAACA TCTTCCACAA GGATCCCGAT 660  
 65 GTGAACATGC TGCACGTGTT TGTTCTGGGC GAATGGCAGC CCATCGAGTA CGGCAAGAAG 720

	AAGCTGAAAT ACCTGCCCTA CAATCACCAAG CACGAATACT TCTTCCTGAT TGGGCCGCCG	780
	CTGCTCATCC CCATGTATTT CCAGTACCAAG ATCATCATGA CCATGATCGT CCATAAGAAC	840
5	TGGGTGGACC TGGCCTGGC CGTCAGCTAC TACATCCGGT TCTTCATCAC CTACATCCCT	900
	TTCTACGGCA TCCTGGGAGC CCTCCTTTTC CTCAACTTCA TCAGGTTCT GGAGAGCCAC	960
10	TGGTTTGTGT GGGTCACACA GATGAATCAC ATCGTCATGG AGATTGACCA GGAGGCCTAC	1020
	CGTGACTGGT TCAGTAGCCA GCTGACAGCC ACCTGCAACG TGGAGCAGTC CTTCTTCAAC	1080
	GACTGGTTCA GTGGACACCT TAACTTCCAG ATTGAGCACC ACCTCTTCCC CACCATGCC	1140
15	CGGCACAACT TACACAAGAT CGCCCCGCTG GTGAAGTCTC TATGTGCCAA GCATGGCATT	1200
	GAATACCAGG AGAAGCCGCT ACTGAGGGCC CTGCTGGACA TCATCAGGTC CCTGAAGAAC	1260
20	TCTGGGAAGC TGTGGCTGGA CGCCTACCTT CACAAATGAA GCCACAGCCC CCGGGACACC	1320
	GTGGGAAGG GGTGCAGGTG GGGTGATGGC CAGAGGAATG ATGGGTTTTT GTTCTGAGGG	1380
	GTGTCCGAGA GGCTGGTGTG TGCACTGCTC ACGGACCCCA TGTTGGATCT TTCTCCCTT	1440
25	CTCCTCTCCT TTTCTCTTC ACATCTCCCC CATAGCACCC TGCCCTCATG GGACCTGCC	1500
	TCCCTCAGCC GTCAGCCATC AGCCATGGCC CTCCCAGTGC CTCCCTAGCCC CTTCTTCAA	1560
30	GGAGCAGAGA GGTGGCCACC GGGGGTGGCT CTGTCCCTACC TCCACTCTCT GCCCCTAAAG	1620
	ATGGGAGGAG ACCAGCGGTC CATGGGTCTG GCCTGTGAGT CTCCCCTTGC AGCCTGGTCA	1680
	CTAGGCATCA CCCCCGCTTT GGTTCTTCAG ATGCTTTGG GGTCATAGG GGCAGGTCT	1740
35	AGTCGGGCAG GGGCCCTGAC CCTCCCCGGCC TGGCTTCACT CTCCCTGACG GCTGCCATTG	1800
	GTCCACCCCTT TCATAGAGAG GCCTGCTTTG TTACAAAGCT CGGGTCTCCC TCCTGCAGCT	1860
40	CGGTTAAGTA CCCGAGGCCT CTCTTAAGAT GTCCAGGGCC CCAGGCCCCGC GGGCACAGCC	1920
	AGCCCCAAACC TTGGGCCCTG GAAGAGTCT CCACCCCATC ACTAGAGTGC TCTGACCCCTG	1980
	GGCTTTCACG GGCCCCATTC CACCGCCTCC CCAACTTGAG CCTGTGACCT TGGGACCAA	2040
45	GGGGGAGTCC CTCGTCTCTT GTGACTCAGC AGAGGCAGTG GCCACGTTCA GGGAGGGGCC	2100
	GGCTGGCCTG GAGGCTCAGC CCACCCCTCA GCTTTCCCT AGGGTGTCT GAGGTCCAAG	2160
	ATTCTGGAGC AATCTGACCC TTCTCCAAAG GCTCTGTTAT CAGCTGGCA GTGCCAGCCA	2220
50	ATCCCTGGCC ATTTGGCCCC AGGGGACGTG GGCCCTG	2257

## (2) INFORMATION FOR SEQ ID NO:28:

55

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 411 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: amino acid (Translation of Contig 2692004)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

65

	His Ala Asp Arg Arg Glu Ile Leu Ala Lys Tyr Pro Glu Ile		
1	5	10	15
	Lys Ser Leu Met Lys Pro Asp Pro Asn Leu Ile Trp Ile Ile Ile		
5	20	25	30
	Met Met Val Leu Thr Gln Leu Gly Ala Phe Tyr Ile Val Lys Asp		
	35	40	45
	Leu Asp Trp Lys Trp Val Ile Phe Gly Ala Tyr Ala Phe Gly Ser		
	50	55	60
10	Cys Ile Asn His Ser Met Thr Leu Ala Ile His Glu Ile Ala His		
	65	70	75
	Asn Ala Ala Phe Gly Asn Cys Lys Ala Met Trp Asn Arg Trp Phe		
	80	85	90
15	Gly Met Phe Ala Asn Leu Pro Ile Gly Ile Pro Tyr Ser Ile Ser		
	95	100	105
	Phe Lys Arg Tyr His Met Asp His His Arg Tyr Leu Gly Ala Asp		
	110	115	120
	Gly Val Asp Val Asp Ile Pro Thr Asp Phe Glu Gly Trp Phe Phe		
	125	130	135
20	Cys Thr Ala Phe Arg Lys Phe Ile Trp Val Ile Leu Gln Pro Leu		
	140	145	150
	Phe Tyr Ala Phe Arg Pro Leu Phe Ile Asn Pro Lys Pro Ile Thr		
	155	160	165
25	Tyr Leu Glu Val Ile Asn Thr Val Ala Gln Val Thr Phe Asp Ile		
	170	175	180
	Leu Ile Tyr Tyr Phe Leu Gly Ile Lys Ser Leu Val Tyr Met Leu		
	185	190	195
	Ala Ala Ser Leu Leu Gly Leu Gly His Pro Ile Ser Gly His		
	200	205	210
30	Phe Ile Ala Glu His Tyr Met Phe Leu Lys Gly His Glu Thr Tyr		
	215	220	225
	Ser Tyr Tyr Gly Pro Leu Asn Leu Leu Thr Phe Asn Val Gly Tyr		
	230	235	240
35	His Asn Glu His His Asp Phe Pro Asn Ile Pro Gly Lys Ser Leu		
	245	250	255
	Pro Leu Val Arg Lys Ile Ala Ala Glu Tyr Tyr Asp Asn Leu Pro		
	260	265	270
	His Tyr Asn Ser Trp Ile Lys Val Leu Tyr Asp Phe Val Met Asp		
	275	280	285
40	Asp Thr Ile Ser Pro Tyr Ser Arg Met Lys Arg His Gln Lys Gly		
	290	295	300
	Glu Met Val Leu Glu *** Ile Ser Leu Val Pro Lys Gly Phe Phe		
	305	310	315
45	Ser Lys Thr Leu Asp Asp Lys Met Glu Phe Leu His Tyr *** Thr		
	320	325	330
	*** Asp Gln *** Cys Ser Glu Ala Pro Leu Ala Gln Phe Gln Ser		
	335	340	345
	Lys Ser Ser Val Ile Pro Arg Ser Glu Ser Gly Phe *** Thr Val		
	350	355	360
50	Ser Leu Thr Leu Tyr Cys Ser Val Ser Leu Thr Gly Asn Leu ***		
	365	370	375
	Leu Val Tyr Tyr Arg His *** Gly Cys Phe Thr His Val Cys His		
	380	385	390
55	Phe Ile Ser Ile Ser Phe Lys Lys Leu Leu Lys Ser Tyr Phe Ala		
	400	405	410
	Arg		

## (2) INFORMATION FOR SEQ ID NO:29:

- 60           (i) SEQUENCE CHARACTERISTICS:  
               (A) LENGTH: 218 amino acids  
               (B) TYPE: amino acid

(C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: amino acid (Translation of Contig 2153526)

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

10	Tyr Leu Leu Arg Pro Leu Leu Pro His Leu Cys Ala Thr Ile Gly	
	1 5	10 15
	Ala Glu Ser Phe Leu Gly Leu Phe Phe Ile Val Arg Phe Leu Glu	
	20 25	30
	Ser Asn Trp Phe Val Trp Val Thr Gln Met Asn His Ile Pro Met	
	35 40	45
15	His Ile Asp His Asp Arg Asn Met Asp Trp Val Ser Thr Gln Leu	
	50 55	60
	Gln Ala Thr Cys Asn Val His Lys Ser Ala Phe Asn Asp Trp Phe	
	65 70	75
20	Ser Gly His Leu Asn Phe Gln Ile Glu His His Leu Phe Pro Thr	
	80 85	90
	Met Pro Arg His Asn Tyr His Lys Val Ala Pro Leu Val Gln Ser	
	95 100	105
	Leu Cys Ala Lys His Gly Ile Glu Tyr Gln Ser Lys Pro Leu Leu	
	110 115	120
25	Ser Ala Phe Ala Asp Ile Ile His Ser Leu Lys Glu Ser Gly Gln	
	125 130	135
	Leu Trp Leu Asp Ala Tyr Leu His Gln *** Gln Gln Pro Pro Cys	
	140 145	150
30	Pro Val Trp Lys Lys Arg Arg Lys Thr Leu Glu Pro Arg Gln Arg	
	155 160	165
	Gly Ala *** Gly Thr Met Pro Leu *** Phe Asn Thr Gln Arg Gly	
	170 175	180
	Leu Gly Leu Gly Thr *** Ser Leu *** Leu Lys Leu Leu Pro Phe	
	185 190	195
35	Ile Phe *** Pro Gln Phe *** Asp Pro Lys Trp Gly Val Asp Thr	
	200 205	210
	Glu Val Pro Arg Arg Glu Gly Ala	
	215	

40

(2) INFORMATION FOR SEQ ID NO:30:

45

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 71 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

50

(ii) MOLECULE TYPE: amino acid (Translation of Contig 3506132)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

55

1	Val Phe Tyr Phe Gly Asn Gly Trp Ile Pro Thr Leu Ile Thr Ala	
	5 10 15	
	Phe Val Leu Ala Thr Ser Gln Ala Gln Ala Gly Trp Leu Gln His	
	20 25 30	
60	Asp Tyr Gly His Leu Ser Val Tyr Arg Lys Pro Lys Trp Asn His	
	35 40 45	
	Leu Val His Lys Phe Val Ile Gly His Leu Lys Gly Ala Ser Ala	

	50	55	60
	Asn Trp Trp Asn His Arg His Phe Gln His His Ala Lys Pro Asn		
	65	70	75
5	Leu Gly Glu Trp Gln Pro Ile Glu Tyr Gly Lys Xxx		
	80	85	

## (2) INFORMATION FOR SEQ ID NO:31:

10

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 306 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

15

(ii) MOLECULE TYPE: amino acid (Translation of Contig 3854933)

20

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:

Gln	Gly	Pro	Thr	Pro	Arg	Tyr	Phe	Thr	Trp	Asp	Glu	Val	Ala	Gln	
1															15
Arg	Ser	Gly	Cys	Glu	Glu	Arg	Trp	Leu	Val	Ile	Asp	Arg	Lys	Val	
25															30
Tyr	Asn	Ile	Ser	Glu	Phe	Thr	Arg	Arg	His	Pro	Gly	Gly	Ser	Arg	
30															45
Val	Ile	Ser	His	Tyr	Ala	Gly	Gln	Asp	Ala	Thr	Asp	Pro	Phe	Val	
35															60
Ala	Phe	His	Ile	Asn	Lys	Gly	Leu	Val	Lys	Lys	Tyr	Met	Asn	Ser	
40															75
Leu	Leu	Ile	Gly	Glu	Leu	Ser	Pro	Glu	Gln	Pro	Ser	Phe	Glu	Pro	
45															90
Thr	Lys	Asn	Lys	Glu	Leu	Thr	Asp	Glu	Phe	Arg	Glu	Leu	Arg	Ala	
50															105
Thr	Val	Glu	Arg	Met	Gly	Leu	Met	Lys	Ala	Asn	His	Val	Phe		
55															120
Leu	Leu	Tyr	Leu	Leu	His	Ile	Leu	Leu	Leu	Asp	Gly	Ala	Ala	Trp	
60															135
Leu	Thr	Leu	Trp	Val	Phe	Gly	Thr	Ser	Phe	Leu	Pro	Phe	Leu		
65															150
Cys	Ala	Val	Leu	Leu	Ser	Ala	Val	Gln	Ala	Gln	Ala	Gly	Trp	Leu	
70															165
Gln	His	Asp	Phe	Gly	His	Leu	Ser	Val	Phe	Ser	Thr	Ser	Lys	Trp	
75															180
Asn	His	Leu	Leu	His	His	Phe	Val	Ile	Gly	His	Leu	Lys	Gly	Ala	
80															195
Pro	Ala	Ser	Trp	Trp	Asn	His	Met	His	Phe	Gln	His	His	Ala	Lys	
85															210
Pro	Asn	Cys	Phe	Arg	Lys	Asp	Pro	Asp	Ile	Asn	Met	His	Pro	Phe	
90															225
Phe	Phe	Ala	Leu	Gly	Lys	Ile	Leu	Ser	Val	Glu	Leu	Gly	Lys	Gln	
95															240
Lys	Lys	Lys	Tyr	Met	Pro	Tyr	Asn	His	Gln	His	Xxx	Tyr	Phe	Phe	
100															255
Leu	Ile	Gly	Pro	Pro	Ala	Leu	Leu	Pro	Leu	Tyr	Phe	Gln	Trp	Tyr	
105															270
Ile	Phe	Tyr	Phe	Val	Ile	Gln	Arg	Lys	Lys	Trp	Val	Asp	Leu	Ala	
110															285
Trp	Ile	Ser	Lys	Gln	Glu	Tyr	Asp	Glu	Ala	Gly	Leu	Pro	Leu	Ser	
115															300
Thr	Ala	Asn	Ala	Ser	Lys										

305

## (2) INFORMATION FOR SEQ ID NO:32:

5

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 566 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

10

(iii) MOLECULE TYPE: amino acid (Translation of Contig 2511785)

15

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:

	His	Leu	Lys	Gly	Ala	Ser	Ala	Asn	Trp	Trp	Asn	His	Arg	His	Phe
1									5		10				15
	Gln	His	His	Ala	Lys	Pro	Asn	Ile	Phe	His	Lys	Asp	Pro	Asp	Val
20						20				25					30
	Asn	Met	Leu	His	Val	Phe	Val	Leu	Gly	Glu	Trp	Gln	Pro	Ile	Glu
						35				40					45
	Tyr	Gly	Lys	Lys	Leu	Lys	Tyr	Leu	Pro	Tyr	Asn	His	Gln	His	
25						50				55					60
	Glu	Tyr	Phe	Leu	Ile	Gly	Pro	Pro	Leu	Leu	Ile	Pro	Met	Tyr	
						65				70					75
	Phe	Gln	Tyr	Gln	Ile	Ile	Met	Thr	Met	Ile	Val	His	Lys	Asn	Trp
30						80				85					90
	Val	Asp	Leu	Ala	Trp	Ala	Val	Ser	Tyr	Tyr	Ile	Arg	Phe	Phe	Ile
35						95				100					105
	Thr	Tyr	Ile	Pro	Phe	Tyr	Gly	Ile	Leu	Gly	Ala	Leu	Leu	Phe	Leu
40						110				115					120
	Asn	Phe	Ile	Arg	Phe	Leu	Glu	Ser	His	Trp	Phe	Val	Trp	Val	Thr
45						125				130					135
	Gln	Met	Asn	His	Ile	Val	Met	Glu	Ile	Asp	Gln	Glu	Ala	Tyr	Arg
50						140				145					150
	Asp	Trp	Phe	Ser	Ser	Gln	Leu	Thr	Ala	Thr	Cys	Asn	Val	Glu	Gln
55						155				160					165
	Ser	Phe	Phe	Asn	Asp	Trp	Phe	Ser	Gly	His	Leu	Asn	Phe	Gln	Ile
60						170				175					180
	Glu	His	His	Leu	Phe	Pro	Thr	Met	Pro	Arg	His	Asn	Leu	His	Lys
						185				190					195
	Ile	Ala	Pro	Leu	Val	Lys	Ser	Leu	Cys	Ala	Lys	His	Gly	Ile	Glu
						200				205					210
	Tyr	Gln	Glu	Lys	Pro	Leu	Leu	Arg	Ala	Leu	Leu	Asp	Ile	Ile	Arg
						215				220					225
	Ser	Leu	Lys	Lys	Ser	Gly	Lys	Leu	Trp	Leu	Asp	Ala	Tyr	Leu	His
						230				235					240
	Lys	***	Ser	His	Ser	Pro	Arg	Asp	Thr	Val	Gly	Lys	Gly	Cys	Arg
						245				250					255
	Trp	Gly	Asp	Gly	Gln	Arg	Asn	Asp	Gly	Leu	Leu	Phe	***	Gly	Val
						260				265					270
	Ser	Glu	Arg	Leu	Val	Tyr	Ala	Leu	Leu	Thr	Asp	Pro	Met	Leu	Asp
						275				280					285
	Leu	Ser	Pro	Phe	Leu	Leu	Ser	Phe	Phe	Ser	Ser	His	Leu	Pro	His
						290				295					300
	Ser	Thr	Leu	Pro	Ser	Trp	Asp	Leu	Pro	Ser	Leu	Ser	Arg	Gln	Pro
						305				310					315
	Ser	Ala	Met	Ala	Leu	Pro	Val	Pro	Pro	Ser	Pro	Phe	Phe	Gln	Gly
						320				325					330
	Ala	Glu	Arg	Trp	Pro	Pro	Gly	Val	Ala	Leu	Ser	Tyr	Leu	His	Ser
						335				340					345

	Leu Pro Leu Lys Met Gly Gly Asp Gln Arg Ser Met Gly Leu Ala		
	350	355	360
	Cys Glu Ser Pro Leu Ala Ala Trp Ser Leu Gly Ile Thr Pro Ala		
	365	370	375
5	Leu Val Leu Gln Met Leu Leu Gly Phe Ile Gly Ala Gly Pro Ser		
	380	385	390
	Arg Ala Gly Pro Leu Thr Leu Pro Ala Trp Leu His Ser Pro ***		
	400	405	410
10	Arg Leu Pro Leu Val His Pro Phe Ile Glu Arg Pro Ala Leu Leu		
	415	420	425
	Gln Ser Ser Gly Leu Pro Pro Ala Ala Arg Leu Ser Thr Arg Gly		
	430	435	440
	Leu Ser *** Asp Val Gln Gly Pro Arg Pro Ala Gly Thr Ala Ser		
	445	450	455
15	Pro Asn Leu Gly Pro Trp Lys Ser Pro Pro Pro His His *** Ser		
	460	465	470
	Ala Leu Thr Leu Gly Phe His Gly Pro His Ser Thr Ala Ser Pro		
	475	480	485
20	Thr *** Ala Cys Asp Leu Gly Thr Lys Gly Gly Val Pro Arg Leu		
	490	495	500
	Leu *** Leu Ser Arg Gly Ser Gly His Val Gln Gly Gly Ala Gly		
	505	510	515
	Trp Pro Gly Gly Ser Ala His Pro Pro Ala Phe Pro Gln Gly Val		
	520	525	530
25	Leu Arg Ser Lys Ile Leu Glu Gln Ser Asp Pro Ser Pro Lys Ala		
	535	540	545
	Leu Leu Ser Ala Gly Gln Cys Gln Pro Ile Pro Gly His Leu Ala		
	550	555	560
30	Pro Gly Asp Val Gly Pro Xxx		
	565		

## (2) INFORMATION FOR SEQ ID NO:33:

- 35           (i) SEQUENCE CHARACTERISTICS:  
               (A) LENGTH: 619 amino acids  
               (B) TYPE: amino acid  
               (C) STRANDEDNESS: single  
               (D) TOPOLOGY: linear
- 40           (ii) MOLECULE TYPE: amino acid (Translation of Contig 2535)
- 45           (xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:

	Val Phe Tyr Phe Gly Asn Gly Trp Ile Pro Thr Leu Ile Thr Ala	
	1               5               10               15	
	Phe Val Leu Ala Thr Ser Gln Ala Gln Ala Gly Trp Leu Gln His	
50	20               25               30	
	Asp Tyr Gly His Leu Ser Val Tyr Arg Lys Pro Lys Trp Asn His	
	35               40               45	
	Leu Val His Lys Phe Val Ile Gly His Leu Lys Gly Ala Ser Ala	
	50               55               60	
55	Asn Trp Trp Asn His Arg His Phe Gln His His Ala Lys Pro Asn	
	65               70               75	
	Ile Phe His Lys Asp Pro Asp Val Asn Met Leu His Val Phe Val	
	80               85               90	
60	Leu Gly Glu Trp Gln Pro Ile Glu Tyr Gly Lys Lys Lys Leu Lys	
	95               100               105	
	Tyr Leu Pro Tyr Asn His Gln His Glu Tyr Phe Phe Leu Ile Gly	
	110               115               120	

	Pro Pro Leu Leu Ile Pro Met Tyr Phe Gln Tyr Gln Ile Ile Met	
	125 130 135	
	Thr Met Ile Val His Lys Asn Trp Val Asp Leu Ala Trp Ala Val	
	140 145 150	
5	Ser Tyr Tyr Ile Arg Phe Phe Ile Thr Tyr Ile Pro Phe Tyr Gly	
	155 160 165	
	Ile Leu Gly Ala Leu Leu Phe Leu Asn Phe Ile Arg Phe Leu Glu	
	170 175 180	
	Ser His Trp Phe Val Trp Val Thr Gln Met Asn His Ile Val Met	
10	185 190 195	
	Glu Ile Asp Gln Glu Ala Tyr Arg Asp Trp Phe Ser Ser Gln Leu	
	200 205 210	
	Thr Ala Thr Cys Asn Val Glu Gln Ser Phe Phe Asn Asp Trp Phe	
	215 220 225	
15	Ser Gly His Leu Asn Phe Gln Ile Glu His His Leu Phe Pro Thr	
	230 235 240	
	Met Pro Arg His Asn Leu His Lys Ile Ala Pro Leu Val Lys Ser	
	245 250 255	
	Leu Cys Ala Lys His Gly Ile Glu Tyr Gln Glu Lys Pro Leu Leu	
20	260 265 270	
	Arg Ala Leu Leu Asp Ile Ile Arg Ser Leu Lys Lys Ser Gly Lys	
	275 280 285	
	Leu Trp Leu Asp Ala Tyr Leu His Lys *** Ser His Ser Pro Arg	
	290 295 300	
25	Asp Thr Val Gly Lys Gly Cys Arg Trp Gly Asp Gly Gln Arg Asn	
	305 310 315	
	Asp Gly Leu Leu Phe *** Gly Val Ser Glu Arg Leu Val Tyr Ala	
	320 325 330	
	Leu Leu Thr Asp Pro Met Leu Asp Leu Ser Pro Phe Leu Leu Ser	
30	335 340 345	
	Phe Phe Ser Ser His Leu Pro His Ser Thr Leu Pro Ser Trp Asp	
	350 355 360	
	Leu Pro Ser Leu Ser Arg Gln Pro Ser Ala Met Ala Leu Pro Val	
	365 370 375	
35	Pro Pro Ser Pro Phe Phe Gln Gly Ala Glu Arg Trp Pro Pro Gly	
	380 385 390	
	Val Ala Leu Ser Tyr Leu His Ser Leu Pro Leu Lys Met Gly Gly	
	400 405 410	
	Asp Gln Arg Ser Met Gly Leu Ala Cys Glu Ser Pro Leu Ala Ala	
40	415 420 425	
	Trp Ser Leu Gly Ile Thr Pro Ala Leu Val Leu Gln Met Leu Leu	
	430 435 440	
	Gly Phe Ile Gly Ala Gly Pro Ser Arg Ala Gly Pro Leu Thr Leu	
	445 450 455	
45	Pro Ala Trp Leu His Ser Pro *** Arg Leu Pro Leu Val His Pro	
	460 465 470	
	Phe Ile Glu Arg Pro Ala Leu Leu Gln Ser Ser Gly Leu Pro Pro	
	475 480 485	
	Ala Ala Arg Leu Ser Thr Arg Gly Leu Ser *** Asp Val Gln Gly	
50	490 495 500	
	Pro Arg Pro Ala Gly Thr Ala Ser Pro Asn Leu Gly Pro Trp Lys	
	505 510 515	
	Ser Pro Pro His His *** Ser Ala Leu Thr Leu Gly Phe His	
	520 525 530	
55	Gly Pro His Ser Thr Ala Ser Pro Thr *** Ala Cys Asp Leu Gly	
	535 540 545	
	Thr Lys Gly Gly Val Pro Arg Leu Leu *** Leu Ser Arg Gly Ser	
	550 555 560	
	Gly His Val Gln Gly Gly Ala Gly Trp Pro Gly Gly Ser Ala His	
60	565 570 575	
	Pro Pro Ala Phe Pro Gln Gly Val Leu Arg Ser Lys Ile Leu Glu	
	580 585 590	

Gln Ser Asp Pro Ser Pro Lys Ala Leu Leu Ser Ala Gly Gln Cys  
 595 600 605  
 Gln Pro Ile Pro Gly His Leu Ala Pro Gly Asp Val Gly Pro Xxx  
 610 615 620

5

## (2) INFORMATION FOR SEQ ID NO:34:

- 10 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 757 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

15 (ii) MOLECULE TYPE: amino acid (Translation of Contig 253538a)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:

20	Gln	Gly	Pro	Thr	Pro	Arg	Tyr	Phe	Thr	Trp	Asp	Glu	Val	Ala	Gln
	1					5				10					15
	Arg	Ser	Gly	Cys	Glu	Glu	Arg	Trp	Leu	Val	Ile	Asp	Arg	Lys	Val
					20					25					30
25	Tyr	Asn	Ile	Ser	Glu	Phe	Thr	Arg	Arg	His	Pro	Gly	Gly	Ser	Arg
					35					40					45
	Val	Ile	Ser	His	Tyr	Ala	Gly	Gln	Asp	Ala	Thr	Asp	Pro	Phe	Val
					50					55					60
30	Ala	Phe	His	Ile	Asn	Lys	Gly	Leu	Val	Lys	Lys	Tyr	Met	Asn	Ser
					65					70					75
	Leu	Leu	Ile	Gly	Glu	Leu	Ser	Pro	Glu	Gln	Pro	Ser	Phe	Glu	Pro
					80					85					90
	Thr	Lys	Asn	Lys	Glu	Leu	Thr	Asp	Glu	Phe	Arg	Glu	Leu	Arg	Ala
					95					100					105
35	Thr	Val	Glu	Arg	Met	Gly	Leu	Met	Lys	Ala	Asn	His	Val	Phe	Phe
					110					115					120
	Leu	Leu	Tyr	Leu	Leu	His	Ile	Leu	Leu	Leu	Asp	Gly	Ala	Ala	Trp
					125					130					135
40	Leu	Thr	Leu	Trp	Val	Phe	Gly	Thr	Ser	Phe	Leu	Pro	Phe	Leu	Leu
					140					145					150
	Cys	Ala	Val	Leu	Leu	Ser	Ala	Val	Gln	Gln	Ala	Gln	Ala	Gly	Trp
					155					160					165
	Leu	Gln	His	Asp	Tyr	Gly	His	Leu	Ser	Val	Tyr	Arg	Lys	Pro	Lys
					170					175					180
45	Trp	Asn	His	Leu	Val	His	Lys	Phe	Val	Ile	Gly	His	Leu	Lys	Gly
					185					190					195
	Ala	Ser	Ala	Asn	Trp	Trp	Asn	His	Arg	His	Phe	Gln	His	His	Ala
					200					205					210
50	Lys	Pro	Asn	Ile	Phe	His	Lys	Asp	Pro	Asp	Val	Asn	Met	Leu	His
					215					220					225
	Val	Phe	Val	Leu	Gly	Glu	Trp	Gln	Pro	Ile	Glu	Tyr	Gly	Lys	Lys
					230					235					240
	Lys	Leu	Lys	Tyr	Leu	Pro	Tyr	Asn	His	Gln	His	Glu	Tyr	Phe	Phe
					245					250					255
55	Leu	Ile	Gly	Pro	Pro	Leu	Leu	Ile	Pro	Met	Tyr	Phe	Gln	Tyr	Gln
					260					265					270
	Ile	Ile	Met	Thr	Met	Ile	Val	His	Lys	Asn	Trp	Val	Asp	Leu	Ala
					275					280					285
60	Trp	Ala	Val	Ser	Tyr	Tyr	Ile	Arg	Phe	Phe	Ile	Thr	Tyr	Ile	Pro
					290					295					300
	Phe	Tyr	Gly	Ile	Leu	Gly	Ala	Leu	Leu	Phe	Leu	Asn	Phe	Ile	Arg
					305					310					315

	Phe Leu Glu Ser His Trp Phe Val Trp Val Thr Gln Met Asn His		
	320	325	330
	Ile Val Met Glu Ile Asp Gln Glu Ala Tyr Arg Asp Trp Phe Ser		
	335	340	345
5	Ser Gln Leu Thr Ala Thr Cys Asn Val Glu Gln Ser Phe Phe Asn		
	350	355	360
	Asp Trp Phe Ser Gly His Leu Asn Phe Gln Ile Glu His His Leu		
	365	370	375
10	Phe Pro Thr Met Pro Arg His Asn Leu His Lys Ile Ala Pro Leu		
	380	385	390
	Val Lys Ser Leu Cys Ala Lys His Gly Ile Glu Tyr Gln Glu Lys		
	400	405	410
	Pro Leu Leu Arg Ala Leu Leu Asp Ile Ile Arg Ser Leu Lys Lys		
	415	420	425
15	Ser Gly Lys Leu Trp Leu Asp Ala Tyr Leu His Lys *** Ser His		
	430	435	440
	Ser Pro Arg Asp Thr Val Gly Lys Gly Cys Arg Trp Gly Asp Gly		
	445	450	455
20	Gln Arg Asn Asp Gly Leu Leu Phe *** Gly Val Ser Glu Arg Leu		
	460	465	470
	Val Tyr Ala Leu Leu Thr Asp Pro Met Leu Asp Leu Ser Pro Phe		
	475	480	485
	Leu Leu Ser Phe Phe Ser Ser His Leu Pro His Ser Thr Leu Pro		
	490	495	500
25	Ser Trp Asp Leu Pro Ser Leu Ser Arg Gln Pro Ser Ala Met Ala		
	505	510	515
	Leu Pro Val Pro Pro Ser Pro Phe Phe Gln Gly Ala Glu Arg Trp		
	520	525	530
	Pro Pro Gly Val Ala Leu Ser Tyr Leu His Ser Leu Pro Leu Lys		
30	535	540	545
	Met Gly Gly Asp Gln Arg Ser Met Gly Leu Ala Cys Glu Ser Pro		
	550	555	560
	Leu Ala Ala Trp Ser Leu Gly Ile Thr Pro Ala Leu Val Leu Gln		
	565	570	575
35	Met Leu Leu Gly Phe Ile Gly Ala Gly Pro Ser Arg Ala Gly Pro		
	580	585	590
	Leu Thr Leu Pro Ala Trp Leu His Ser Pro *** Arg Leu Pro Leu		
	595	600	605
40	Val His Pro Phe Ile Glu Arg Pro Ala Leu Leu Gln Ser Ser Gly		
	610	615	620
	Leu Pro Pro Ala Ala Arg Leu Ser Thr Arg Gly Leu Ser *** Asp		
	625	630	635
	Val Gln Gly Pro Arg Pro Ala Gly Thr Ala Ser Pro Asn Leu Gly		
	640	645	650
45	Pro Trp Lys Ser Pro Pro His His *** Ser Ala Leu Thr Leu		
	655	660	665
	Gly Phe His Gly Pro His Ser Thr Ala Ser Pro Thr *** Ala Cys		
	670	675	680
50	Asp Leu Gly Thr Lys Gly Gly Val Pro Arg Leu Leu *** Leu Ser		
	685	690	695
	Arg Gly Ser Gly His Val Gln Gly Gly Ala Gly Trp Pro Gly Gly		
	700	705	710
	Ser Ala His Pro Pro Ala Phe Pro Gln Gly Val Leu Arg Ser Lys		
	715	720	725
55	Ile Leu Glu Gln Ser Asp Pro Ser Pro Lys Ala Leu Leu Ser Ala		
	730	735	740
	Gly Gln Cys Gln Pro Ile Pro Gly His Leu Ala Pro Gly Asp Val		
	745	750	755
60	Gly Pro Xxx		

What is claimed is:

1. An isolated nucleic acid comprising:
  - a nucleotide sequence depicted in a SEQ ID NO. 1
2. A polypeptide encoded by said nucleic acid of claim 1.
- 5 3. A purified or isolated polypeptide comprising an amino acid sequence depicted in SEQ ID NO: 2.
4. An isolated nucleic acid encoding the polypeptide of SEQ ID NO: 2.
5. An isolated nucleic acid comprising:
  - 10 a nucleotide sequence which encodes a polypeptide that desaturates a fatty acid molecule at carbon 5 from the carboxyl end of said fatty acid molecule.
  6. The isolated nucleic acid according to Claim 5, wherein said nucleotide sequence is derived from eukaryotic cell.
  - 15 7. The isolated nucleic acid according to Claim 6, wherein said eukaryotic cell is a fungal cell.
  8. The isolated nucleic acid according to Claim 7, wherein said fungal cell is of the genus *Mortierella*.
  9. The isolated nucleic acid according to Claim 8, wherein said 20 *Mortierella* cell is of the species *Mortierella alpina*.
  10. The isolated nucleic acid according to Claim 5, wherein said nucleotide sequence anneals to a nucleotide sequence depicted in SEQ ID NO: 1.
  11. The nucleic acid of claim 10, wherein said nucleotide sequence encodes an amino acid sequence depicted in SEQ ID NO: 2.
  - 25 12. The nucleic acid of claim 11, wherein said amino acid sequence depicted in SEQ ID NO: 2 is selected from the group consisting of amino acid residues 30-38, 41-44, 171-175, 203-212, and 387-394.

13. An isolated or purified polypeptide which desaturates a fatty acid molecule at carbon 5 from the carboxyl end of said fatty acid molecule.

14. An isolated nucleic acid comprising:

5 a nucleotide sequence which is substantially identical to a sequence of at least 50 nucleotides in SEQ ID NO 1.

15. An isolated nucleic acid sequence having at least about 50% identity to SEQ ID NO 1.

16. A nucleic acid construct comprising:

10 a nucleotide sequence depicted in a SEQ ID NO: 1 linked to a heterologous nucleic acid.

17. A nucleic acid construct comprising:

a nucleotide sequence depicted in a SEQ ID NO: 1 operably linked to a promoter.

18. The nucleic acid construct of claim 17, wherein said promoter is functional in a microbial cell.

19. The nucleic acid construct of claim 18, wherein said microbial cell is a yeast cell.

20. The nucleic acid construct of claim 17, wherein said nucleotide sequence is derived from a fungus.

21. The nucleic acid according to Claim 19, wherein said fungus is of the genus *Mortierella*.

22. The nucleic acid according to Claim 20, wherein said fungus is of the species *Mortierella alpina*.

23. A nucleic acid construct comprising:

25 a nucleotide sequence which encodes a polypeptide comprising an amino acid sequence which corresponds to or is complementary to an amino acid sequence depicted in SEQ ID NO: 2, wherein said nucleotide sequence is operably linked to a promoter which is functional in a host cell, wherein said nucleotide

sequence encodes a polypeptide which desaturates a fatty acid molecule at carbon 5 from the carboxyl end of a fatty acid molecule.

24. A nucleic acid construct comprising:

a nucleotide sequence which encodes a functionally active Δ5-desaturase, said desaturase having an amino acid sequence which corresponds to or is complementary to all of or a portion of an amino acid sequence depicted in a SEQ ID NO: 2, wherein said nucleotide sequence is operably linked to a promoter functional in a host cell.

25. A recombinant yeast cell comprising:

10 a nucleic construct according to Claim 23 or Claim 24.

26. The recombinant yeast cell according to Claim 25, wherein said yeast cell is a *Saccharomyces* cell.

27. A host cell comprising:

15 at least one copy of a nucleotide sequence which encodes a polypeptide which converts dihomo-γ-linolenic acid to arachidonic acid, wherein said microbial cell or an ancestor of said microbial cell was transformed with a vector comprising said nucleotide sequence, and wherein said nucleotide sequence is operably linked to a promoter functional in said host cell.

28. The microbial cell according to Claim 27, wherein said cell is a host cell selected from the group consisting of a fungal cell and an algal cell.

29. The microbial cell according to Claim 28, wherein said fungal cell is a yeast cell and said algae cell is marine algal cell.

30. The microbial cell according to Claim 27, wherein said cell is enriched for 20:3 fatty acids as compared to a host cell which is devoid of said nucleotide sequence.

31. The microbial cell according to Claim 27, wherein said cell is enriched for 20:4 or ω-3 20:4 fatty acids as compared to a host cell which is devoid of said DNA sequence.

32. The microbial cell according to Claim 27, wherein said cell is enriched for 20:5 fatty acids as compared to a host cell which is devoid of said DNA sequence.

5 33. The microbial cell according to Claim 27, wherein said cell has an altered amount of 20:3 (8, 11, 14) fatty acid as compared to an untransformed microbial cell.

34. A method for production of arachidonic acid in a microbial cell culture, said method comprising:

10 growing a microbial cell culture having a plurality of microbial cells, wherein said microbial cells or ancestors of said microbial cells were transformed with a vector comprising one or more nucleic acids having a nucleotide sequence which encodes a polypeptide which converts dihomo- $\gamma$ -linolenic acid to arachidonic acid, wherein said one or more nucleic acids are operably linked to a promoter, under conditions wherein said one or more nucleic acids are expressed and arachidonic acid is produced in said microbial 15 cell culture.

35. The method of Claim 34, wherein said polypeptide is an enzyme which desaturates a fatty acid molecule at carbon 5 from the carboxyl end of said fatty acid molecule.

20 36. The method of Claim 34, wherein said nucleotide sequence is derived from a *Mortierella species*.

37. The method according to Claim 34, wherein said dihomo- $\gamma$ -linolenic acid is exogenously supplied.

25 38. The method according to Claim 34, wherein said microbial cells are yeast cells.

39. The method according to Claim 38, wherein said yeast cells are *Saccharomyces species* cells.

40. The method according to Claim 34, wherein said conditions are inducible.

41. A recombinant yeast cell which converts greater than about 5% of a 20:3 fatty acid to a 20:4 fatty acid.
42. A nucleic acid probe comprising:  
a nucleotide sequence as represented by SEQ ID NO:1.
- 5 A host cell comprising:  
a nucleic acid construct according to Claim 23 or Claim 24.
43. A host cell comprising:  
a vector which includes a nucleic acid which encodes a fatty acid desaturase derived from *Mortierella alpina*, wherein said fatty acid desaturase comprises an amino acid sequence represented by SEQ ID NO:2, wherein said nucleic acid is operably linked to a promoter.
- 10 44. The host cell according to Claim 43, wherein said host cell is a eukaryotic cell.
45. The host cell according to Claim 44, wherein said host cell is a eukaryotic cell.
- 15 46. The host cell according to Claim 45, wherein said eukaryotic cell is selected from the group consisting of a mammalian cell, a plant cell, a fungal cell, an avian cell and an algal cell.
47. The host cell according to Claim 45, wherein said host cell contains dihomo-gamma-linolenic acid.
- 20 48. The host cell according to Claim 45, wherein said host cell contains EPA.
49. The host cell according to Claim 44, wherein said promoter is exogenously supplied.
- 25 50. A method for desaturating a dihomo- $\gamma$ -linolenic acid, said method comprising:  
culturing a recombinant microbial cell according to Claim 37, under conditions suitable for expression of polypeptide encoded by said nucleic acid, wherein said host cell further comprises a fatty acid substrate of said polypeptide.

51. A fatty acid desaturated by the method according to Claim 50.
52. An oil comprising a fatty acid according to Claim 51.
53. A method for obtaining altered long chain polyunsaturated fatty acid biosynthesis comprising the steps of:
  - 5 growing a microbe having cells which contain a transgene which encodes a transgene expression product which desaturates a fatty acid molecule at carbon 5 from the carboxyl end of said fatty acid molecule, wherein said transgene is operably associated with an expression control sequence, under conditions whereby said transgene is expressed, whereby long chain polyunsaturated fatty acid biosynthesis in said cells is altered.
  - 10 54. A method for obtaining altered long chain polyunsaturated fatty acid biosynthesis comprising the steps of:
    - growing a microbe having cells which contain a transgene, derived from a fungus or algae, which encodes a transgene expression product which desaturates a fatty acid molecule at carbon 5 from the carboxyl end of said fatty acid molecule, wherein said transgene is operably associated with an expression control sequence, under conditions whereby said one or more transgenes is expressed, whereby long chain polyunsaturated fatty acid biosynthesis in said cells is altered.
  - 15 55. The method according to claims 53 or 54, wherein said long chain polyunsaturated fatty acid is selected from the group consisting of ARA, DGLA and EPA.
  - 20 56. A microbial oil or fraction thereof produced according to the method of claims 53 or 54.
  - 25 57. A method of treating or preventing malnutrition comprising administering said microbial oil of claim 56 to a patient in need of said treatment or prevention in an amount sufficient to effect said treatment or prevention.
  58. A pharmaceutical composition comprising said microbial oil or fraction of claim 56 and a pharmaceutically acceptable carrier.

59. The pharmaceutical composition of claim 58, wherein said pharmaceutical composition is in the form of a solid or a liquid.

60. The pharmaceutical composition of claim 59, wherein said pharmaceutical composition is in a capsule or tablet form.

5 61. The pharmaceutical composition of claim 58 further comprising at least one nutrient selected from the group consisting of a vitamin, a mineral, a carbohydrate, a sugar, an amino acid, a free fatty acid, a phospholipid, an antioxidant, and a phenolic compound.

10 62. A nutritional formula comprising said microbal oil or fraction thereof of claim 56.

63. The nutritional formula of claim 62, wherein said nutritional formula is selected from the group consisting of an infant formula, a dietary supplement, and a dietary substitute.

15 64. The nutritional formula of claim 63, wherein said infant formula, dietary supplement or dietary supplement is in the form of a liquid or a solid.

65. An infant formula comprising said microbal oil or fraction thereof of claim 56.

20 66. The infant formula of claim 65 further comprising at least one macronutrient selected from the group consisting of coconut oil, soy oil, canola oil, mono- and diglycerides, glucose, edible lactose, electrodialysed whey, electrodialysed skim milk, milk whey, soy protein, and other protein hydrolysates.

25 67. The infant formula of claim 66 further comprising at least one vitamin selected from the group consisting of Vitamins A, C, D, E, and B complex; and at least one mineral selected from the group consisting of calcium, magnesium, zinc, manganese, sodium, potassium, phosphorus, copper, chloride, iodine, selenium, and iron.

68. A dietary supplement comprising said microbal oil or fraction thereof of claim 56.

69. The dietary supplement of claim 68 further comprising at least one macronutrient selected from the group consisting of coconut oil, soy oil, canola oil, mono- and diglycerides, glucose, edible lactose, electrodialysed whey, electrodialysed skim milk, milk whey, soy protein, and other protein hydrolysates.

5           70. The dietary supplement of claim 69 further comprising at least one vitamin selected from the group consisting of Vitamins A, C, D, E, and B complex; and at least one mineral selected from the group consisting of calcium, magnesium, zinc, manganese, sodium, potassium, phosphorus, copper, chloride, iodine, selenium, and iron.

10           71. The dietary supplement of claim 68 or claim 70, wherein said dietary supplement is administered to a human or an animal.

72. A dietary substitute comprising said microbial oil or fraction thereof of claim 56.

15           73. The dietary substitute of claim 72 further comprising at least one macronutrient selected from the group consisting of coconut oil, soy oil, canola oil, mono- and diglycerides, glucose, edible lactose, electrodialysed whey, electrodialysed skim milk, milk whey, soy protein, and other protein hydrolysates.

20           74. The dietary substitute of claim 73 further comprising at least one vitamin selected from the group consisting of Vitamins A, C, D, E, and B complex; and at least one mineral selected from the group consisting of calcium, magnesium, zinc, manganese, sodium, potassium, phosphorus, copper, chloride, iodine, selenium, and iron.

25           75. The dietary substitute of claim 72 or claim 74, wherein said dietary substitute is administered to a human or animal.

30           76. A method of treating a patient having a condition caused by insufficient intake or production of polyunsaturated fatty acids comprising administering to said patient said dietary substitute of claim 72 or said dietary supplement of claim 68 in an amount sufficient to effect said treatment.

77. The method of claim 72, wherein said dietary substitute or said dietary supplement is administered enterally or parenterally.

78. A cosmetic comprising said microbial oil or fraction thereof of claim 56.

5 79. The cosmetic of claim 78, wherein said cosmetic is applied topically.

80. The pharmaceutical composition of claim 58, wherein said pharmaceutical composition is administered to a human or an animal.

10 81. An animal feed comprising said microbial oil or fraction thereof of claim 56.

82. The method of claim 54 wherein said fungus is *Mortierella species*.

83. The method of claim 82 wherein said fungus is *Mortierella alpina*.

15 84. An isolated nucleotide sequence selected from the group consisting of SEQ ID NO:13 and SEQ ID NO:15.

85. An isolated nucleotide sequence from the group consisting of SEQ ID NO:7 and SEQ ID NO:19.

86. An isolated nucleotide sequence comprising a nucleotide sequence selected from the group consisting of: SEQ ID NO:13; SEQ ID NO:15; SEQ ID NO:17; SEQ ID NO:19; SEQ ID NO:21; SEQ ID NO:22; SEQ ID NO:23; SEQ ID NO:24; SEQ ID NO:25; SEQ ID NO:26 and SEQ ID NO:27.

20 87. An isolated peptide sequence comprising a peptide sequence selected from the group consisting of: SEQ ID NO:14; SEQ ID NO:16; SEQID NO:18; SEQ ID NO:20; SEQ ID NO:28; SEQ ID NO:29; SEQ ID NO:30; SEQ ID NO:31; SEQ ID NO:32; SEQ ID NO:33 and SEQ ID NO:34.

25 88. Purified polypeptides produced from the nucleotide sequences of claims 84-86.

1/17




FIG. 1




FIG. 2

FIG. 3A

GCTTCCTCCA GTTCATCCTC CATTGCGCA CCTGCGATCTT TTACGACCGT TAAGCAA  
 60      \*  
 ATG CGA ACG GAC CAA GGA AAA ACC TTC ACC TGG GAA GAG CTG GCG GCC  
 Met Gly Thr Asp Glu Lys Thr Phe Thr Phe Thr Trp Glu Glu Leu Ala Ala  
 120      \*  
 CAT AAC ACC AAG GAC GAC CTA CTC TTG GCC ATC CGC GGC AGG GTG TAC  
 His Asn Thr Lys Asp Asp Leu Leu Ala Ile Arg Gly Arg Val Tyr  
 180      \*  
 GAT GTC ACA AAG TTC TTG AGC CGC CAT CCT GGT GGA GTG GAC ACT CTC  
 Asp Val Thr Lys Phe Leu Ser Arg His Pro Gly Gly Val Asp Thr Leu  
 240      \*  
 CTG CTC GGA GCT GGC CGA GAT GTT ACT CCG GTC TTT GAG ATG TAT CAC  
 Leu Leu Gly Ala Gly Arg Asp Val Thr Pro Val Phe Glu Met Tyr His  
 GCG TTT GGG GCT GCA GAT GCC ATT ATG AAG TAC TAT GTC GGT ACA  
 Ala Phe Gly Ala Ala Asp Ala Ile Met Lys Lys Tyr Tyr Val Gly Thr  
 300      \*  
 CTG GTC TCG AAT GAG CTG CCC ATC TTC CCG GAG CCA ACG GTG TTC CAC  
 Leu Val Ser Asn Glu Leu Pro Ile Phe Pro Glu Pr Thr Val Phe His  
 360      \*  
 AAA ACC ATC AAG ACG AGA GTC GAG GGC TAC TTT ACC GAT CGG AAC ATT  
 Lys Thr Ile Lys Thr Arg Val Glu Gly Tyr Phe Thr Asp Arg Asn Ile

FIG. 3B

GAT CCC AAG AAT AGA CCA GAG ATC TGG GGA CGA TAC GCT CCT ATC TTT  
 Asp Pro Lys Asn Arg Pro Glu Ile Trp Gly Arg Tyr Ala Leu Ile Phe  
 420

GGA TCC TTG ATC GCT TCC TAC TAC GCG CAG CTC TTT GTG CCT TTC GTT  
 Gly Ser Leu Ile Ala Ser Tyr Tyr Ala Gln Leu Phe Val Pro Phe Val  
 480

GTC GAA CGC ACA TGG CTT CAG GTG GTG TTT GCA ATC ATC ATG GGA TTT.  
 Val Glu Arg Thr Trp Leu Gln Val Val Phe Ala Ile Ile Met Gly Phe  
 540

GCG TGC GCA CAA GTC GGA CTC AAC CCT CTT CAT GAT GCG TCT CAC TTT  
 Ala Cys Ala Gln Val Gly Leu Asn Pro Leu His Asp Ala Ser His Phe  
 600

TCA GTG ACC GAC AAC CCC ACT GTC TGG AAG ATT CTG GGA GCC ACG CAC  
 Ser Val Thr His Asn Pro Thr Val Trp Lys Ile Leu Gly Ala Thr His  
 660

GAC TTT TTC AAC GGA GCA TCG TAC CTG GTG TGG ATG TAC CAA CAT ATG  
 Asp Phe Asn Gly Ala Ser Tyr Leu Val Val Trp Met Tyr Gln His Met  
 720

CTC GGC CAT CAC CCC TAC ACC AAC ATT CCT GGA GCA GAT CCC GAC GTG  
 Leu Gly His His Pro Tyr Thr Asn Ile Ala Gly Ala Asp Pro Asp Val

## FIG. 3C

TCG ACC TCT GAG CCC GAT CCT CGT CGT ATC AAG CCC AAC CAA AAG TCG  
Ser Thr Ser Glu Pro Asp Val Arg Arg Ile Lys Pro Asn Gln Lys Trp

780

TTC GTC AAC CAC ATC AAC CAG CAC ATG TTT GTT CCT TTC CTG TAC GGA  
Phe Val Asn His Ile Asn Gln His Met Phe Val Pro Phe Leu Tyr Gly

840

CTG CTG GCG TTC AAG GTG CGC ATT CAG GAC ATC AAC ATT TAC TAC TTT  
Leu Leu Ala Phe Lys Val Arg Ile Gln Asp Ile Asn Ile Asn Ile Leu Tyr Phe

900

GTC AAG ACC AAT GAC GCT ATT CGT GTC ATT CCC ATC TCG ACA TGG CAC  
Val Lys Thr Asn Asp Ala Ile Arg Val Asn Pro Ile Ser Thr Trp His

960

ACT GTC ATG TTC TGG GGC AAG GCT TTC TTT GTC TGG TAT CGC CTG  
Thr Val Met Phe Trp Gly Gly Lys Ala Phe Val Trp Tyr Arg Leu

1020

ATT GTT CCC CTG CAG TAT CTG CCC CTG GGC AAG GTC CTG CTC TGG TTC  
Ile Val Pro Leu Gln Tyr Leu Pro Ile Lys Val Leu Leu Leu Phe

ACG GTC GCG GAC ATG GTG TCG TCT TAC TGG CTG GCG CTG ACC TTC CAG  
Thr Val Ala Asp Met Val Ser Ser Tyr Trp Leu Ala Leu Thr Phe Gln

## FIG. 3D

1080                    GCG AAC CAC GTT GAG GAA GTT CAG TGG CCG TTG CCT GAC GAG AAC  
Ala Asn His Val Val Glu Glu Val Gln Trp Pro Leu Pro Asp Glu Asn

1140                    GGG ATC ATC CAA AAG GAC TGG GCA GCT ATG CAG GTC GAG ACT ACG CAG  
Gly Ile Ile Gln Lys Asp Trp Ala Ala Met Gln Val Glu Thr Thr Gln 1200

1260                    GAT TAC GCA CAC GAT TCG CAC CTC TGG ACC AGC ATC ATC GGC AGC TTC  
Asp Tyr Ala His Asp Ser His Leu Trp Thr Ser Ile Thr Gly Ser Leu

                          AAC TAC CAG GCT GTG CAC CAT CTG TTC CCC AAC GTG TCG CAG CAC CAT  
Asn Tyr Gln Ala Val His His Leu Phe Pro Asn Val Ser Gln His His

1320                    TAT CCC GAT ATT CTG GCC ATC ATC AAG AAC ACC TGC AGC GAG TAC AAG  
Tyr Pro Asp Ile Ile Leu Ala Ile Ile Lys Asn Thr Cys Ser Glu Tyr Lys

1380                    GTT CCA TAC CTT GTC AAG GAT ACC TTT TGG CAA GCA TTT GCT TCA CAT  
Val Pro Tyr Leu Val Lys Asp Thr Phe Trp Gln Ala Phe Ala Ser His

1440                    TTG GAG CAC TTG CGT GTR CTR GGA CTC CGT CCC AAG GAA GAG TAGA  
Leu Glu His Leu Arg Val Leu Gly Leu Arg Pro Lys Glu Glu

                          AGAAAAAAAG CGCCGAATGA AGTATTGCC CCAAGATGCC AAAAGGAGAT  
                          CAAAGTGACA TTCTCTATGA AGA

7/17

**FIG. 4**

10	20	30	40	50	60
LHHTYTNIAG ADPDVSTSEP DVRRIKPNQK WFVNHNINQHM FVPFLYGLLA FKVRIQDINI					
70	80	90	100	110	120
LYFVKTNDAI RVNPISTWHT VMFWGGKAFF VVYRLIVPLQ YLPLGKVLLL FTVADMVSSY					
130	140	150	160	170	180
WLALTFQANY VVEEVQWPLP DENGIIQKDW AAMQVETTQD YAHDSHLWTS ITGSLNYQXV					
HHLFPH					

8/17

1429	M	G I D D Q - K T P T M -	- E E L A A H N T D D L L A I R O V Y V U T K S R H P O G Y D I L G A C O D V T H -	70
HS24	A	R A A P S V R I F J R A E V U N A B A L M E Q A K D A B A P - C U M I D N K Y D Y E E V U P D H P O G S V I U T H V - G R K D G T D Y -	75	
Bx06	A	- A Q I K K Y I T S D E I K N D K P G I D W I S Q D K A U D Y	76	
Sy68036	W	W L - T A E - R I	77	
Sp165	V	W L - S T T S - [W] V	78	
				79
				80
				81
				82
				83
				84
				85
				86
				87
				88
				89
				90
				91
				92
				93
				94
				95
				96
				97
				98
				99
				100
				101
				102
				103
				104
				105
				106
				107
				108
				109
				110
				111
				112
				113
				114
				115
				116
				117
				118
				119
				120
				121
				122
				123
				124
				125
				126
				127
				128
				129
				130
				131
				132
				133
				134
				135
				136
				137
				138
				139
				140
				141
				142
				143
				144
				145
				146
				147
				148
				149
				150
				151
				152
				153
				154
				155
				156
				157
				158
				159
				160
				161
				162
				163
				164
				165
				166
				167
				168
				169
				170
				171
				172
				173
				174
				175
				176
				177
				178
				179
				180
				181
				182
				183
				184
				185
				186
				187
				188
				189
				190
				191
				192
				193
				194
				195
				196
				197
				198
				199
				200
				201
				202
				203
				204
				205
				206
				207
				208
				209
				210
				211
				212
				213
				214
				215
				216
				217
				218
				219
				220
				221
				222
				223
				224
				225
				226
				227
				228
				229
				230
				231
				232
				233
				234
				235
				236
				237
				238
				239
				240
				241
				242
				243
				244
				245
				246
				247
				248
				249
				250
				251
				252
				253
				254
				255
				256
				257
				258
				259
				260
				261
				262
				263
				264
				265
				266
				267
				268
				269
				270
				271
				272
				273
				274
				275
				276
				277
				278
				279
				280
				281
				282
				283
				284
				285
				286
				287
				288
				289
				290
				291
				292
				293
				294
				295
				296
				297
				298
				299
				300
				301
				302
				303
				304
				305
				306
				307
				308
				309
				310
				311
				312
				313
				314
				315
				316
				317
				318
				319
				320
				321
				322
				323
				324
				325
				326
				327
				328
				329
				330
				331
				332
				333
				334
				335
				336
				337
				338
				339
				340
				341
				342
				343
				344
				345
				346
				347
				348
				349
				350
				351
				352
				353
				354
				355
				356
				357
				358
				359
				360
				361
				362
				363
				364
				365
				366
				367
				368
				369
				370
				371
				372
				373
				374
				375
				376
				377
				378
				379
				380
				381
				382
				383
				384
				385
				386
				387
				388
				389
				390
				391
				392
				393
				394
				395
				396
				397
				398
				399
				400
				401
				402
				403
				404
				405
				406
				407
				408
				409
				410
				411
				412
				413
				414
				415
				416
				417
				418
				419
				420

FIG. 5

**Effect of Timing of Substrate Addition on  
Expression of *Mortierella* Delta-5-desaturase  
Gene in Yeast (SC334)**

(Induction Temperature 15 °C)


A

Fatty acid (% wt)

■ 20:3n-6
■ 20:4n-6

Conversion (%)

B



**Substrate Addition Time**

**FIG. 6**

**Effect of Concentration of Inducer (Galactose) on  
Expression of *Mortierella*/a Delta-5-desaturase  
Gene in Yeast (SC334)  
(Induction Temperature 15 C)**




FIG. 7

# Effect of Induction Temperature on Expression of *Mortierella*-Delta-5-desaturase Gene in Yeast (Strain SC334)




FIG. 8

# Effect of Yeast Strain on Expression of *Mortierella* Delta-5-desaturase Gene (Induction Temperature 15 C)




FIG. 9

**Effect of Yeast Strain on Expression of  
*Mortierella* Delta-5-desaturase Gene  
(Induction Temperature 30 C)**




FIG. 10

## Expression of delta-5-desaturase in DBY746 versus SC334




FIG. 11

# Effect of Medium Composition and Temperature on Expression of delta-5-desaturase Activity in Two Host Strains (SC334 and INVSC1)

A SC344  
B INVSC1




FIG. 12

16 / 17

## FastA Match of ma29 and contig 253538a

**SCORES** Initl: 117 Initn: 225 Opt: 256  
**Smith-Waterman score:** 408; 27.0% identity in 441 aa overlap

	10	20	30	40	50
ma29gcf.pep	MGTDQGKT---	FTWEELAAHNTKDDLLL	AIRGRVYDVTKF	LSRHPGGVDTLL	GAGR DVT
		: :  : : :	::  :  :  :	::	:  :  :
253538a	QGPTPRYFTWDEVAQRSGCEERWLVIDRKVNISEFTRRH	PGGSRVISHYAGODAT			
	10	20	30	40	50

ma29gcf.pep	60	70	80	90	100	110
	PVFE MYHAF-GAADA IMKKYYGTLVSNELPIFPEPTVFHKTIKTRVEGYFTDRNIDPKN					
	:   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :					
253538a	DPFVA FHKGLVKYK MNSLLIGEL-SPEQPSF-EPTK NKELTDEFREL RATVERMGLMK					
	60	70	80	90	100	110

	120	130	140	150	160	170
ma29gcf.pep	RPEIWGRYALIFGSLIASYYAQLFVPFVVERTWLQVVF-AIIMGFACAOVGLNPLHDASH	::: :   : ::   : :   : ::   : :: :   ::   :   :				
253538a	ANHVF--FLLYLLHILLLDGAALWTLWVFGTSFLPFLCAVLLSAVQAQAGWLQ-HDYGH					
	120	130	140	150	160	170

ma29gcf.pep	180 FSVTHNPTVWKILGATHDF----FNGASYLVWMYQHMLGHHPYTNIAAGADPDVSTSE---	
	:   :: :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :	
253538a	LSVYRKPK-WNHL--VHKFVIGHLKGASANWNHNRH-FQHHAKPNIFHKDPDVNMLHVVF	
	180 190 200 210 220	
	180 190 200 210 220	

ma29gcf.pep	230	240	250	260	270	280	
	----PDVRRRIKPNQKWF-VNHINQHMFV--PFLYGLLAFKVRIQDINILYFVKTNDAIRV						
	::     :     ::        ::     :     :     :     :     :     :     :						
253538a	LGEWQPIEYGKKKLKYLPYNHQHEYFFLIGPPLIPMYFQYQI---IMTMIVHKNWVDL	230	240	250	260	270	280

ma29gcf.pep	290	300	310	320	330	340
	NP1STWHTVMFWGGKAFFWYRLIVPLQYLPLGVLLLFTVADMVSSYWLAFTQANHHV					
	:  : ::	:	:  :	: :::	:: : ::: :	::
253538a	----AWAVSYI---	RFFITY	---IPF-YGILG-ALLFNFIREFLESHWEVWVTQMRNHIV			
	290	300	310	320	330	

	350	360	370	380	390
ma29gcf.pep	EEVQWPLPDENGIIQKDWAAMQVETT---QDYAHDSLWTSITGSLNYQAVHHLFPNVS				
	::: :::: :   :   :     :: :          :::       ::				
253538a	MEI----DOEAY--RDWFSSQLTATCNVEQSFFND---WFS--GHLNFQIEHHLFPTMP				
	340	350	360	370	

ma29gcf.pep	400	410	420	430	440
	QHYPDILAIKNTCSEYKV <sup>P</sup> YLVKDTFWQAFASHLEHLRVGLRPKEEX				
	:!:   :!  :!:: :				
253538a	RHNLHKIAPLVKSLCAKGHIEYQEKP <sup>L</sup> RLLDIIRSLKKSGKLWLDAYLHKX				
	380	390	400	410	420
					430

**Figure 13**

17/17

## FastA Match of ma524 and contig 253538a

SCORES Init1: 231 Initn: 499 Opt: 401  
 Smith-Waterman score: 620; 27.3% identity in 455 aa overlap

ma524gcf.pep	MAAAPSVRTFTRAEVLAEALNEGKDKDAEAPFLMIIDNKVYDVREFVPDHPGGSVILTH-	10	20	30	40	50	59
	QGPTPRYPTWDEV-----	10	20	30	40	50	
253538a	AGQDATDPFFAFPHINKGLVKKYMNSLLIGELSPEQSPSPEPTKNEELTDEFRELATVERM	60	70	80	90	100	110
	AGQDATDPFFAFPHINKGLVKKYMNSLLIGELSPEQSPSPEPTKNEELTDEFRELATVERM	60	70	80	90	100	110
ma524gcf.pep	GYYDSSKAYYAFKVSFNLCIWGLSTIVAKWGTSTLANVLSAALLGLFWQQCGWLADDF	120	130	140	150	160	170
	GLMKANHIVPFLYLHILLLDGAANLTLWVPG-TSPLPFLLCAVLLSAVQAQAGWLQHDY	120	130	140	150	160	
253538a	LHMQVFPQDRFWGDLFGAFLGGVCQGFSSSWKDKINTHHAAPNVHGEDOPDIDTHPLLTWS	180	190	200	210	220	230
	GHLSVYRKPKANHLVHKFVIGHLKGSANWWNHRHPOMHAKPNIFHKDPPDN--ML--	170	180	190	200	210	220
ma524gcf.pep	EHALEMFSVPDEELTRMWSRFMVLANQTFWFYFPILS---FARLSWCQSILFVLPNGQAH	240	250	260	270	280	290
	-HVF-VLGEWQPIEYKKKLKYLPHQHEYFLIGPPLIIPMYFOYQIIMMTI---VH	230	240	250	260	270	
253538a	KPSGARVPISLVEQLSLAMHWIWYLATMFLFIK--DPVNMLVYFLVSQAVCGNLLAIVFS	300	310	320	330	340	349
	NWVDLAWAVSYIIRFFITYIPFYGILGALLFLNFIRPLESHWFVVWTQ	280	290	300	310	320	
ma524gcf.pep	LNHNMPVISKEEAVLMDFFTQIIITGRDVHPGLFANWFTGGLNYQIEHHLFPSMPRHNF	350	360	370	380	390	400
	MNHIVMEI--DQEAYR-DWFSSQLTATCNVEQSFFNDWFSGHLNQIEHHLFPTMPRHNL	330	340	350	360	370	380
253538a	SKIOPAVETLCKKYNRVYHTTGMIETGAEVFSRLNEVSKAASKMGKAQX	410	420	430	440	450	
	HKIAPLVKSLCAKHGIEYQEKPPLRALLDIIRSLLKSGKLWLDAYLHKX	390	400	410	420	430	

Figure 14

**INTERNATIONAL SEARCH REPORT**

Inte ional Application No  
PCT/US 98/07422

<b>A. CLASSIFICATION OF SUBJECT MATTER</b>					
IPC 6	C12N15/53	C12N15/82	C12N5/10	C12P7/64	C11B1/00
	A61K31/20	A23L1/30	A23K1/00		

According to International Patent Classification(IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
IPC 6 C12N C12P C11B A61K A23L A23K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	COVELLO P. ET AL.: "Functional expression of the extraplastidial Arabidopsis thaliana oleate desaturase gene (FAD2) in Saccharomyces cerevisiae" PLANT PHYSIOLOGY, vol. 111, no. 1, May 1996, pages 223-226, XP002075211 see the whole document ---	1-83
A	WO 93 06712 A (RHONE POULENC AGROCHIMIE) 15 April 1993 cited in the application see the whole document ---	1-83
A	WO 94 18337 A (MONSANTO CO ;UNIV MICHIGAN (US); GIBSON SUSAN IRMA (US); KISHORE G) 18 August 1994 * see the whole document * ---	1-83
	-/-	

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

\* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the International filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

7 September 1998

21/09/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Kania, T

**INTERNATIONAL SEARCH REPORT**

International Application No
PCT/US 98/07422

**C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT**

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 96 21022 A (RHONE POULENC AGROCHIMIE) 11 July 1996 cited in the application * see the whole document *	1-83
A	EP 0 561 569 A (LUBRIZOL CORP) 22 September 1993 cited in the application see the whole document	1-83
A	SPYCHALLA J. ET AL.: "Identification of an animal w3 fatty acid desaturase by heterologous expression in Arabidopsis" PNAS, U.S.A., vol. 94, no. 4, 18 February 1997, pages 1142-1147, XP002076628 * see esp. discussion *	1-83
A	HILLIER L. ET AL.: "The WashU-Merck EST Project, AC W49761" EMBL DATABASE, 30 May 1996, XP002076629 Heidelberg * corresponding to SEQ ID NO: 21 * see the whole document	86
A	NATHANS J.: "Adult human retina cDNA, AC W28140" EMBL DATABASE, 14 May 1996, XP002076630 Heidelberg * corresponding to SEQ ID NO: 22 * see the whole document	86
A	HILLIER L. ET AL.: "The WashU-Merck EST Project, AC W67716" EMBL DATABASE, 16 June 1996, XP002076631 Heidelberg * corresponding to SEQ ID NO: 24 * see the whole document	86
A	HILLIER L. ET AL.: "The WashU-Merck EST Project, AC H17219" EMBL DATABASE, 1 July 1995, XP002076632 Heidelberg * corresponding to SEQ ID NO: 25,27 * see the whole document	86
	-/-	

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 98/07422

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	HILLIER L. ET AL.: "The WashU-Merck EST Project, AC H19385" EMBL DATABASE, 7 July 1995, XP002076633 Heidelberg * corresponding to SEQ ID NO: 26 * see the whole document -----	86
P, X	YOSHINOR. ET AL.: "AC C25549" EMBL DATABASE, 24 July 1997, XP002076634 Heidelberg * corresponding to SEQ ID NO: 13 * see the whole document -----	84, 86-88
P, X	CADENA D. ET AL.: "AC AF002668" EMBL DATABASE, 4 July 1997, XP002076635 Heidelberg * corresponding to SEQ ID NO: 21 * see the whole document -----	86-88
T	MICHAELSON L. ET AL.: "Isolation of a delta5-fatty acid desaturase gene from Mortierella alpina" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 273, no. 30, 24 July 1998, pages 19055-19059, XP002076636 see the whole document -----	1-83

**INTERNATIONAL SEARCH REPORT**International application No.  
PCT/US 98/07422**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:

Remark: Although claims 57, 76, 77 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

2.  Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3.  Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1.  As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3.  As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4.  No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

**Remark on Protest**

- The additional search fees were accompanied by the applicant's protest.  
 No protest accompanied the payment of additional search fees.

## INTERNATIONAL SEARCH REPORT

International Application No. PCT/ US 98/07422

### FURTHER INFORMATION CONTINUED FROM PCT/SAV 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

#### 1. Claims: 1-83

Nucleic acids, polypeptides, constructs comprising delta-5 desaturase according to SEQ ID NO: 1,2 derived from the fungus Mortierella alpina. Recombinant host cells comprising said nucleic acids or constructs.

Methods for the production of arachidonic acid in a microbial cell comprising a cell containing a vector encoding an enzyme activity which converts dihomoy-linolenic acid to arachidonic acid, preferentially a delta-5 desaturase, more preferentially from Mortierella. A recombinant yeast cell converting more than 5% of a 20:3 fatty acid to a 20:4 fatty acid.

Methods for desaturating dihomoy-linolenic acid using said microbial cells, fatty acids and oils obtained thereby.

Methods for obtaining altered long chain polyunsaturated fatty acid biosynthesis using microbes comprising delta-5 desaturase derived from fungi or algae.

Microbial oils derived from thereof and their use for therapeutical, nutritional, and cosmetical purposes, as well as products derived therefrom.

#### 2. Claims: 84,86-88 partially

An isolated sequence comprising the sequence of SEQ ID NO: 13, purified polypeptides produced thereof, esp. comprising SEQ ID NO: 14.

#### 3. Claims: 84, 86-88 partially

An isolated nucleotide comprising the sequence of SEQ ID NO: 15, purified polypeptides produced thereof, esp. comprising SEQ ID NO: 16.

#### 4. Claims: 85 completely, 86-88 partially

An isolated nucleotide sequence consisting of SEQ ID NO: 17 and SEQ ID NO: 19, purified polypeptides produced therefrom, esp. comprising SEQ ID NO: 18 and SEQ ID NO: 20.

./.

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International Application No	
PCT/US 98/07422	

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9306712	A 15-04-1993	AU 667848 B AU 2881292 A BG 98695 A BR 9206613 A CA 2120629 A CN 1072722 A CN 1174236 A CZ 9400817 A EP 0666918 A HU 69781 A JP 7503605 T MX 9205820 A NZ 244685 A US 5552306 A US 5614393 A US 5689050 A US 5663068 A US 5789220 A ZA 9207777 A		18-04-1996 03-05-1993 31-05-1995 11-04-1995 15-04-1993 02-06-1993 25-02-1998 13-09-1995 16-08-1995 28-09-1995 20-04-1995 01-04-1993 27-06-1994 03-09-1996 25-03-1997 18-11-1997 02-09-1997 04-08-1998 21-04-1993
WO 9418337	A 18-08-1994	EP 0684998 A JP 8506490 T		06-12-1995 16-07-1996
WO 9621022	A 11-07-1996	US 5614393 A AU 4673596 A CA 2207906 A CN 1177379 A EP 0801680 A US 5789220 A		25-03-1997 24-07-1996 11-07-1996 25-03-1998 22-10-1997 04-08-1998
EP 0561569	A 22-09-1993	AU 3516793 A CA 2092661 A JP 6014667 A US 5777201 A		16-09-1993 14-09-1993 25-01-1994 07-07-1998

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**

**THIS PAGE BLANK (USPTO)**